
<html lang="en"     class="pb-page"  data-request-id="b2be54a6-2bfe-4b1c-9250-0fca4de36f2a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b00907;issue:issue:10.1021/jmcmar.2017.60.issue-24;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)" /></meta><meta name="dc.Creator" content="David C.  Tully" /></meta><meta name="dc.Creator" content="Paul V.  Rucker" /></meta><meta name="dc.Creator" content="Donatella  Chianelli" /></meta><meta name="dc.Creator" content="Jennifer  Williams" /></meta><meta name="dc.Creator" content="Agnès  Vidal" /></meta><meta name="dc.Creator" content="Phil B.  Alper" /></meta><meta name="dc.Creator" content="Daniel  Mutnick" /></meta><meta name="dc.Creator" content="Badry  Bursulaya" /></meta><meta name="dc.Creator" content="James  Schmeits" /></meta><meta name="dc.Creator" content="Xiangdong  Wu" /></meta><meta name="dc.Creator" content="Dingjiu  Bao" /></meta><meta name="dc.Creator" content="Jocelyn  Zoll" /></meta><meta name="dc.Creator" content="Young  Kim" /></meta><meta name="dc.Creator" content="Todd  Groessl" /></meta><meta name="dc.Creator" content="Peter  McNamara" /></meta><meta name="dc.Creator" content="H. Martin  Seidel" /></meta><meta name="dc.Creator" content="Valentina  Molteni" /></meta><meta name="dc.Creator" content="Bo  Liu" /></meta><meta name="dc.Creator" content="Andrew  Phimister" /></meta><meta name="dc.Creator" content="Sean B.  Joseph" /></meta><meta name="dc.Creator" content="Bryan  Laffitte" /></meta><meta name="dc.Description" content="The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases bile acid co..." /></meta><meta name="Description" content="The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases bile acid co..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 8, 2017" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00907" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00907" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00907" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00907" /></link>
        
    
    

<title>Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00907" /></meta><meta property="og:title" content="Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0014.jpeg" /></meta><meta property="og:description" content="The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases bile acid conjugation, transport, and excretion, thereby protecting the liver from the harmful effects of bile accumulation, leading to considerable interest in FXR as a therapeutic target for the treatment of cholestasis and nonalcoholic steatohepatitis. We identified a novel series of highly potent non-bile acid FXR agonists that introduce a bicyclic nortropine-substituted benzothiazole carboxylic acid moiety onto a trisubstituted isoxazole scaffold. Herein, we report the discovery of 1 (tropifexor, LJN452), a novel and highly potent agonist of FXR. Potent in vivo activity was demonstrated in rodent PD models by measuring the induction of FXR target genes in various tissues. Tropifexor has advanced into phase 2 human clinical trials in patients with NASH and PBC." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00907"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00907">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00907&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00907&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00907&amp;href=/doi/10.1021/acs.jmedchem.7b00907" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 9960-9973</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00358" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.7b01663" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+C.++Tully">David C. Tully</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2249-8669" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+V.++Rucker">Paul V. Rucker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Donatella++Chianelli">Donatella Chianelli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Williams">Jennifer Williams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Agn%C3%A8s++Vidal">Agnès Vidal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Phil+B.++Alper">Phil B. Alper</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-4115-0633" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Mutnick">Daniel Mutnick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Badry++Bursulaya">Badry Bursulaya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Schmeits">James Schmeits</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiangdong++Wu">Xiangdong Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dingjiu++Bao">Dingjiu Bao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jocelyn++Zoll">Jocelyn Zoll</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Young++Kim">Young Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Todd++Groessl">Todd Groessl</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++McNamara">Peter McNamara</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=H.+Martin++Seidel">H. Martin Seidel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Valentina++Molteni">Valentina Molteni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Liu">Bo Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Phimister">Andrew Phimister</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sean+B.++Joseph">Sean B. Joseph</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bryan++Laffitte">Bryan Laffitte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Novartis Institutes for Biomedical Research, Emeryville, California 94608, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: (510) 879-9456. E-mail: <a href="/cdn-cgi/l/email-protection#c6a2a7b0afa2e8b2b3aaaabf86a8a9b0a7b4b2afb5e8a5a9ab"><span class="__cf_email__" data-cfemail="492d283f202d673d3c2525300927263f283b3d203a672a2624">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00907&amp;href=/doi/10.1021%2Facs.jmedchem.7b00907" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 9960–9973</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 16, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 October 2017</li><li><span class="item_label"><b>Published</b> online</span>8 December 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 December 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00907" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00907</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editors’ Choice" /></img><span>ACS Editors’ Choice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00907"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">14656</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">84</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00907" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;C. Tully&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;V. Rucker&quot;},{&quot;first_name&quot;:&quot;Donatella&quot;,&quot;last_name&quot;:&quot;Chianelli&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Agnès&quot;,&quot;last_name&quot;:&quot;Vidal&quot;},{&quot;first_name&quot;:&quot;Phil&quot;,&quot;last_name&quot;:&quot;B. Alper&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Mutnick&quot;},{&quot;first_name&quot;:&quot;Badry&quot;,&quot;last_name&quot;:&quot;Bursulaya&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Schmeits&quot;},{&quot;first_name&quot;:&quot;Xiangdong&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Dingjiu&quot;,&quot;last_name&quot;:&quot;Bao&quot;},{&quot;first_name&quot;:&quot;Jocelyn&quot;,&quot;last_name&quot;:&quot;Zoll&quot;},{&quot;first_name&quot;:&quot;Young&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Todd&quot;,&quot;last_name&quot;:&quot;Groessl&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;McNamara&quot;},{&quot;first_name&quot;:&quot;H.&quot;,&quot;last_name&quot;:&quot;Martin Seidel&quot;},{&quot;first_name&quot;:&quot;Valentina&quot;,&quot;last_name&quot;:&quot;Molteni&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Phimister&quot;},{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;B. Joseph&quot;},{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;Laffitte&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;9960-9973&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00907&quot;},&quot;abstract&quot;:&quot;The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases bile acid conjugation, transport, and excretion, thereby protecting the liver from the harmful effects of bile accumulation, leading to considerable interest in FXR as a therapeutic target for the treatment of cholestasis and nonalcoholic steatohepatitis. We identified a novel series of highly potent non-bile acid FXR agonists that introduce a bicyclic nortropine-substituted benzothiazole carboxylic acid moiety onto a trisubstituted isoxazole scaffold. Herein, we report the discovery of 1 (tropifexor, LJN452), a novel and highly potent agonist of FXR. Potent in vivo activity was demonstrated in rodent PD models by measuring the induction of FXR target genes in various tissues. Tropifexor has advanced into phase 2 human clinical trials in patients with NASH and PBC.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00907&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00907" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00907&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00907" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00907&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00907" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00907&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00907&amp;href=/doi/10.1021/acs.jmedchem.7b00907" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00907" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00907" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00907%26sid%3Dliteratum%253Aachs%26pmid%3D29148806%26genre%3Darticle%26aulast%3DTully%26date%3D2017%26atitle%3DDiscovery%2Bof%2BTropifexor%2B%2528LJN452%2529%252C%2Ba%2BHighly%2BPotent%2BNon-bile%2BAcid%2BFXR%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BCholestatic%2BLiver%2BDiseases%2Band%2BNonalcoholic%2BSteatohepatitis%2B%2528NASH%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D24%26spage%3D9960%26epage%3D9973%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/jmcmar.2017.60.issue-24/20171228/jmcmar.2017.60.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases bile acid conjugation, transport, and excretion, thereby protecting the liver from the harmful effects of bile accumulation, leading to considerable interest in FXR as a therapeutic target for the treatment of cholestasis and nonalcoholic steatohepatitis. We identified a novel series of highly potent non-bile acid FXR agonists that introduce a bicyclic nortropine-substituted benzothiazole carboxylic acid moiety onto a trisubstituted isoxazole scaffold. Herein, we report the discovery of <b>1</b> (tropifexor, LJN452), a novel and highly potent agonist of FXR. Potent in vivo activity was demonstrated in rodent PD models by measuring the induction of FXR target genes in various tissues. Tropifexor has advanced into phase 2 human clinical trials in patients with NASH and PBC.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction and Biological Rationale</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28440" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28440" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The farnesoid X receptor (FXR) is a ligand-activated nuclear receptor that is highly expressed in the liver, gall bladder, intestines, and kidney and acts as a key regulator of bile acid production, conjugation, and transport.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Bile acids are resorbed in the ileum and activate FXR, which leads to increased expression of bile acid binding proteins and FGF19, a key metabolic regulator. In the liver, FXR activation modulates expression of genes involved in bile acid transport and metabolism as well as glucose and lipid metabolism. Specifically, activation of FXR directly increases the expression of enzymes responsible for bile acid detoxification and canalicular and basolateral bile acid efflux while also inhibiting bile acid synthesis and basolateral bile acid uptake by hepatocytes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Activation of FXR can repress bile acid synthesis by either of two complementary mechanisms. In the liver, FXR activation induces SHP (NR0B2), which is a negative regulator of CYP7A1 expression, an enzyme which catalyzes the rate limiting step of the neutral bile acid biosynthetic pathway.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Activation of FXR in the intestines induces transcription of the endocrine hormone FGF19, which is secreted into portal circulation and subsequently binds to the FGFR4 receptor in the liver, which in turn activates a MAPK signaling pathway that results in the downregulation of CYP7A1 expression, thereby inhibiting bile acid synthesis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Cholestasis is a pathological condition in which bile flow from the liver to the intestine is reduced or interrupted due either to impaired secretion by hepatocytes or to obstruction of bile flow through the bile ducts. The consequence of the accumulation of bile salts is disruption of cellular membranes, which results in injury to the affected tissues, whereby the liver is typically most affected. Primary biliary cholangitis (PBC) is a chronic and progressive cholestatic disease, presumed to be autoimmune in origin, which results from the progressive destruction of intrahepatic bile ducts.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Decreased FXR expression and mutations of the FXR target genes ABCB11 (encoding BSEP) or ABCB4 (encoding MDR3) are observed in hereditary forms of human cholestasis and lead to a severe form of cholestasis known as progressive familial intrahepatic cholestasis (PFIC-2 and -3).<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> In addition, loss-of-function mutations in the NR1H4 gene that encodes FXR have been determined to be the cause for a neonatal form of PFIC.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Ursodeoxycholic acid (UDCA) is a naturally occurring primary bile acid and, though not an FXR agonist, is currently the standard of care for the treatment of PBC. Obeticholic acid (OCA), a synthetic bile acid FXR agonist, recently received accelerated approval for the treatment of PBC in combination with UDCA for patients who do not respond adequately to UDCA therapy alone.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">In addition to its role in bile acid metabolism and signaling, FXR is also involved in regulation of triglyceride metabolism and lipogenesis. FXR activation suppresses the activity of SREBP-1c, a key transcription factor that regulates triglyceride synthesis by inducing enzymes involved in lipogenesis. Nonalcoholic steatohepatitis (NASH) is a condition characterized by the accumulation of fat in the liver (steatosis), inflammation, hepatocyte ballooning, and fibrosis. NASH is a leading cause of cirrhosis and liver transplantation, and cases are expected to rise due to the increased prevalence worldwide of obesity and type 2 diabetes. It is hypothesized that FXR activation can reduce the liver steatosis, inflammation, and fibrosis in patients with NASH by suppressing lipogenesis and promoting triglyceride oxidation and clearance.</div><div class="NLM_p">In a recent clinical trial in patients with NASH, treatment with OCA led to improvements in serum transaminases and liver histology,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> however, higher rates of pruritus were experienced by patients treated with OCA compared to placebo-treated patients.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Pruritus, or severe itch, is a common symptom associated with cholestatic disorders, and recent clinical trials have demonstrated that OCA therapy in patients with PBC further exacerbates pruritus, which may ultimately limit the clinical utility of OCA in susceptible patient populations.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> OCA also caused adverse effects on serum lipid profiles including elevated LDL cholesterol and total cholesterol in heathy volunteers and in patients with NASH, which is a concern in a patient population with an elevated risk for cardiovascular disease.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10-13)</a></div><div class="NLM_p last">Our efforts to discover safe and more effective therapies for the treatment of cholestatic disorders have focused on the development of novel FXR agonists to improve upon the efficacy, safety, and tolerability of the current standard of care. To achieve this goal, the intended target drug candidate profile was for a highly potent and selective, non-bile acid, FXR agonist that would be effective at low systemic exposures. As FXR is expressed predominantly in the liver and intestines, the desire to limit the oral bioavailability and avoid high systemic exposures stemmed from the wish to avoid the prolonged systemic activation of FXR. Herein, we report our discovery of a novel series of highly potent non-bile acid FXR agonists that features a bicyclic [3.2.1] tropane linker ring as the key component responsible for the exceptional potency. This series potently and selectively activates FXR in vitro, and optimized analogues potently regulate FXR target genes in vivo at very low systemic exposures in preclinical pharmacodynamic models. The most advanced compound from this series (<b>1</b>) has progressed into phase II clinical trials for the treatment of patients with PBC<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and NASH.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Background</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Researchers at Glaxo-SmithKline (GSK) previously described the biological and pharmacological activity of the synthetic FXR agonist GW4064 (<b>2</b>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Since this initial report, there have been extensive optimization efforts by several groups to overcome liabilities of this scaffold class such as low aqueous solubility and overall poor ADME and PK properties.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22">(17-22)</a> Detailed accounts of much of this research has been thoroughly summarized in recent review articles (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> Researchers at GSK demonstrated that the stilbene moiety of <b>2</b> could be replaced with a fused biaryl ring system such as the isoquinoline in GSK2324 (<b>3</b>, EC<sub>50</sub> = 50 nM, 102% efficacy).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> This additional conformational restraint retained potent in vitro activity with full efficacy; however, such analogues likely lacked the necessary physicochemical properties and PK to progress into development. More recently, researchers at Eli Lilly reported that the central phenyl ring could be replaced by a piperidine ring exemplified by <b>4</b> (LY2562175, EC<sub>50</sub> = 193 nM, 41% efficacy).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The replacement of the extended conjugated aromatic system with a piperidine linker resulted in an improvement in overall drug-like properties despite resulting in a loss of potency and only partial FXR agonist activity relative to <b>2</b> and <b>3</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of FXR agonists reported in the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51511" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51511" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Early in our efforts to identify a novel full FXR agonist with improved potency and PK, we discovered that replacement of the indole moiety of the partial FXR agonist <b>4</b> with a 2-substituted benzothiazole-6-carboxylic acid resulted in a dramatic improvement in potency and exhibited full agonist efficacy in a cellular assay.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> The ligand-induced interaction with a coactivator protein is a critical step in transcriptional activation by FXR, and this is determined in the FXR-HTRF biochemical assay that measures the interaction between FXR and the steroid receptor coactivator-1 (SRC1). Benzothiazole <b>5</b> was determined to have an EC<sub>50</sub> = 8.3 nM with 96% efficacy relative to <b>2</b>, the most commonly used comparator FXR agonist (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The potent functional activity of <b>5</b> translates well in the FXR BSEP-luc reporter gene cellular assay, which is designed to measure cellular transcriptional activity of full length FXR on the BSEP promoter driving a luciferase reporter gene. Compound <b>5</b> has an EC<sub>50</sub> = 9.5 nM in this cellular assay and activates FXR as a full agonist with 118% efficacy relative to <b>2</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Optimization of Phenyl Substituent and Linker<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0012.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Values are the mean of three or more experiments.</p></div></div><div></div></div><div class="NLM_p">The pharmacokinetics in rats was determined, and <b>5</b> exhibited high plasma clearance and low oral bioavailability (<i>F</i> = 6%) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). In vitro metabolic stability in rat and human liver microsomes (RLM, HLM) showed moderate to high extraction ratios (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), which was consistent with the observed in vivo rat clearance and suggested that oral bioavailability was limited by the high in vivo clearance. Furthermore, in vitro metabolite ID studies in liver microsomes suggested oxidative metabolism on the 2,6-dichlorophenyl ring as the primary route for metabolic clearance, which was not surprising due to the highly lipophilic nature of that moiety.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Rat PK Data of Selected FXR Agonists</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">intravenous<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">oral administration<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (h·nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">0.55</td><td class="colsep0 rowsep0" align="char" char=".">0.34</td><td class="colsep0 rowsep0" align="char" char=".">390</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">4571</td><td class="colsep0 rowsep0" align="char" char=".">382</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1923</td><td class="colsep0 rowsep0" align="char" char=".">173</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">0.84</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">832</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">2670</td><td class="colsep0 rowsep0" align="char" char=".">1988</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">0.72</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">6042</td><td class="colsep0 rowsep0" align="char" char=".">2279</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">0.70</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">3446</td><td class="colsep0 rowsep0" align="char" char=".">2121</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">0.60</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">3636</td><td class="colsep0 rowsep0" align="char" char=".">2108</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">IV: 3 mg/kg 75%PEG300:25%D5W, solution.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">PO: 10 mg/kg solution vehicle: 75% PEG300:25% D5W (compounds <b>5</b>, <b>8</b>, <b>12</b>, <b>13</b>) or microemulsion vehicle: water (90%), cremophor RH40 (4.5%), corn oil (1.8%), PEG400 (2.7%), and ethanol (1%) (compounds <b>1</b>, <b>14</b>, <b>15</b>, <b>16</b>).</p></div></div></div><div class="NLM_p">Having identified that benzothiazole moiety provides a significant improvement in potency versus <b>4</b> with full agonist efficacy, this carboxylic acid-bearing pharmacophore was fixed while exploring the SAR in other regions of the scaffold for further optimization. To address the metabolic liability, replacement of the 2,6-dichlorophenyl group was explored in the attempt to improve the metabolic clearance and aqueous solubility. Replacement of the 2,6-dichlorophenyl with either 2,6-difluorophenyl (<b>6</b>) or 2-trifluoromethylphenyl (<b>7</b>) resulted in a modest loss of FXR agonist activity and metabolic stability in RLM was not improved, although the HLM stability showed some improvement compared to <b>5</b>. In contrast, the 2-trifluoromethoxyphenyl group (compound <b>8</b>) proved to be highly beneficial in several respects. Compound <b>8</b>, in addition to improved FXR agonist activity (EC<sub>50</sub> = 19 nM) and full efficacy (100%), showed a notable improvement in metabolic stability, with low extraction ratios in rat and human liver microsomes. The improvement in the in vitro metabolic stability translated nicely in vivo, as <b>8</b> had significantly improved rat pharmacokinetics versus the 2,6-dichloro analogue <b>5</b>, with moderate clearance (24 mL/min/kg) and modest oral bioavailability (<i>F</i> = 37%).</div><div class="NLM_p">Next, we examined the SAR involving replacements for the piperidine ring which serves as the framework linking the essential trisubstituted isoxazole pharmacophore to the aryl carboxylic acid moiety. A decrease in ring size to the azetidine (<b>9</b>) or pyrrolidine (<b>10</b>) was not tolerated and resulted in a substantial loss of FXR agonist activity (>100-fold). Conversely, an increase in ring size to the racemic azepane (<b>11</b>) afforded a modest improvement in potency compared to piperidine <b>8</b>. However, despite this improvement in FXR potency versus the piperidine <b>8</b>, the azepane analogue <b>11</b> was undesirable due to its poor metabolic stability in liver microsomes and displayed high extraction ratios in both RLM and HLM (0.75, 0.89).</div><div class="NLM_p">In the continued effort to optimize the linker moiety, we sought to increase the conformational restraint of this central scaffolding ring. We therefore installed the 8-azabicyclo[3.2.1]octane ring derived from nortropine, which resulted in a dramatic improvement in potency. Nortropine <b>12</b> had full FXR agonist efficacy with sub-nM potency in both the FXR-HTRF coactivator interaction assay (EC<sub>50</sub> = 0.54 nM) and FXR BSEP-luc cellular assay (EC<sub>50</sub> = 0.69 nM). This significant development represented a 30-fold improvement in potency over piperidine precursor <b>8</b> and more than 2 orders of magnitude greater potency versus <b>4</b>.</div><div class="NLM_p">Importantly, the in vitro ADME properties of nortropine <b>12</b> were attractive, with decent solubility (110 μM) in fasted state simulated intestinal fluid (FASSIF, pH = 6.8), and they showed moderate and low extraction ratios in rat (0.51) and human (<0.20) liver microsomes, respectively. Nortropine <b>12</b> exhibited reduced plasma clearance in rats (CL = 17 mL/min/kg) versus piperidine <b>8</b>, although the terminal half-life was short and oral bioavailability was low (<i>F</i> = 11%) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Having achieved a remarkable improvement in potency for this scaffold, we focused on further optimization of this promising nortropine lead. The focus of continued optimization remained to achieve reduced metabolic clearance and longer in vivo half-life in order to improve in vivo activity in a rodent PD model measuring induction of FXR target genes in the liver and intestines. Along with preserving the highly potent FXR agonist activity, limited systemic exposure and oral bioavailability was desired in order to minimize prolonged systemic activation in FXR, particularly in tissues other than liver and intestines.</div><div class="NLM_p">To this end, we examined the influence of various substituents at the synthetically accessible 4-position of the benzothiazole ring (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). While the addition of either a methyl (<b>13</b>) or methoxy (<b>14</b>) group retained potent FXR activity, the rat PK was not significantly improved, as both compounds had low oral bioavailability and short <i>T</i><sub>1/2</sub> despite the low clearance (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). In contrast, the 4-fluoro substituted analogue <b>1</b> gave further modest improvement in the FXR agonist activity (EC<sub>50</sub> = 0.26 nM) compared to <b>12</b> with full agonist activity in the FXR BSEP cellular assay. Likewise, the solubility in FASSIF (600 μM) was improved considerably compared to close analogues <b>12</b>, <b>13</b>, and <b>14</b>, possibly explained by the lower p<i>K</i><sub>a</sub> of the 4-fluoro substituted benzothiazole carboxylic acid (p<i>K</i><sub>a</sub> = 4.0).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Optimization of Benzothiazole Substituent<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0013.gif" alt="" id="GRAPHIC-d133e963-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">cLogD</th><th class="colsep0 rowsep0" align="center" char=".">p<i>K</i><sub>a</sub> (carboxylic acid)</th><th class="colsep0 rowsep0" align="center">FXR HTRF EC<sub>50</sub> (nM) (% efficacy)</th><th class="colsep0 rowsep0" align="center">FXR BSEP-luciferase EC<sub>50</sub> (nM) (% efficacy)</th><th class="colsep0 rowsep0" align="center" char=".">solubility pH = 6.8 FASSIF (μM)</th><th class="colsep0 rowsep0" align="center">metabolic stability RLM, HLM (ER)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">–OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">–H</td><td class="colsep0 rowsep0" align="char" char=".">3.40</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="center">0.54 (93)</td><td class="colsep0 rowsep0" align="center">0.69 (89)</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="left">0.51, <0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">–OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">–Me</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="center">0.49 (91)</td><td class="colsep0 rowsep0" align="center">0.82 (79)</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="left"><0.18, <0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">–OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">–OMe</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="center">0.57 (78)</td><td class="colsep0 rowsep0" align="center">0.42 (89)</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="left">0.50, 0.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">–OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="center">0.20 (92)</td><td class="colsep0 rowsep0" align="center">0.26 (89)</td><td class="colsep0 rowsep0" align="char" char=".">600</td><td class="colsep0 rowsep0" align="left"><0.18, 0.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">–OCHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="center">0.27 (92)</td><td class="colsep0 rowsep0" align="center">0.80 (87)</td><td class="colsep0 rowsep0" align="char" char=".">750</td><td class="colsep0 rowsep0" align="left">0.40, 0.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">–CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="center">0.46 (90)</td><td class="colsep0 rowsep0" align="center">0.54 (77)</td><td class="colsep0 rowsep0" align="char" char=".">510</td><td class="colsep0 rowsep0" align="left">0.19, 0.36</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Values are the mean of three or more experiments.</p></div></div></div><div class="NLM_p">Moreover, the rat pharmacokinetics were further improved, as compound <b>1</b> had low clearance (CL = 9 mL/min/kg) and a significantly longer terminal half-life (<i>T</i><sub>1/2</sub> = 3.7 h) than what had been observed with previous analogues from this scaffold and was consistent with the low extraction ratio seen in rat liver microsomes. Oral bioavailability of <b>1</b> in the rat was 20% from an aqueous microemulsion formulation, a modest improvement over other nortropine analogues (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). With the 4-fluorobenzothiazole in place, further examination of the phenyl ring substituent demonstrated that the <i>ortho</i>-trifluoromethoxy group could be modified to either difluoromethoxy <b>15</b> or trifluoromethyl <b>16</b> (LJP305) while preserving similarly potent FXR agonist activity with comparable rat pharmacokinetics.</div><div class="NLM_p">To help rationalize the remarkable boost in potency attained through the introduction of the novel nortropine-benzothiazole pharmacophore, we examined computational molecular modeling simulations of <b>1</b> docked into the X-ray structure of the FXR ligand binding domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DCT">3DCT</a>). In good agreement with published X-ray co-crystal structures of related isoxazoles bound to the FXR ligand binding domain, the docking model in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> showed the key H-bond between the isoxazole nitrogen and H447 and hydrophobic interactions with W468 of helix 12.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17-19)</a> The cyclopropyl group fills the hydrophobic pocket formed by side chains of F284, L287, F461, and W454, while the 2-trifluoromethoxyphenyl ring establishes hydrophobic contacts with M328, M365, and I352. The bridged bicyclic nortropine ring system fills the central portion of the binding pocket and, due to its limited flexibility, provides conformational restraint to the central linker section of the ligand. Furthermore, the ethylene bridge establishes a favorable intramolecular hydrophobic interaction with the face of the 2-trifluoromethoxyphenyl ring. Additionally, the benzothiazole ring efficiently fills the narrow portion of the hydrophobic pocket and delivers the optimal geometry for the carboxylic acid substituent to establish the essential electrostatic interaction with R331 in helix 5.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Model of <b>1</b> docked into FXR ligand binding domain from X-ray structure of PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DCT">3DCT</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having achieved the optimization of highly potent FXR agonists with improved rat PK, compounds <b>1</b> and <b>16</b> were selected for further evaluation in preclinical models of FXR activation. Compound <b>1</b> was examined in rat primary hepatocytes in an assay designed to measure the induction of FXR target genes BSEP and SHP mRNA by quantitative real-time PCR (qPCR). Robust induction of both target genes was observed in primary cells by <b>1</b> in a concentration-dependent manner (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). BSEP induction above vehicle (DMSO) control was observed at concentrations as low as 1 nM, while strong induction of SHP (15-fold above vehicle) was observed at 10 nM and modest induction of SHP at 1 nM (3-fold).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Induction of FXR target genes BSEP and SHP in vitro in rat primary hepatocytes by compound <b>1</b>. Primary rat hepatocytes were treated for 24 h with compound <b>1</b> or vehicle only, and gene expression was determined by real-time quantitative PCR. *<i>p</i> ≤ 0.01, **<i>p</i> ≤ 0.001, and ***<i>p</i> ≤ 0.0001 compared to vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>1</b> and <b>16</b> were evaluated in a PD model designed to measure the induction of FXR target genes in the rat following a single oral dose. Both test compounds were administered orally using a range of four doses (0.03, 0.1, 0.3, and 1.0 mg/kg) and compared directly to the vehicle control group (vehicle: 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension). Tissues were harvested 7 h postdose, and mRNA was isolated from the liver and ileum and analyzed by real-time quantitative PCR using primer and probe sets specific to SHP (NR0B4), BSEP (ABCB11), and FGF15. Both compounds demonstrated robust induction of FXR target genes in a dose-dependent fashion with highly potent in vivo activity. Similar levels of induction of SHP in the liver were observed, with maximal induction of ∼6-fold achieved at 1.0 mg/kg for both compounds <b>1</b> and <b>16</b>, while significant BSEP induction was observed at the lower dose of 0.3 mg/kg (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). In the ileum, where FXR is also highly expressed, FXR target genes SHP and FGF15 (rodent orthologue of human FGF19) were potently induced by <b>16</b> at 0.3 mg/kg (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Even more impressively, compound <b>1</b> demonstrated highly potent induction of SHP and FGF15 in the ileum as doses as low as 0.1 mg/kg, with mRNA levels >20-fold above vehicle treated animals (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Induction of FXR target genes SHP and BSEP in rat liver by compounds <b>1</b> and <b>16</b> following single oral dose. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. *<i>p</i> ≤ 0.01 versus vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Induction of FXR target genes SHP and FGF15 in rat ileum by compounds <b>1</b> and <b>16</b> following single oral dose. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. #<i>p</i> ≤ 0.05 and *<i>p</i> ≤ 0.01 vs vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To more extensively evaluate the pharmacological activity and PK/PD relationship of compound <b>1</b> at steady state, an integrated PK/PD study was carried out in naı̈ve rats that were treated orally with compound <b>1</b> once daily for 14 days. Considering the potent activity observed in the previous single dose PD study, a wide range of seven doses was chosen to better determine the minimally efficacious dose and exposure required for regulation of FXR target genes, 0.003, 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg, all administered orally using a standard suspension formulation (0.5% methylcellulose, 0.5% Tween80, 99% water). Multiple plasma samples were collected from each group on days 1 and 11 for determination of pharmacokinetics. Tissues (liver and ileum) were harvested on day 14 of the study 7 h after the final dose, and mRNA was analyzed by real-time qPCR. In addition, the total compound concentrations in the liver were determined at 1 and 7 h for each dosing group.</div><div class="NLM_p">In the liver, robust induction of SHP was observed at 0.01 mg/kg of compound <b>1</b> with maximal levels of gene induction achieved at 0.3 mg/kg. Initial BSEP induction in the liver appeared at the lowest dose tested (0.003 mg/kg), and maximal BSEP target gene induction was achieved above 0.1 mg/kg (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Activation of FXR in the liver resulted in the downregulation of sterol 12-α hydroxylase (CYP8B1) gene transcription, thereby reducing the conversion of cholesterol to bile acids. Expression of CYP8B1 mRNA following 14 day treatment with <b>1</b> was already apparent at the lowest dose (0.003 mg/kg), and CYP8B1 gene expression was fully repressed at doses above 0.03 mg/kg. Extrapolation of the data provided a mean ED<sub>50</sub> of approximately 0.02 mg/kg in the liver for SHP and BSEP and 0.01 mg/kg for CYP8B1 (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). In the ileum, FXR target genes SHP and FGF15 are robustly induced at similarly low doses down to 0.01 mg/kg as shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>. The mean ED<sub>50</sub> for induction of SHP in the ileum was determined to be approximately 0.01 mg/kg, while for FGF15 in the ileum ED<sub>50</sub> was around 0.05 mg/kg.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Induction of FXR target genes SHP, BSEP, and CYP8B1 in rat liver following oral administration of compound <b>1</b> once daily for 14 days. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. *<i>p</i> ≤ 0.01 and **<i>p</i> ≤ 0.001 versus vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Induction of FXR target genes SHP and FGF15 in rat liver following oral administration of compound <b>1</b> once daily for 14 days. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. *<i>p</i> ≤ 0.01 and **<i>p</i> ≤ 0.001 versus vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mean ED<sub>50</sub> at 7 h for Selected FXR Target Genes in Liver and Ileum Following Oral Administration of Compound <b>1</b> Once Daily for 14 Days</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">gene (mRNA)</th><th class="colsep0 rowsep0" align="center" char=".">ED<sub>50</sub> at 7 h (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CV (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver SHP</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">28.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver BSEP</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">34.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver CYP8B1</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td><td class="colsep0 rowsep0" align="char" char=".">64.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ileum SHP</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td><td class="colsep0 rowsep0" align="char" char=".">75.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ileum FGF15</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char=".">32.8</td></tr></tbody></table></div></div><div class="NLM_p">Serum triglycerides and plasma FGF15 protein levels were also analyzed, as these circulating biomarkers could potentially be utilized as clinically translatable indicators of target engagement. Activation of FXR in the ileum induces the expression of FGF15/FGF19, which is then secreted in the portal blood and signals repression of CYP7A1 expression in the liver. In agreement with the observation of increased FGF15 mRNA expression in the ileum, treatment of rats with compound <b>1</b> exhibited a clear dose-dependent increase in plasma FGF15 protein, with maximal levels of FGF15 detected at 7 h postdose (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). Importantly, at 24 h following the final dose, plasma FGF15 protein concentrations had normalized to baseline levels, suggesting that repeat daily administration of compound <b>1</b> does not result in the prolonged activation of FXR.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Plasma FGF15 levels on day 14, at 1, 7, and 24 h following oral administration of compound <b>1</b> once daily for 14 days. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Serum triglycerides are an indirect biomarker of FXR activation, whereby FXR directly induces SHP and downregulates the transcription factor SREBP-1c which is a master regulator of fatty acid and lipid synthesis. Treatment with compound <b>1</b> for 14 days produced a robust dose-dependent reduction in serum triglycerides and reached a maximal response with a 0.3 mg/kg dose, resulting in a decrease of triglyceride levels to approximately 79% below the vehicle control group (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Serum triglycerides on day 15, at 24 h following oral administration of compound <b>1</b> once daily for 14 days. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. *<i>p</i> ≤ 0.01 and **<i>p</i> ≤ 0.001 versus vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Plasma samples were collected at multiple time points (0.5, 1, 3, 7, and 24 h) on days 1 and 11 for determination of the pharmacokinetics of compound <b>1</b> in this study following the first dose and at steady state. The plasma <i>C</i><sub>max</sub> occurred between 3 and 7 h, and total concentrations were generally similar on day 1 as on 11, ranging from 150 pM at the lowest dose to 171 nM at the highest dose. Compound <b>1</b> demonstrated a linear increase in exposure with increasing dose across the entire range of doses. The plasma exposures were very low at efficacious doses, with AUC ranging from 2 nM·h at the lowest dose (0.003 mg/kg) up to 1688 nM·h at the highest dose (3.0 mg/kg) (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> and <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). Importantly, no significant accumulation was observed at steady state following multiple days of administration compared to the exposures observed on day 1 following the initial dose.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Steady state pharmacokinetics (day 11) of compound <b>1</b>; mean total plasma concentration versus time profiles (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Steady State Pharmacokinetics (Days 1 and 11) of Compound <b>1</b>; Mean <i>C</i><sub>max</sub> and AUC (0–24 h) (n = 3)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">day</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC(0–24hr) nM·h</th><th class="colsep0 rowsep0" align="center" char=".">AUC(0–24 h)/dose</th><th class="colsep0 rowsep0" align="center" char=".">accumulation AUC day 11/day 1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">668</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">756</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">443</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">496</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">503</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">658</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">410</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">80</td><td class="colsep0 rowsep0" align="char" char=".">796</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">13.5</td><td class="colsep0 rowsep0" align="char" char=".">117</td><td class="colsep0 rowsep0" align="char" char=".">390</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char=".">14.8</td><td class="colsep0 rowsep0" align="char" char=".">190</td><td class="colsep0 rowsep0" align="char" char=".">633</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">39.3</td><td class="colsep0 rowsep0" align="char" char=".">461</td><td class="colsep0 rowsep0" align="char" char=".">461</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char=".">43.1</td><td class="colsep0 rowsep0" align="char" char=".">562</td><td class="colsep0 rowsep0" align="char" char=".">562</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">171.8</td><td class="colsep0 rowsep0" align="char" char=".">1344</td><td class="colsep0 rowsep0" align="char" char=".">448</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char=".">127.1</td><td class="colsep0 rowsep0" align="char" char=".">1688</td><td class="colsep0 rowsep0" align="char" char=".">563</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr></tbody></table></div></div><div class="NLM_p">Liver exposures were determined at the end of study on day 14 at 1 and 7 h following the final dose (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Mean concentrations of <b>1</b> in the liver were low single-digit nM levels at the lowest doses and ranged between 600 and 900 nM at the highest dose. The liver concentrations averaged approximately 9-fold higher than mean plasma concentrations, with the exception of the two lowest doses, which showed somewhat higher liver:plasma concentration ratios (average of 18.5). The higher liver:plasma ratios observed at the two lowest doses may have been due to inherent variability in the quantitation methods as the plasma concentrations were well below 1 nM and near the limit of detection.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mean Plasma and Liver Concentrations of Compound <b>1</b> at Steady State, 1 and 7 h Post-Dose, Following Oral Administration Once Daily for 14 Days</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">time (h)</th><th class="colsep0 rowsep0" align="center">tissue</th><th class="colsep0 rowsep0" align="center" char=".">..</th><th class="colsep0 rowsep0" align="center" char=".">SD (nM)</th><th class="colsep0 rowsep0" align="center" char=".">ratio liver/plasma</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">2.92</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">2.30</td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">8.35</td><td class="colsep0 rowsep0" align="char" char=".">0.51</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td><td class="colsep0 rowsep0" align="char" char=".">0.07</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">5.18</td><td class="colsep0 rowsep0" align="char" char=".">0.71</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">1.29</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">11.86</td><td class="colsep0 rowsep0" align="char" char=".">3.35</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">1.16</td><td class="colsep0 rowsep0" align="char" char=".">0.49</td><td class="colsep0 rowsep0" align="char" char=".">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">9.74</td><td class="colsep0 rowsep0" align="char" char=".">1.26</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">3.95</td><td class="colsep0 rowsep0" align="char" char=".">1.17</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">27.35</td><td class="colsep0 rowsep0" align="char" char=".">10.48</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">4.89</td><td class="colsep0 rowsep0" align="char" char=".">1.01</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">44.98</td><td class="colsep0 rowsep0" align="char" char=".">9.67</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">6.84</td><td class="colsep0 rowsep0" align="char" char=".">0.34</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">84.46</td><td class="colsep0 rowsep0" align="char" char=".">3.64</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">13.78</td><td class="colsep0 rowsep0" align="char" char=".">1.52</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">92.78</td><td class="colsep0 rowsep0" align="char" char=".">6.91</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">16.41</td><td class="colsep0 rowsep0" align="char" char=".">2.16</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">159.11</td><td class="colsep0 rowsep0" align="char" char=".">45.58</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">40.54</td><td class="colsep0 rowsep0" align="char" char=".">18.31</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">229.84</td><td class="colsep0 rowsep0" align="char" char=".">44.40</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">62.61</td><td class="colsep0 rowsep0" align="char" char=".">1.97</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">872.12</td><td class="colsep0 rowsep0" align="char" char=".">405.26</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">114.72</td><td class="colsep0 rowsep0" align="char" char=".">17.88</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="char" char=".">639.75</td><td class="colsep0 rowsep0" align="char" char=".">235.68</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p">It is noteworthy that efficacy was observed at such low doses (mean ED<sub>50</sub> range 0.01–0.05 mg/kg) with plasma <i>C</i><sub>max</sub> concentrations near 1 nM and below, especially considering that PPB of compound <b>1</b> is approximately 99.9%. This implies that the unbound concentration of <b>1</b> in the plasma is well below the cellular EC<sub>50</sub> (0.26 nM) at efficacious doses. Moreover, the minimal total plasma concentrations of <b>1</b> that are sufficient to regulate FXR target gene expression in the liver and intestines are only marginally higher than the cellular EC<sub>50</sub> (day 11 <i>C</i><sub>max</sub> = 1.9 at 0.03 mg/kg dose). The liver concentrations of <b>1</b> at the lowest effective doses (0.01 and 0.03 mg/kg, nearest to ED<sub>50</sub> values in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) ranged from 5 to 12 nM, which are roughly 8–22-fold higher than corresponding plasma concentrations at the same doses. Unbound concentrations of <b>1</b> in the liver were not determined in this study because drug concentrations were quantified from tissue homogenates, and therefore a strict PK/PD relationship for the free drug concentrations of <b>1</b> required to regulate target gene expression in tissues cannot be explicitly determined. Moreover, while this PK data suggests that the concentration of compound <b>1</b> required for pharmacological activity is within the vicinity of the cellular EC<sub>50</sub>, further studies are warranted to delineate whether the pharmacodynamics of an FXR agonist regulating target gene expression is driven primarily by <i>C</i><sub>max</sub> or by AUC.</div><div class="NLM_p">It is instructive to compare the minimum effective concentrations of <b>1</b> required for induction of BSEP and SHP in the liver in the rat PD model to the concentrations required in primary rat hepatocytes (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). The liver concentrations of <b>1</b> (5–12 nM) at the lowest effective doses (0.01–0.03 mg/kg) are consistent with and in the same range as the lowest effective concentrations required in vitro to drive expression of FXR target genes BSEP and SHP in primary hepatocytes (1–10 nM range, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Considering these relatively low total drug concentrations in the liver and very high PPB (∼99.9%), it is reasonable to estimate that the efficacious free drug concentrations in the liver are likely near or possibly even below the cellular EC<sub>50</sub> (0.26 nM). This suggests the notion that the activation, or occupancy, of only a fraction of the total available receptors is required for a full agonist of FXR to elicit a pharmacological response, as is often the case for agonists of other nuclear receptors and GPCRs.</div><div class="NLM_p">Extensive preclinical profiling demonstrated that <b>1</b> was highly selective for FXR: a broad panel screen of enzyme, ion channel, nuclear receptor, and GPCR assays showed no significant off-target activity (>10000-fold selectivity for FXR, data not shown). Importantly, compound <b>1</b> displayed no measurable activity on TGR5, the bile acid-activated GPCR (>10 μM) (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). This is significant as several recent reports have proposed that activation of TGR5 may be responsible for mediating bile acid-induced itch.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> Recent clinical trials in patients with PBC treated with OCA have established a dose-dependent relationship between OCA and the incidence and severity of pruritus.<a onclick="showRef(event, 'ref11 ref30'); return false;" href="javascript:void(0);" class="ref ref11 ref30">(11, 30)</a> To further highlight the potential advantages of a non-bile acid derived FXR agonist, we also tested OCA and its primary active metabolites, the glycine and taurine conjugates of OCA in the same assay measuring TGR5 activation. Whereas OCA itself is a rather weak agonist of hTGR5 with EC<sub>50</sub> = 0.918 μM (83% efficacy), the glycine and taurine conjugates are considerably more potent hTGR5 agonists, with EC<sub>50</sub> values 0.315 and 0.205 μM, respectively, and with full (100%) efficacy versus control (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). Following daily administration of OCA, the glycine and taurine conjugates of OCA undergo enterohepatic recirculation and eventually incorporate into the bile acid pool, reaching steady state serum concentrations of 13.8- and 12.3-fold higher than parent OCA itself.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Moreover, at therapeutic doses of OCA, the total concentration of OCA and its taurine and glycine conjugates are near or above the EC<sub>50</sub> concentrations for hTGR5 activation, which could help explain the dose-dependent relationship between OCA and pruritus.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. TGR5 Agonist Activities of Compound <b>1</b>, OCA, and OCA Conjugates</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">hTGR5 EC<sub>50</sub> (μM) (% vs control)</th><th class="colsep0 rowsep0" align="center">mTGR5 EC<sub>50</sub> (μM) (% vs control)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">OCA</td><td class="colsep0 rowsep0" align="center">0.918 (83%)</td><td class="colsep0 rowsep0" align="center">5.74 (68%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">OCA–taurine conjugate</td><td class="colsep0 rowsep0" align="center">0.205 (102%)</td><td class="colsep0 rowsep0" align="center">0.906 (97%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">OCA–glycine conjugate</td><td class="colsep0 rowsep0" align="center">0.315 (101%)</td><td class="colsep0 rowsep0" align="center">0.637 (98%)</td></tr></tbody></table></div></div><div class="NLM_p">The pharmacokinetics of compound <b>1</b> was evaluated in the mouse and in the dog, and this data is shown in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a> for comparison to rat PK. In the mouse, following IV administration, compound <b>1</b> exhibited low clearance and small volume of distribution with a half-life of 2.6 h. In the dog, following IV injection, the clearance was low and <i>T</i><sub>1/2</sub> was 7.4 h, also with a small volume of distribution (0.46 L/kg). Plasma samples from the dog PK studies were also monitored for any conjugated metabolites of compound <b>1</b>. Only very low levels of the acylglucuronide metabolite (≤1 nM) could be detected in some animals, however, there were no taurine or glycine conjugated metabolites of <b>1</b> observed in any of the animals. Oral bioavailability in all three species (mouse, rat, and dog) was about 10% following administration using an aqueous methylcellulose suspension formulation. The pharmacokinetic parameters from all three species were used for prediction of human PK and estimation of the efficacious human clinical dose using GastroPlus modeling and simulation software. Simulated human PK predicted human clearance to be low, with a moderate <i>T</i><sub>1/2</sub>, and oral bioavailability projected at 17%. Using the simulated human PK, the clinically efficacious human dose of compound <b>1</b> was projected to be in the range of 30–110 μg once daily, and thereby supported advancement to the clinic.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. PK Profile of <b>1</b> Across Multiple Species<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">IV = 5 PO = 10</td><td class="colsep0 rowsep0" align="char" char=".">IV = 3 PO = 1</td><td class="colsep0 rowsep0" align="char" char=".">IV = 0.5 PO = 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">5.3</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">0.70</td><td class="colsep0 rowsep0" align="char" char=".">0.72</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV <i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral AUC (h·nM)</td><td class="colsep0 rowsep0" align="char" char=".">4785</td><td class="colsep0 rowsep0" align="char" char=".">307</td><td class="colsep0 rowsep0" align="char" char=".">3660</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral <i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="char" char=".">1186</td><td class="colsep0 rowsep0" align="char" char=".">53</td><td class="colsep0 rowsep0" align="char" char=".">332</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral <i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB (% bound)</td><td class="colsep0 rowsep0" align="char" char=".">∼99.9</td><td class="colsep0 rowsep0" align="char" char=".">∼99.9</td><td class="colsep0 rowsep0" align="char" char=".">∼99.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">IV: 3 mg/kg 75% PEG300:25% D5W, solution (mouse and rat); 20% PEG300, 5% solutol, 75% carbonate buffer pH = 8, solution (dog). PO: vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension (mouse, rat, and dog).</p></div></div></div><div class="NLM_p last">A first-in-human phase 1 clinical study was recently completed in which the safety, tolerability, PK, and PD of compound <b>1</b> was assessed in healthy volunteers. Compound <b>1</b> was found to be generally safe and well-tolerated following single oral doses ranging from 10 μg to 3 mg. Notably, dose-dependent, transient increases in circulating levels of FGF19 protein were observed, demonstrating potent on-target FXR agonist activity. Preliminary data from this clinical study has recently been disclosed,<a onclick="showRef(event, 'cit32a'); return false;" href="javascript:void(0);" class="ref cit32a">(32a)</a> and detailed data and results will be published elsewhere.<a onclick="showRef(event, 'cit32b'); return false;" href="javascript:void(0);" class="ref cit32b">(32b)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Chemical Synthesis of Compound <b>1</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compound <b>1</b>, outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, was initiated from the commercially available 2-(trifluoromethoxy)benzaldehyde (<b>17a</b>). Chloroxime <b>19a</b> was prepared from aldehyde <b>17a</b> by condensation with hydroxylamine, followed by chlorination with NCS, with both steps proceeding in high yield. Next, cycloaddition of <b>19a</b> with methyl 3-cyclopropyl-3-oxopropanoate afforded the desired isoxazole <b>20a</b> in moderate yield. The methyl ester was then reduced using LiAlH<sub>4</sub> to give the corresponding primary alcohol <b>21a</b>. Subsequent bromination of alcohol <b>21a</b>, followed by alkylation with <i>N</i>-Boc nortropine under basic conditions resulted in the Boc-protected intermediate <b>1f</b>, which was then treated with TFA to afford nortropine <b>1g</b>. Benzothiazole <b>25a</b> was prepared in two steps from commercially available aniline <b>23a</b>, which was treated with NaSCN and bromine using the classical Hugerschoff reaction to generate the aminobenzothiazole <b>24a</b>. Next, the aminobenzothiazole <b>24a</b> was brominated under modified Sandmeyer reaction conditions using <i>tert</i>-butyl nitrite to yield the desired bromobenzothiazole <b>25a</b>. N-Arylation of amine <b>1g</b> with <b>25a</b> was carried out under mild thermal conditions using Cs<sub>2</sub>CO<sub>3</sub> in DMF. Finally, saponification of the methyl ester generated the carboxylic acid <b>1</b> in nine total linear steps. The synthesis and characterization of all other analogues is described in <a href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_001.pdf" class="ext-link">Supporting Information</a> and in refs <a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">24,25</a>.</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) NH<sub>2</sub>OH·HCl, H<sub>2</sub>O, 10 min, 0 °C, 83%; (b) NCS, DMF, 1 h, 25 °C, 99%; (c) K<sub>2</sub>CO<sub>3</sub>, methyl 3-cyclopropyl-3-oxopropanoate, THF, −5 to 35 °C, 52%; (d) LiAlH<sub>4</sub>, THF, −10 °C, 30 min, 93%; (e) CBr<sub>4</sub>, PPh<sub>3</sub>, THF, 1 h, rt, 87%; (f) <i>N</i>-Boc nortropine, 18-crown-6, THF, potassium <i>tert</i>-butoxide, 18 h, rt, 69%; (g) TFA, DCM, 1 h, rt, 94%; (h) <b>25a</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 1 h, rt to 60 °C, 75%; (i) KOH, MeOH, THF, 1 h, 70 °C, 91%; (l) NaSCN, AcOH, Br<sub>2</sub>, 0 to 30 °C over 48 h 66%; (m) CuBr<sub>2</sub>, MeCN, <i>t</i>-BuONO, 0 to 30 °C, 48 h, 24%.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Lead optimization successfully overcame the ADME and physicochemical liabilities of earlier phenylisoxazole FXR agonists by significantly improving the potency and modestly improving the ADME and PK properties. Compound <b>1</b> is a highly potent and efficacious non-bile acid FXR agonist that is effective at inducing FXR target genes in the liver and intestines following very low doses and systemic exposures. Compound <b>1</b> (LJN452, tropifexor) was found to be generally safe and well-tolerated at pharmacologically active doses in healthy volunteers and has progressed into clinical development where it is currently under evaluation in several phase 2 human clinical trials in patients with PBC and NASH.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Materials and Methods</h3><div class="NLM_p">Commercially available starting materials were used as supplied without further purification. Reactions were carried out by using dry organic solvents (DCM, ACN, DMF, etc.) unless otherwise noted. Reactions were monitored using thin layer chromatography and an Agilent Technologies 1200 series 6140 Quadrupole LC-MS with UV detection at 254 nm in electrospray ionization (ESI) mode. For LC-MS, all retention times reported are at 254 nm UV channel unless otherwise noted. All NMR spectra were recorded on a Bruker AVANCE-400 spectrometer operating at a frequency of 400.13 MHz for <sup>1</sup>H and 100.61 MHz for <sup>13</sup>C equipped with a 5 mm QNP cryoprobe with Z-gradient. Chemical shifts for <sup>1</sup>H and <sup>13</sup>C spectra were referenced to residual solvent. MS were obtained on an Agilent Technologies 1200 series 6140 quadrupole LC-MS in electrospray ionization (ESI) mode. HRMS-ESI data were recorded using an Agilent 6520 Accurate-Mass Q-TOF LC-MS system with HPLC-Chip Cube interface and an Agilent 1200 HPLC. All final compounds were isolated analytically pure, >99% purity by HPLC unless otherwise indicated. More information is in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div id="sec6-1-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>N</i>-Hydroxy-2-(trifluoromethoxy)benzimidoyl Chloride (<b>19a</b>)</h4><div class="NLM_p last">To a solution of sodium hydroxide (7.00 g, 175 mmol, 1.19 equiv) in water (120 mL) was added a stirred solution of NH<sub>2</sub>OH·HCl (11.8 g, 170 mmol, 1.15 equiv) in water (120 mL) at 0 °C. The resulting solution was stirred for 10 min at 0 °C. A solution of 2-(trifluoromethoxy)benzaldehyde <b>17a</b> (28.0 g, 147 mmol, 1.00 equiv) in ethanol (120 mL) was then added. The reaction was allowed to stir for an additional 1 h at room temperature, at which point it was diluted with water (500 mL). The aqueous layer was extracted with ethyl acetate (2 × 700 mL), and the organic layers were combined, washed with brine (2 × 300 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum to give 30.0 g of (<i>E</i>)-2-(trifluoromethoxy)benzaldehyde oxime <b>18a</b> (83% yield). The oxime <b>18a</b> was carried directly into the next step without further purification. LC-MS <i>m</i>/<i>z</i> 206.0 (M + H); method A; RT = 1.43 min. NCS (22.0 g, 166 mmol, 1.12 equiv) was slowly added to a stirred solution of (<i>E</i>)-2-(trifluoromethoxy) benzaldehyde oxime <b>18a</b> (30.0 g, 146 mmol, 1.00 equiv) in DMF (300 mL), keeping the internal temperature below 25 °C. The reaction mixture was stirred for 1 h at room temperature and then diluted with water (300 mL) and extracted with ethyl acetate (2 × 500 mL). The organic layers were combined, washed with brine (5 × 300 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum to give 35.0 g of <i>N</i>-hydroxy-2-(trifluoromethoxy)benzimidoyl chloride <b>19a</b> as a light-yellow residue (99% yield). This material was used directly in the next step without further purification. <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>, 400 MHz) δ 7.95–7.90 (m, 1H), 7.83 (d, <i>J</i> = 7.6, 1H), 7.62–7.43 (m, 2H). LC-MS <i>m</i>/<i>z</i> 240.0 (M + H); method A; RT = 2.03 min.</div></div><div id="sec6-1-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Methyl 5-Cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate (<b>20a</b>)</h4><div class="NLM_p last">Potassium carbonate (11.0 g, 79.7 mmol, 1.09 equiv) was suspended in THF (100 mL), and the mixture was cooled to −10 °C and treated with a solution of methyl 3-cyclopropyl-3-oxopropanoate (11.0 g, 77.5 mmol, 1.06 equiv) in THF (50 mL) dropwise over 5 min. To this reaction mixture was then added a solution of <i>N</i>-hydroxy-2-(trifluoromethoxy)benzimidoyl chloride <b>19a</b> (17.6 g, 73.6 mmol, 1.0 equiv) in THF (50 mL) and monitored to ensure that the internal temperature did not exceed −5 °C during the time of the addition. Following this addition, the reaction was warmed to 35 °C. Upon cooling, the reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (2 × 300 mL). The organic layer was washed with brine (2 × 200 mL), dried over anhydrous sodium sulfate, concentrated under vacuum, and then purified by silica gel column chromatography using ethyl acetate/petroleum ether (1:100–1:20) to afford methyl 5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate <b>20a</b> as a white solid, 12.5 g (52% yield); mp 145–150 °C (broad). <sup>1</sup>H NMR (MeOD-<i>d</i><sub>4</sub>, 400 MHz) δ 7.65–7.60 (m, 1H), 7.53 (dd, <i>J</i> = 7.6, 2 Hz, 1H), 7.48–7.43 (m, 2H), 3.68 (s, 3H), 2.89 (pentet, <i>J</i> = 6.8 Hz, 1H), 1.30 (app br d, <i>J</i> = 6.8 Hz, 4H). LC-MS <i>m</i>/<i>z</i> 328.1 (M + H); method A; RT = 2.91 min.</div></div><div id="sec6-1-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (5-Cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)-methanol (<b>21a</b>)</h4><div class="NLM_p last">A 250 mL round-bottom flask was purged and maintained with an inert atmosphere of nitrogen and then charged with a suspension of LiAlH<sub>4</sub> (2.50 g, 65.8 mmol, 2.87 equiv) in THF (50 mL). A solution of methyl 5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl) isoxazole-4-carboxylate <b>20a</b> (7.50 g, 22.9 mmol, 1.00 equiv) in tetrahydrofuran (50 mL) was added dropwise at −10 °C. The resulting solution was stirred for 30 min at −10 °C, and the reaction was quenched by the sequential addition of ethyl acetate (3 mL), water (3 mL), and 15% aqueous NaOH (10 mL). The resulting mixture was filtered through Celite, and the filter cake was washed with ethyl acetate (200 mL). The filtrate was washed with brine (2 × 100 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum, affording 7 g of (5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanol <b>21a</b> as yellow oil, (93% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.57–7.55 (m, 2H), 7.41–7.40 (m, 2H), 4.50 (s, 2H), 2.22–2.20 (m, 1H), 1.72 (s, 1H) 1.11–1.28 (m, 4H). LC-MS <i>m</i>/<i>z</i> 300.1 (M + H); method B; RT = 1.69 min.</div></div><div id="sec6-1-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>tert</i>-Butyl 3-((5-Cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octane-8-carboxylate (<b>1f</b>)</h4><div class="NLM_p last">Into a 100 mL round-bottom flask was placed (5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)-methanol <b>21a</b> (4.00 g, 13.3 mmol), triphenylphosphine (5.6 g, 20 mmol, 1.5 equiv), and dichloromethane (40 mL). The mixture was stirred until completely dissolved and then slowly added dropwise to a solution of carbon tetrabromide (6.6 g, 20 mmol, 1.5 equiv) in dichloromethane (20 mL). The reaction was stirred for 1 h, and the solvent was evaporated in vacuo. The crude material was purified by silica gel chromatography using a gradient of ethyl acetate/hexanes (0–50%). The bromide <b>22a</b> was obtained as a clear oil (4.18 g, 87% yield) and then used immediately (owing to stability) in the next step. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.55–7.50 (m, 1H), 7.49–7.45 (m, 1H), 7.40–7.32 (m, 2H), 4.27 (s, 2H), 2.11–1.99 (m, 1H), 1.24–1.17 (m, 2H), 1.17–1.09 (m, 2H). LC-MS <i>m</i>/<i>z</i> 362.0/364.0 (M + H); (Br isotope pattern); method B; RT = 1.62 min. Into a dry 250 mL flask was placed <i>N</i>-Boc nortropine (2.9 g, 13 mmol), 18-crown-6 (3.4 g, 12 mmol), and anhydrous THF (80 mL). Potassium <i>tert</i>-butoxide (2.9 g, 26 mmol) was added portionwise, and the mixture was stirred vigorously under nitrogen for 1 h. 4-(Bromomethyl)-5-cyclopropyl-3-(2-(trifluoromethoxy)-phenyl)isoxazole <b>22a</b> (4.18 g, 11.6 mmol) was dissolved in anhydrous THF (20 mL) and added dropwise. The reaction mixture was stirred overnight under a positive nitrogen pressure. The solvent was removed in vacuo, and the mixture was diluted with water (100 mL) and ethyl acetate (100 mL). The organic layer was separated, dried (MgSO<sub>4</sub>), evaporated under vacuum, and then purified by silica gel chromatography using a gradient of ethyl acetate/hexanes (0–100%) to provide the desired product as a yellow oil, 4.07 g (69% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 7.98–7.64 (m, 3H), 7.64 (app d, <i>J</i> = 7.6, 1H), 4.38 (s, 2H), 3.82 (bs, 2H), 3.56 (t, <i>J</i> = 4.5 Hz, 1H), 2.36–1.98 (m, 3H), 1.82–1.70 (m, 6H), 1.15 (s, 9H), 1.14–1.07 (m, 4H). LC-MS <i>m</i>/z 509.2 (M + H); method A; RT = 2.42 min.</div></div><div id="sec6-1-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-((8-Azabicyclo[3.2.1]octan-3-yloxy)methyl)-5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole (<b>1g</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octane-8-carboxylate <b>1f</b> (3.98 g) was dissolved in a solution of 20% TFA in dichloromethane (30 mL). The solution was stirred for 1 h at room temperature, and then the solvent was evaporated. The residue was dissolved in ethyl acetate (125 mL) and washed with a saturated solution of sodium bicarbonate (100 mL). The organic layer was dried with anhydrous sodium sulfate and evaporated in vacuo. The crude residue was purified by silica gel chromatography using a gradient of 0–20% ethanol/dichloromethane to afford 3.01 g of the desired product <b>1g</b> as a colorless oil (94% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.51 (br s, 1H, NH), 7.72–7.68 (m, 1H), 7.64 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.58–7.52 (m, 2H), 4.33 (s, 2H), 3.81 (bs, 2H), 3.55 (t, <i>J</i> = 4.5 Hz, 1H), 2.36–2.33 (m, 1H), 1.98 (app dt, <i>J</i> = 14.8, 4.0 Hz, 2H), 1.91–1.76 (m, 6H), 1.14–1.07 (m, 4H). LC-MS <i>m</i>/<i>z</i> 409.2 (M + H); method A; RT = 1.72 min.</div></div><div id="sec6-1-6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-(3-((5-Cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorobenzo[<i>d</i>]thiazole-6-carboxylic Acid (<b>1</b>)</h4><div class="NLM_p">Into a 25 mL round-bottom flask equipped with a stir bar, the following were added sequentially: 4-((8-azabicyclo[3.2.1]octan-3-yloxy)methyl)-5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole <b>1g</b> (0.525 g, 1.29 mmol), 3.6 mL of DMA, cesium carbonate (1.08 g, 3.31 mmol), and methyl 2-chloro-4-methoxybenzo[<i>d</i>]thiazole-6-carboxylate <b>25a</b> (synthesis in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_001.pdf" class="ext-link">Supporting Information</a>, 1.12 g, 3.87 mmol). After the resulting slurry was stirred at room temperature for 10 min, the mixture was warmed to 60 °C and stirred for 1 h. The reaction was then allowed to cool to room temperature, and it was diluted with 200 mL of ethyl acetate and washed with water (3 × 30 mL). The organic solvent extract was concentrated under vacuum and purified using by silica gel chromatography (40 g silica column) with a gradient of ethyl acetate/hexanes (10–60%, 15 min gradient). Desired fractions were concentrated under vacuum, and the resulting residue crystallized upon standing to furnish 0.60 g of desired intermediate methyl ester <b>1h</b> (75% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.13 (d, <i>J</i> = 1.6 Hz, 1H), 7.67–7.59 (m, 3H), 7.54–7.50 (m, 2H), 4.41 (s, 2H), 4.31 (bs, 2H), 3.90 (s, 3H), 3.60 (t, <i>J</i> = 4.8 Hz, 1H), 2.31–2.25 (m, 1H), 2.10 (app dt, <i>J</i> = 14.8, 4.0 Hz, 2H), 2.02–1.91 (m, 4H), 1.83 (app d, <i>J</i> = 14.8 Hz, 2H), 1.19–1.15 (m, 4H). LC-MS <i>m</i>/<i>z</i> 618.2 (M + H); method A; RT = 3.26 min. Into a 25 mL round-bottom flask equipped with a stir bar was added sequentially: the methyl ester <b>1h</b> (0.55 g, 0.89 mmol), THF (4.0 mL), MeOH (2.0 mL), and 3 N aqueous KOH solution (1 mL, 3 mmol). The resulting homogeneous solution was stirred for 1 h at 70 °C and then allowed to cool to room temperature. The reaction was quenched with AcOH (0.2 mL of glacial acetic acid, 3 mmol) until pH = 6 was achieved as monitored by pH strip paper (Whatman class type CF catalogue no. 2613991). The resulting solution was diluted with ethyl acetate (40 mL) and washed with water (3 × 5 mL). The ethyl acetate layer was concentrated down to an oily residue via vacuum in a 40 mL Wheaton glass vial, and this oil was then dissolved into MeOH (6 mL). The resulting homogeneous solution soon began to crystallize and allowed to stand for 2.5 h. The mother liquor was withdrawn, and the crystals were washed with ice-cold MeOH (3 × 2 mL). The crystals were dried under vacuum (10 mmHg pressure at 45 °C overnight). A first crop of crystals (516 mg, 91% yield) were harvested and shown to be the methanol solvate by elemental analysis. Elemental Analysis as the methanol solvate: (C<sub>30</sub>H<sub>29</sub>F<sub>4</sub>N<sub>3</sub>O<sub>6</sub>S): C 56.69, H 4.60, N 6.61; Found: C 56.79, H 4.61, N 6.65. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz, for the methanol solvate) δ (d, <i>J</i> = 2.0 Hz, 1H), 7.76 (dd, <i>J</i> = 9.0, 1.0 Hz, 1H), 7.57–7.50 (m, 2H), 7.43–7.36 (m, 2H), 4.37 (s, 2H), 4.35 (bs, 2H), 3.60 (t, <i>J</i> = 4.8 Hz, 1H), 3.50 (br s, 3H, peak corresponding to the presence of the methanol solvate), 2.19–2.10 (m, 3H), 2.03–1.90 (m, 4H), 1.83 (app d, <i>J</i> = 12.8 Hz, 2H), 1.22–1.19 (m, 2H), 1.15–1.09 (m, 2H). LC-MS <i>m</i>/<i>z</i> 604.2 (M + 1).</div><div class="NLM_p last">The methanol solvate form of <b>1</b> was converted into a solvate-free crystalline form using the following procedure: The methanol solvate of <b>1</b> (500 mg) was fully dissolved in dry acetonitrile (50 mL) with gentle heating for 8 min (60 °C). This solution was allowed to stand for 4 days to crystallize. Upon drying, 484 mg of crystals were obtained with two collection crops. High resolution mass spectroscopic analysis, 604.1514 for the [M + H]<sup>+</sup> ion, is consistent with the molecular formula C<sub>29</sub>H<sub>25</sub>F<sub>4</sub>N<sub>3</sub>O<sub>5</sub>S, with a deviation of 1.6 ppm from the calculated [M + H]<sup>+</sup> ion mass of 604.1530. Purity was found to be >99% by LC-MS analysis, two separate protocols. First protocol: [M + H]<sup>+</sup> = 604.2 using LC-MS method A, RT = 3.22 min. Second LC-MS method B, RT = 2.21 min, MS <i>m</i>/<i>z</i> 604.1 (M + H). IR (cm <sup>–1</sup>): major stretches at 1679 (C═O stretch), 1242 (C–O–C stretch), 1213 (C–N stretch), 1167 (C–F stretch). Elemental Analysis of solvate free form (C<sub>29</sub>H<sub>25</sub>F<sub>4</sub>N<sub>3</sub>O<sub>5</sub>S): C 57.71, H 4.18, N 6.96. Found: C: 57.66, H: 4.20, N: 6.94. <sup>1</sup>H NMR (DMSO<i>d</i><sub>6</sub>, 400 MHz) δ 12.96 (br s, 1H), 8.20 (d, <i>J</i> = 1.5 Hz, 1H), 7.69–7.66 (m, 1H), 7.64 (dd, J = 7.6, 1.7 Hz, 1H), 7.59–7.57 (m, 1H), 7.56–7.55 (m, 1H), 7.54 (d, <i>J</i> = 1.1 Hz, 1H), 4.34 (s, 2H), 4.22 (app d, <i>J</i> = 5.7 Hz, 2H), 3.55 (t, <i>J</i> = 4.7 Hz, 1H), 2.34 (tt, <i>J</i> = 8.39, 5.18, 1H), 2.01–1.95 (m, 2H), 1.86–1.82 (m, 4H), 1.75 (app d, <i>J</i> =14.5 Hz, 2H), 1.16–1.13 (m, 2H), 1.10–1.07 (m, 2H). <sup>19</sup>F (DMSO-<i>d</i><sub>6</sub>, 376 MHz) −126.4, −56.3 ppm. <sup>13</sup>C (DMSO-<i>d</i><sub>6</sub>, 100 MHz) 171.79, 166.77, 166.37, 159.41, 151.70 (d, <i>J</i> = 249 Hz), 146.35, 145.10, 133.65 (d, <i>J</i> = 5.2 Hz), 132.26, 132.11, 128.25, 124.09, 123.22, 121.88, 120.40 (q, <i>J</i> = 258.3 Hz), 119.78, 113.39 (dd, <i>J</i> = 19.2, 2.4 Hz), 112.11, 72.35, 59.68, 57.28, 33.68, 27.91, 8.43, 7.50. mp = 221 °C sharp, corrected. Assignment table for proton and carbon spectra is in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00907">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00907" class="ext-link">10.1021/acs.jmedchem.7b00907</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures and analytical data for the synthesis of all compounds, FXR-HTRF coactivator interaction biochemical assay, FXR BSEP-luc reporter gene cellular assay, rat in vitro hepatocyte gene expression assay, PK protocols, in vivo rat PD study protocols (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_001.pdf">jm7b00907_si_001.pdf (307.55 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_002.csv">jm7b00907_si_002.csv (1.49 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00907" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David C. Tully</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Novartis
Institutes for Biomedical Research, Emeryville, California 94608, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2249-8669" title="Orcid link">http://orcid.org/0000-0002-2249-8669</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bfdbdec9d6db91cbcad3d3c6ffd1d0c9decdcbd6cc91dcd0d2"><span class="__cf_email__" data-cfemail="7a1e1b0c131e540e0f1616033a14150c1b080e130954191517">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul V. Rucker</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donatella Chianelli</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Williams</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agnès Vidal</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phil B. Alper</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4115-0633" title="Orcid link">http://orcid.org/0000-0002-4115-0633</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Mutnick</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Badry Bursulaya</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Schmeits</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiangdong Wu</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dingjiu Bao</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jocelyn Zoll</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Young Kim</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Todd Groessl</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter McNamara</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">H. Martin Seidel</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valentina Molteni</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Liu</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Phimister</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for Biomedical Research, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean B. Joseph</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan Laffitte</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank David Jones for NMR assistance, Vivian Wang for technical assistance, Wendy Richmond and Perry Gordon for formulation support, Barbara Saechao for bioanalytical support, and Glen Spraggon for X-ray crystallography.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i29" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i29"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i30" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i30"> Abbreviations Used</h2><tr><td class="NLM_term">FXR</td><td class="NLM_def"><p class="first last">farnesoid X Receptor</p></td></tr><tr><td class="NLM_term">NASH</td><td class="NLM_def"><p class="first last">nonalcoholic steatohepatitis</p></td></tr><tr><td class="NLM_term">PBC</td><td class="NLM_def"><p class="first last">primary biliary cholangitis</p></td></tr><tr><td class="NLM_term">PFIC</td><td class="NLM_def"><p class="first last">progressive familial intrahepatic cholestasis</p></td></tr><tr><td class="NLM_term">BSEP</td><td class="NLM_def"><p class="first last">bile salt export pump</p></td></tr><tr><td class="NLM_term">UDCA</td><td class="NLM_def"><p class="first last">ursodeoxycholic acid or ursodiol</p></td></tr><tr><td class="NLM_term">SHP</td><td class="NLM_def"><p class="first last">short heterodimer partner</p></td></tr><tr><td class="NLM_term">FGF15/FGF19</td><td class="NLM_def"><p class="first last">fibroblast growth factor 15/19</p></td></tr><tr><td class="NLM_term">FGFR4</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 4</p></td></tr><tr><td class="NLM_term">LDL</td><td class="NLM_def"><p class="first last">low-density lipoprotein</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">CYP7A1</td><td class="NLM_def"><p class="first last">cytochrome P450 7A1 or cholesterol 7 α-hydroxylase</p></td></tr><tr><td class="NLM_term">SREPB-1c</td><td class="NLM_def"><p class="first last">sterol regulatory element-binding protein 1c</p></td></tr><tr><td class="NLM_term">TGR5</td><td class="NLM_def"><p class="first last">G protein-coupled bile acid receptor 1 (GPBAR1)</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">OCA</td><td class="NLM_def"><p class="first last">obeticholic acid</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time resolved fluorescence</p></td></tr><tr><td class="NLM_term">MDR3</td><td class="NLM_def"><p class="first last">multidrug resistance protein</p></td></tr><tr><td class="NLM_term">ABCB4/ABCB11</td><td class="NLM_def"><p class="first last">ATP-binding cassette, subfamily B member 4/11</p></td></tr><tr><td class="NLM_term">NR1H4</td><td class="NLM_def"><p class="first last">nuclear receptor subfamily 1, group H, member 4</p></td></tr><tr><td class="NLM_term">SRC1</td><td class="NLM_def"><p class="first last">steroid receptor coactivator-1</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">FASSIF</td><td class="NLM_def"><p class="first last">fasted state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">qPCR</td><td class="NLM_def"><p class="first last">quantitative polymerase chain reaction</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Chiang, J. Y. L.</span><span> </span><span class="NLM_article-title">Bile Acids: Regulation of Synthesis</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1955</span><span class="NLM_x">–</span> <span class="NLM_lpage">1966</span><span class="refDoi"> DOI: 10.1194/jlr.R900010-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1194%2Fjlr.R900010-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=19346330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2qsLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1955-1966&author=J.+Y.+L.+Chiang&title=Bile+Acids%3A+Regulation+of+Synthesis&doi=10.1194%2Fjlr.R900010-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acids: regulation of synthesis</span></div><div class="casAuthors">Chiang, John Y. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1955-1966</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Bile acids are physiol. detergents that generate bile flow and facilitate intestinal absorption and transport of lipids, nutrients, and vitamins.  Bile acids also are signaling mols. and inflammatory agents that rapidly activate nuclear receptors and cell signaling pathways that regulate lipid, glucose, and energy metab.  The enterohepatic circulation of bile acids exerts important physiol. functions not only in feedback inhibition of bile acid biosynthesis but also in control of whole-body lipid homeostasis.  In the liver, bile acids activate a nuclear receptor, farnesoid X receptor (FXR), that induces an atypical nuclear receptor small heterodimer partner, which subsequently inhibits nuclear receptors, liver-related homolog-1, and hepatocyte nuclear factor 4α and results in inhibiting transcription of the crit. regulatory gene in bile acid biosynthesis, cholesterol 7α-hydroxylase (cytochrome P 450 7A1; CYP7A1).  In the intestine, FXR induces an intestinal hormone, fibroblast growth factor 15 (FGF15; or FGF19 in humans), which activates hepatic FGF receptor 4 (FGFR4) signaling to inhibit bile acid biosynthesis.  However, the mechanism by which FXR/FGF19/FGFR4 signaling inhibits CYP7A1 remains unknown.  Bile acids are able to induce FGF19 in human hepatocytes, and the FGF19 autocrine pathway may exist in the human livers.  Bile acids and bile acid receptors are therapeutic targets for development of drugs for treatment of cholestatic liver diseases, fatty liver diseases, diabetes, obesity, and metabolic syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzJA-wyOlA7Vg90H21EOLACvtfcHk0ljSaiNZ466KbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2qsLjL&md5=5868a2630c5625dfb63b9ebf9b35d45c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R900010-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R900010-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DJ.%2BY.%2BL.%26atitle%3DBile%2520Acids%253A%2520Regulation%2520of%2520Synthesis%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2009%26volume%3D50%26spage%3D1955%26epage%3D1966%26doi%3D10.1194%2Fjlr.R900010-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Calkin, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontonoz, P.</span><span> </span><span class="NLM_article-title">Transcriptional Integration of Metabolism by the Nuclear Sterol-Activated Receptors LXR and FXR</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span><span class="refDoi"> DOI: 10.1038/nrm3312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1038%2Fnrm3312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=22414897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjslelurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=213-224&author=A.+C.+Calkinauthor=P.+Tontonoz&title=Transcriptional+Integration+of+Metabolism+by+the+Nuclear+Sterol-Activated+Receptors+LXR+and+FXR&doi=10.1038%2Fnrm3312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR</span></div><div class="casAuthors">Calkin, Anna C.; Tontonoz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-224</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nuclear receptors are integrators of hormonal and nutritional signals, mediating changes to metabolic pathways within the body.  Given that modulation of lipid and glucose metab. has been linked to diseases including type 2 diabetes, obesity and atherosclerosis, a greater understanding of pathways that regulate metab. in physiol. and disease is crucial.  The liver X receptors (LXRs) and the farnesoid X receptors (FXRs) are activated by oxysterols and bile acids, resp.  Mounting evidence indicates that these nuclear receptors have essential roles, not only in the regulation of cholesterol and bile acid metab. but also in the integration of sterol, fatty acid and glucose metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomZtKGuHssqbVg90H21EOLACvtfcHk0ljSaiNZ466KbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjslelurs%253D&md5=07454f4951b0af4c1efa251e23cfa264</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm3312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3312%26sid%3Dliteratum%253Aachs%26aulast%3DCalkin%26aufirst%3DA.%2BC.%26aulast%3DTontonoz%26aufirst%3DP.%26atitle%3DTranscriptional%2520Integration%2520of%2520Metabolism%2520by%2520the%2520Nuclear%2520Sterol-Activated%2520Receptors%2520LXR%2520and%2520FXR%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D13%26spage%3D213%26epage%3D224%26doi%3D10.1038%2Fnrm3312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Goodwin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galardi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliewer, S. A.</span><span> </span><span class="NLM_article-title">A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1016/S1097-2765(00)00051-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2FS1097-2765%2800%2900051-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=11030332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntVyhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=517-526&author=B.+Goodwinauthor=S.+A.+Jonesauthor=R.+R.+Priceauthor=M.+A.+Watsonauthor=D.+D.+McKeeauthor=L.+B.+Mooreauthor=C.+Galardiauthor=J.+G.+Wilsonauthor=M.+C.+Lewisauthor=M.+E.+Rothauthor=P.+R.+Maloneyauthor=T.+M.+Willsonauthor=S.+A.+Kliewer&title=A+Regulatory+Cascade+of+the+Nuclear+Receptors+FXR%2C+SHP-1%2C+and+LRH-1+Represses+Bile+Acid+Biosynthesis&doi=10.1016%2FS1097-2765%2800%2900051-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis</span></div><div class="casAuthors">Goodwin, Bryan; Jones, Stacey A.; Price, Roger R.; Watson, Michael A.; McKee, David D.; Moore, Linda B.; Galardi, Cristin; Wilson, Joan G.; Lewis, Michael C.; Roth, Matthew E.; Maloney, Patrick R.; Willson, Timothy M.; Kliewer, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">517-526</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bile acids repress the transcription of cytochrome P 450 7A1 (CYP7A1), which catalyzes the rate-limiting step in bile acid biosynthesis.  Although bile acids activate the farnesoid X receptor (FXR), the mechanism underlying bile acid-mediated repression of CYP7A1 remained unclear.  We have used a potent, nonsteroidal FXR ligand to show that FXR induces expression of small heterodimer partner 1 (SHP-1), an atypical member of the nuclear receptor family that lacks a DNA-binding domain.  SHP-1 represses expression of CYP7A1 by inhibiting the activity of of liver receptor homolog 1 (LRH-1), an orphan nuclear receptor that is known to regulate CYP7A1 expression pos.  This bile acid-activated regulatory cascade provides a mol. basis for the coordinate suppression of CYP7A1 and other genes involved in bile acid biosynthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUMa4HDRxLWrVg90H21EOLACvtfcHk0lhwFhg2RmGfZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntVyhs7o%253D&md5=a2fe31512a56ba5747b1aa8c89b93713</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2900051-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252900051-4%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DPrice%26aufirst%3DR.%2BR.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DGalardi%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26aulast%3DLewis%26aufirst%3DM.%2BC.%26aulast%3DRoth%26aufirst%3DM.%2BE.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26atitle%3DA%2520Regulatory%2520Cascade%2520of%2520the%2520Nuclear%2520Receptors%2520FXR%252C%2520SHP-1%252C%2520and%2520LRH-1%2520Represses%2520Bile%2520Acid%2520Biosynthesis%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D517%26epage%3D526%26doi%3D10.1016%2FS1097-2765%2800%2900051-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Schaap, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trauner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, P. L. M.</span><span> </span><span class="NLM_article-title">Bile Acid Receptors as Targets for Drug Development</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1038/nrgastro.2013.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1038%2Fnrgastro.2013.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=23982684" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=55-67&author=F.+G.+Schaapauthor=M.+Traunerauthor=P.+L.+M.+Jansen&title=Bile+Acid+Receptors+as+Targets+for+Drug+Development&doi=10.1038%2Fnrgastro.2013.151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.151%26sid%3Dliteratum%253Aachs%26aulast%3DSchaap%26aufirst%3DF.%2BG.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DP.%2BL.%2BM.%26atitle%3DBile%2520Acid%2520Receptors%2520as%2520Targets%2520for%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2013%26volume%3D11%26spage%3D55%26epage%3D67%26doi%3D10.1038%2Fnrgastro.2013.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Dyson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirschfield, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuers, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindor, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. E. J.</span><span> </span><span class="NLM_article-title">Novel Therapeutic Targets in Primary Biliary Cirrhosis</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.1038/nrgastro.2015.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1038%2Fnrgastro.2015.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25645973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFCntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=147-158&author=J.+K.+Dysonauthor=G.+M.+Hirschfieldauthor=D.+H.+Adamsauthor=U.+Beuersauthor=D.+A.+Mannauthor=K.+D.+Lindorauthor=D.+E.+J.+Jones&title=Novel+Therapeutic+Targets+in+Primary+Biliary+Cirrhosis&doi=10.1038%2Fnrgastro.2015.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel therapeutic targets in primary biliary cirrhosis</span></div><div class="casAuthors">Dyson, Jessica K.; Hirschfield, Gideon M.; Adams, David H.; Beuers, Ulrich; Mann, Derek A.; Lindor, Keith D.; Jones, David E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">147-158</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Primary biliary cirrhosis (PBC) is a chronic immune-mediated liver disease characterized by progressive cholestasis, biliary fibrosis and eventually cirrhosis.  It results in characteristic symptoms with marked effects on life quality.  The advent of large patient cohorts has challenged the view of PBC as a benign condition treated effectively by the single licensed therapy-ursodeoxycholic acid (UDCA).  UDCA nonresponse or under-response has a major bearing on outcome, substantially increasing the likelihood that liver transplantation will be required or that patients will die of the disease.  In patients with high-risk, treatment-unresponsive or highly symptomatic disease the need for new treatment approaches is clear.  Evolution in our understanding of disease mechanisms is rapidly leading to the advent of new and re-purposed therapeutic agents targeting key processes.  Notable opportunities are offered by targeting what could be considered as the 'upstream' immune response, 'midstream' biliary injury and 'downstream' fibrotic processes.  Combination therapy targeting several pathways or the development of novel agents addressing multiple components of the disease pathway might be required.  Ultimately, PBC therapeutics will require a stratified approach to be adopted in practice.  This Review provides a current perspective on potential approaches to PBC treatment, and highlights the challenges faced in evaluating and implementing those treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulgGBl_f3-rVg90H21EOLACvtfcHk0lhwFhg2RmGfZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFCntLs%253D&md5=8cef843d9d9818aca9bbb4a55c8743ce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2015.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2015.12%26sid%3Dliteratum%253Aachs%26aulast%3DDyson%26aufirst%3DJ.%2BK.%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DAdams%26aufirst%3DD.%2BH.%26aulast%3DBeuers%26aufirst%3DU.%26aulast%3DMann%26aufirst%3DD.%2BA.%26aulast%3DLindor%26aufirst%3DK.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BE.%2BJ.%26atitle%3DNovel%2520Therapeutic%2520Targets%2520in%2520Primary%2520Biliary%2520Cirrhosis%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D12%26spage%3D147%26epage%3D158%26doi%3D10.1038%2Fnrgastro.2015.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Srivastava, A.</span><span> </span><span class="NLM_article-title">Progressive Familial Intrahepatic Cholestasis</span> <span class="citation_source-journal">J. Clin. Exp. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1016/j.jceh.2013.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.jceh.2013.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25755532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A280%3ADC%252BC2MnislGmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=25-36&author=A.+Srivastava&title=Progressive+Familial+Intrahepatic+Cholestasis&doi=10.1016%2Fj.jceh.2013.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Progressive familial intrahepatic cholestasis</span></div><div class="casAuthors">Srivastava Anshu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and experimental hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>
        ISSN:<span class="NLM_cas:issn">0973-6883</span>.
    </div><div class="casAbstract">Progressive familial intrahepatic cholestasis (PFIC) is a group of rare disorders which are caused by defect in bile secretion and present with intrahepatic cholestasis, usually in infancy and childhood.  These are autosomal recessive in inheritance.  The estimated incidence is about 1 per 50,000 to 1 per 100,000 births, although exact prevalence is not known.  These diseases affect both the genders equally and have been reported from all geographical areas.  Based on clinical presentation, laboratory findings, liver histology and genetic defect, these are broadly divided into three types-PFIC type 1, PFIC type 2 and PFIC type 3.  The defect is in ATP8B1 gene encoding the FIC1 protein, ABCB 11 gene encoding BSEP protein and ABCB4 gene encoding MDR3 protein in PFIC1, 2 and 3 respectively.  The basic defect is impaired bile salt secretion in PFIC1/2 whereas in PFIC3, it is reduced biliary phospholipid secretion.  The main clinical presentation is in the form of cholestatic jaundice and pruritus.  Serum gamma glutamyl transpeptidase (GGT) is normal in patients with PFIC1/2 while it is raised in patients with PFIC3.  Treatment includes nutritional support (adequate calories, supplementation of fat soluble vitamins and medium chain triglycerides) and use of medications to relieve pruritus as initial therapy followed by biliary diversion procedures in selected patients.  Ultimately liver transplantation is needed in most patients as they develop progressive liver fibrosis, cirrhosis and end stage liver disease.  Due to the high risk of developing liver tumors in PFIC2 patients, monitoring is recommended from infancy.  Mutation targeted pharmacotherapy, gene therapy and hepatocyte transplantation are being explored as future therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnmBqw7L9yv4xhnOQkIHOxfW6udTcc2eYdzGo9O-l_37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnislGmuw%253D%253D&md5=7d62a527b62fc7972e61dfa10603ba1f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.jceh.2013.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jceh.2013.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DA.%26atitle%3DProgressive%2520Familial%2520Intrahepatic%2520Cholestasis%26jtitle%3DJ.%2520Clin.%2520Exp.%2520Hepatol.%26date%3D2014%26volume%3D4%26spage%3D25%26epage%3D36%26doi%3D10.1016%2Fj.jceh.2013.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Chen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthanarayanan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neimark, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knisely, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strautnieks, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magid, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchy, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shneider, B. L.</span><span> </span><span class="NLM_article-title">Progressive Familial Intrahepatic Cholestasis, Type 1, Is Associated with Decreased Farnesoid X Receptor Activity</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span><span class="refDoi"> DOI: 10.1053/j.gastro.2003.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1053%2Fj.gastro.2003.12.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=756-764&author=F.+Chenauthor=M.+Ananthanarayananauthor=S.+Emreauthor=E.+Neimarkauthor=L.+N.+Bullauthor=A.+S.+Kniselyauthor=S.+S.+Strautnieksauthor=R.+J.+Thompsonauthor=M.+S.+Magidauthor=R.+Gordonauthor=N.+Balasubramanianauthor=F.+J.+Suchyauthor=B.+L.+Shneider&title=Progressive+Familial+Intrahepatic+Cholestasis%2C+Type+1%2C+Is+Associated+with+Decreased+Farnesoid+X+Receptor+Activity&doi=10.1053%2Fj.gastro.2003.12.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2003.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2003.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAnanthanarayanan%26aufirst%3DM.%26aulast%3DEmre%26aufirst%3DS.%26aulast%3DNeimark%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DL.%2BN.%26aulast%3DKnisely%26aufirst%3DA.%2BS.%26aulast%3DStrautnieks%26aufirst%3DS.%2BS.%26aulast%3DThompson%26aufirst%3DR.%2BJ.%26aulast%3DMagid%26aufirst%3DM.%2BS.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DBalasubramanian%26aufirst%3DN.%26aulast%3DSuchy%26aufirst%3DF.%2BJ.%26aulast%3DShneider%26aufirst%3DB.%2BL.%26atitle%3DProgressive%2520Familial%2520Intrahepatic%2520Cholestasis%252C%2520Type%25201%252C%2520Is%2520Associated%2520with%2520Decreased%2520Farnesoid%2520X%2520Receptor%2520Activity%26jtitle%3DGastroenterology%26date%3D2004%26volume%3D126%26spage%3D756%26epage%3D764%26doi%3D10.1053%2Fj.gastro.2003.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Gomez-Ospina, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manickam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shneider, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picarsic, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knisely, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finegold, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzny, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerwinkle, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupski, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plon, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washington, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteus, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berquist, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kambham, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enns, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, D. D.</span><span> </span><span class="NLM_article-title">Mutations in the Nuclear Bile Acid Receptor FXR Cause Progressive Familial Intrahepatic Cholestasis</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">10713</span><span class="refDoi"> DOI: 10.1038/ncomms10713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1038%2Fncomms10713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=26888176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislylu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10713&author=N.+Gomez-Ospinaauthor=C.+J.+Potterauthor=R.+Xiaoauthor=K.+Manickamauthor=M.-S.+Kimauthor=K.+H.+Kimauthor=B.+L.+Shneiderauthor=J.+L.+Picarsicauthor=T.+A.+Jacobsonauthor=J.+Zhangauthor=W.+Heauthor=P.+Liuauthor=A.+S.+Kniselyauthor=M.+J.+Finegoldauthor=D.+M.+Muznyauthor=E.+Boerwinkleauthor=J.+R.+Lupskiauthor=S.+E.+Plonauthor=R.+A.+Gibbsauthor=C.+M.+Engauthor=Y.+Yangauthor=G.+C.+Washingtonauthor=M.+H.+Porteusauthor=W.+E.+Berquistauthor=N.+Kambhamauthor=R.+J.+Singhauthor=F.+Xiaauthor=G.+M.+Ennsauthor=D.+D.+Moore&title=Mutations+in+the+Nuclear+Bile+Acid+Receptor+FXR+Cause+Progressive+Familial+Intrahepatic+Cholestasis&doi=10.1038%2Fncomms10713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis</span></div><div class="casAuthors">Gomez-Ospina, Natalia; Potter, Carol J.; Xiao, Rui; Manickam, Kandamurugu; Kim, Mi-Sun; Kim, Kang Ho; Shneider, Benjamin L.; Picarsic, Jennifer L.; Jacobson, Theodora A.; Zhang, Jing; He, Weimin; Liu, Pengfei; Knisely, A. S.; Finegold, Milton J.; Muzny, Donna M.; Boerwinkle, Eric; Lupski, James R.; Plon, Sharon E.; Gibbs, Richard A.; Eng, Christine M.; Yang, Yaping; Washington, Gabriel C.; Porteus, Matthew H.; Berquist, William E.; Kambham, Neeraja; Singh, Ravinder J.; Xia, Fan; Enns, Gregory M.; Moore, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10713</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neonatal cholestasis is a potentially life-threatening condition requiring prompt diagnosis.  Mutations in several different genes can cause progressive familial intrahepatic cholestasis, but known genes cannot account for all familial cases.  Here we report four individuals from two unrelated families with neonatal cholestasis and mutations in NR1H4, which encodes the farnesoid X receptor (FXR), a bile acid-activated nuclear hormone receptor that regulates bile acid metab.  Clin. features of severe, persistent NR1H4-related cholestasis include neonatal onset with rapid progression to end-stage liver disease, vitamin K-independent coagulopathy, low-to-normal serum gamma-glutamyl transferase activity, elevated serum alpha-fetoprotein and undetectable liver bile salt export pump (ABCB11) expression.  Our findings demonstrate a pivotal function for FXR in bile acid homeostasis and liver protection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8Z3Xkz9YRIrVg90H21EOLACvtfcHk0ljKLuTlEiTTjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislylu7k%253D&md5=9a9da92cbe59e519a1031b7826c5ede8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fncomms10713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10713%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Ospina%26aufirst%3DN.%26aulast%3DPotter%26aufirst%3DC.%2BJ.%26aulast%3DXiao%26aufirst%3DR.%26aulast%3DManickam%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DM.-S.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DShneider%26aufirst%3DB.%2BL.%26aulast%3DPicarsic%26aufirst%3DJ.%2BL.%26aulast%3DJacobson%26aufirst%3DT.%2BA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DKnisely%26aufirst%3DA.%2BS.%26aulast%3DFinegold%26aufirst%3DM.%2BJ.%26aulast%3DMuzny%26aufirst%3DD.%2BM.%26aulast%3DBoerwinkle%26aufirst%3DE.%26aulast%3DLupski%26aufirst%3DJ.%2BR.%26aulast%3DPlon%26aufirst%3DS.%2BE.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DEng%26aufirst%3DC.%2BM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWashington%26aufirst%3DG.%2BC.%26aulast%3DPorteus%26aufirst%3DM.%2BH.%26aulast%3DBerquist%26aufirst%3DW.%2BE.%26aulast%3DKambham%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26aulast%3DXia%26aufirst%3DF.%26aulast%3DEnns%26aufirst%3DG.%2BM.%26aulast%3DMoore%26aufirst%3DD.%2BD.%26atitle%3DMutations%2520in%2520the%2520Nuclear%2520Bile%2520Acid%2520Receptor%2520FXR%2520Cause%2520Progressive%2520Familial%2520Intrahepatic%2520Cholestasis%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10713%26doi%3D10.1038%2Fncomms10713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ali, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindor, K. D.</span><span> </span><span class="NLM_article-title">Recent Advances in the Development of Farnesoid X Receptor Agonists</span> <span class="citation_source-journal">Ann. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">5</span><span class="refDoi"> DOI: 10.3978/j.issn.2305-5839.2014.12.06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.3978%2Fj.issn.2305-5839.2014.12.06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25705637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlGrsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=5&issue=1&author=A.+H.+Aliauthor=E.+J.+Careyauthor=K.+D.+Lindor&title=Recent+Advances+in+the+Development+of+Farnesoid+X+Receptor+Agonists&doi=10.3978%2Fj.issn.2305-5839.2014.12.06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of farnesoid X receptor agonists</span></div><div class="casAuthors">Ali, Ahmad H.; Carey, Elizabeth J.; Lindor, Keith D.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5/1-5/16</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">Farnesoid X receptors (FXRs) are nuclear hormone receptors expressed in high amts. in body tissues that participate in bilirubin metab. including the liver, intestines, and kidneys.  Bile acids (BAs) are the natural ligands of the FXRs.  FXRs regulate the expression of the gene encoding for cholesterol 7 alpha-hydroxylase, which is the rate-limiting enzyme in BA synthesis.  In addn., FXRs play a crit. role in carbohydrate and lipid metab. and regulation of insulin sensitivity.  FXRs also modulate live growth and regeneration during liver injury.  Preclin. studies have shown that FXR activation protects against cholestasis-induced liver injury.  Moreover, FXR activation protects against fatty liver injury in animal models of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and improved hyperlipidemia, glucose intolerance, and insulin sensitivity.  Obeticholic acid (OCA), a 6α-Et deriv. of the natural human BA chenodeoxycholic acid (CDCA) is the first-in-class selective FXR agonist that is ∼100-fold more potent than CDCA.  Preliminary human clin. trials have shown that OCA is safe and effective.  In a phase II clin. trial, administration of OCA was well-tolerated, increased insulin sensitivity and reduced markers of liver inflammation and fibrosis in patients with type II diabetes mellitus and NAFLD.  In two clin. trials of OCA in patients with primary biliary cirrhosis (PBC), a progressive cholestatic liver disease, OCA significantly reduced serum alk. phosphatase (ALP) levels, an important disease marker that correlates well with clin. outcomes of patients with PBC.  Together, these studies suggest that FXR agonists could potentially be used as therapeutic tools in patients suffering from nonalcoholic fatty and cholestatic liver diseases.  Larger and Longer-term studies are currently ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ7xVIB1gg47Vg90H21EOLACvtfcHk0lggruawcmRMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlGrsbjN&md5=5fb87bbd5d25a4b63c615c710884b05b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2305-5839.2014.12.06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2305-5839.2014.12.06%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DA.%2BH.%26aulast%3DCarey%26aufirst%3DE.%2BJ.%26aulast%3DLindor%26aufirst%3DK.%2BD.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Development%2520of%2520Farnesoid%2520X%2520Receptor%2520Agonists%26jtitle%3DAnn.%2520Transl.%2520Med.%26date%3D2015%26volume%3D3%26issue%3D1%26spage%3D5%26doi%3D10.3978%2Fj.issn.2305-5839.2014.12.06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Neuschwander-Tetri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loomba, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanyal, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavine, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Natta, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdelmalek, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalasani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dasarathy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hameed, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCullough, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrault, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonascia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunt, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doo, E.</span><span> </span><span class="NLM_article-title">Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicenter, Randomized, Placebo-Controlled Trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">9972</span><span class="NLM_x">–</span> <span class="NLM_lpage">0065</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61933-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2FS0140-6736%2814%2961933-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=9972-0065&author=B.+A.+Neuschwander-Tetriauthor=R.+Loombaauthor=A.+J.+Sanyalauthor=J.+E.+Lavineauthor=M.+L.+Van+Nattaauthor=M.+F.+Abdelmalekauthor=N.+Chalasaniauthor=S.+Dasarathyauthor=A.+M.+Diehlauthor=B.+Hameedauthor=K.+V.+Kowdleyauthor=A.+McCulloughauthor=N.+Terraultauthor=J.+M.+Clarkauthor=J.+Tonasciaauthor=E.+M.+Bruntauthor=D.+E.+Kleinerauthor=E.+Doo&title=Farnesoid+X+Nuclear+Receptor+Ligand+Obeticholic+Acid+for+Non-Cirrhotic%2C+Non-Alcoholic+Steatohepatitis+%28FLINT%29%3A+A+Multicenter%2C+Randomized%2C+Placebo-Controlled+Trial&doi=10.1016%2FS0140-6736%2814%2961933-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961933-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961933-4%26sid%3Dliteratum%253Aachs%26aulast%3DNeuschwander-Tetri%26aufirst%3DB.%2BA.%26aulast%3DLoomba%26aufirst%3DR.%26aulast%3DSanyal%26aufirst%3DA.%2BJ.%26aulast%3DLavine%26aufirst%3DJ.%2BE.%26aulast%3DVan%2BNatta%26aufirst%3DM.%2BL.%26aulast%3DAbdelmalek%26aufirst%3DM.%2BF.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DDasarathy%26aufirst%3DS.%26aulast%3DDiehl%26aufirst%3DA.%2BM.%26aulast%3DHameed%26aufirst%3DB.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DMcCullough%26aufirst%3DA.%26aulast%3DTerrault%26aufirst%3DN.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DTonascia%26aufirst%3DJ.%26aulast%3DBrunt%26aufirst%3DE.%2BM.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DDoo%26aufirst%3DE.%26atitle%3DFarnesoid%2520X%2520Nuclear%2520Receptor%2520Ligand%2520Obeticholic%2520Acid%2520for%2520Non-Cirrhotic%252C%2520Non-Alcoholic%2520Steatohepatitis%2520%2528FLINT%2529%253A%2520A%2520Multicenter%252C%2520Randomized%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D9972%26epage%3D0065%26doi%3D10.1016%2FS0140-6736%2814%2961933-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Hirschfield, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luketic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodhenheimer, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parés, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trauner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marschall, H.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adorini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beecher-Jones, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelloe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böhm, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D.</span><span> </span><span class="NLM_article-title">Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">–</span> <span class="NLM_lpage">761</span><span class="refDoi"> DOI: 10.1053/j.gastro.2014.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1053%2Fj.gastro.2014.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25500425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFGmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=751-761&author=G.+M.+Hirschfieldauthor=A.+Masonauthor=V.+Luketicauthor=K.+Lindorauthor=S.+C.+Gordonauthor=M.+Mayoauthor=K.+V.+Kowdleyauthor=C.+Vincentauthor=H.+C.+Bodhenheimerauthor=A.+Par%C3%A9sauthor=M.+Traunerauthor=H.-U.+Marschallauthor=L.+Adoriniauthor=C.+Sciaccaauthor=T.+Beecher-Jonesauthor=E.+Castelloeauthor=O.+B%C3%B6hmauthor=D.+Shapiro&title=Efficacy+of+Obeticholic+Acid+in+Patients+With+Primary+Biliary+Cirrhosis+and+Inadequate+Response+to+Ursodeoxycholic+Acid&doi=10.1053%2Fj.gastro.2014.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid</span></div><div class="casAuthors">Hirschfield, Gideon M.; Mason, Andrew; Luketic, Velimir; Lindor, Keith; Gordon, Stuart C.; Mayo, Marlyn; Kowdley, Kris V.; Vincent, Catherine; Bodhenheimer, Henry C., Jr.; Pares, Albert; Trauner, Michael; Marschall, Hanns-Ulrich; Adorini, Luciano; Sciacca, Cathi; Beecher-Jones, Tessa; Castelloe, Erin; Bohm, Olaf; Shapiro, David</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">751-761.e8</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We evaluated the efficacy and safety of obeticholic acid (OCA, α-ethylchenodeoxycholic acid) in a randomized controlled trial of patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid therapy.  We performed a double-blind study of 165 patients with primary biliary cirrhosis (95% women) and levels of alk. phosphatase (ALP) 1.5- to 10-fold the upper limit of normal.  Patients were randomly assigned to groups given 10 mg, 25 mg, or 50 mg doses of OCA or placebo, once daily for 3 mo.  Patients maintained their existing dose of ursodeoxycholic acid throughout the study.  The primary outcome was change in level of ALP from baseline (day 0) until the end of the study (day 85 or early termination).  We also performed an open-label extension of the trial in which 78 patients were enrolled and 61 completed the first year.  OCA was superior to placebo in achieving the primary end point.  Subjects given OCA had statistically significant relative redns. in mean ALP from baseline to the end of the study (P < .0001 all OCA groups vs placebo).  Levels of ALP decreased 21%-25% on av. from baseline in the OCA groups and 3% in the placebo group.  Sixty-nine percent (68 of 99) of patients given OCA had at least a 20% redn. in ALP compared with 8% (3 of 37) of patients given placebo (P < .0003).  Among secondary end points, levels of γ-glutamyl transpeptidase decreased 48%-63%, on av., among subjects given OCA, vs a 7% decrease in the group given placebo; levels of alanine aminotransferase decreased 21%-35% on av. among subjects given OCA vs none of the patients given placebo.  Pruritus was the principal adverse event; incidence values in the OCA 10 mg, 25 mg, and 50 mg groups were 47% (not significantly different), 87% (P < .0003), and 80% (P < .006), resp., vs 50% in the placebo group.  In the extension study, levels of ALP continued to decrease to a mean level of 202 ± 11 U/L after 12 mo vs 285 ± 15 U/L at baseline.  Daily doses of OCA, ranging from 10 to 50 mg, significantly reduced levels of ALP, γ-glutamyl transpeptidase, and alanine aminotransferase, compared with placebo, in patients with primary biliary cirrhosis who had inadequate responses to ursodeoxycholic acid.  The incidence and severity of pruritus were lowest among patients who received 10 mg/d OCA.  Biochem. responses to OCA were maintained in a 12-mo open-label extension trial.  ClinicalTrials.gov ID: NCT00550862.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEVC_XNJt84bVg90H21EOLACvtfcHk0lggruawcmRMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFGmtbc%253D&md5=88ad43649d1dec228af49f4570247523</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2014.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2014.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DMason%26aufirst%3DA.%26aulast%3DLuketic%26aufirst%3DV.%26aulast%3DLindor%26aufirst%3DK.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DMayo%26aufirst%3DM.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DVincent%26aufirst%3DC.%26aulast%3DBodhenheimer%26aufirst%3DH.%2BC.%26aulast%3DPar%25C3%25A9s%26aufirst%3DA.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DMarschall%26aufirst%3DH.-U.%26aulast%3DAdorini%26aufirst%3DL.%26aulast%3DSciacca%26aufirst%3DC.%26aulast%3DBeecher-Jones%26aufirst%3DT.%26aulast%3DCastelloe%26aufirst%3DE.%26aulast%3DB%25C3%25B6hm%26aufirst%3DO.%26aulast%3DShapiro%26aufirst%3DD.%26atitle%3DEfficacy%2520of%2520Obeticholic%2520Acid%2520in%2520Patients%2520With%2520Primary%2520Biliary%2520Cirrhosis%2520and%2520Inadequate%2520Response%2520to%2520Ursodeoxycholic%2520Acid%26jtitle%3DGastroenterology%26date%3D2015%26volume%3D148%26spage%3D751%26epage%3D761%26doi%3D10.1053%2Fj.gastro.2014.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Bowlus, C.</span><span> </span><span class="NLM_article-title">Obeticholic Acid for the Treatment of Primary Biliary Cholangitis in Adult Patients: Clinical Utility and Patient Selection</span> <span class="citation_source-journal">Hepatic Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.2147/HMER.S91709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.2147%2FHMER.S91709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=27621676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A280%3ADC%252BC2svgtVKjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=89-95&author=C.+Bowlus&title=Obeticholic+Acid+for+the+Treatment+of+Primary+Biliary+Cholangitis+in+Adult+Patients%3A+Clinical+Utility+and+Patient+Selection&doi=10.2147%2FHMER.S91709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection</span></div><div class="casAuthors">Bowlus Christopher L</div><div class="citationInfo"><span class="NLM_cas:title">Hepatic medicine : evidence and research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-95</span>
        ISSN:<span class="NLM_cas:issn">1179-1535</span>.
    </div><div class="casAbstract">Primary biliary cholangitis (PBC), previously known as primary biliary "cirrhosis", is a rare autoimmune liver disease characterized by the hallmark autoantibodies to mitochondrial antigens and immune-mediated destruction of small bile duct epithelial cells leading to cholestasis and cirrhosis.  Surprisingly, while immune modulators have not been effective in the treatment of PBC, supplementation with the hydrophilic bile acid (BA) ursodeoxycholic acid (UDCA) has been demonstrated to slow the disease progression.  However, a significant minority of PBC patients do not have a complete response to UDCA and remain at risk of continued disease progression.  Although the mechanisms of action are not well understood, UDCA provided proof of concept for BA therapy in PBC.  Obeticholic acid (OCA), a novel derivative of the human BA chenodeoxycholic acid, is a potent agonist of the nuclear hormone receptor farnesoid X receptor, which regulates BA synthesis and transport.  A series of clinical trials of OCA in PBC, primarily in combination with UDCA, have established that OCA leads to significant reductions in serum alkaline phosphatase that are predicted to lead to improved clinical outcomes, while dose-dependent pruritus has been the most common adverse effect.  On the basis of these studies, OCA was given conditional approval by the US Food and Drug Administration with plans to establish the long-term clinical efficacy of OCA in patients with advanced PBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrtYKwZhE3_sULxIEhxUjPfW6udTcc2eYNCyRBdMp0gLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svgtVKjtg%253D%253D&md5=aae2c3b5bce3ace0442a0e85b925200d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2147%2FHMER.S91709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHMER.S91709%26sid%3Dliteratum%253Aachs%26aulast%3DBowlus%26aufirst%3DC.%26atitle%3DObeticholic%2520Acid%2520for%2520the%2520Treatment%2520of%2520Primary%2520Biliary%2520Cholangitis%2520in%2520Adult%2520Patients%253A%2520Clinical%2520Utility%2520and%2520Patient%2520Selection%26jtitle%3DHepatic%2520Med.%26date%3D2016%26volume%3D8%26spage%3D89%26epage%3D95%26doi%3D10.2147%2FHMER.S91709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pencek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liberman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooshmand-Rad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. A.</span><span> </span><span class="NLM_article-title">Effects of Obeticholic Acid on Lipoprotein Metabolism in Healthy Volunteers</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">936</span><span class="NLM_x">–</span> <span class="NLM_lpage">940</span><span class="refDoi"> DOI: 10.1111/dom.12681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1111%2Fdom.12681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=27109453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOmsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=936-940&author=R.+Pencekauthor=T.+Marmonauthor=J.+D.+Rothauthor=A.+Libermanauthor=R.+Hooshmand-Radauthor=M.+A.+Young&title=Effects+of+Obeticholic+Acid+on+Lipoprotein+Metabolism+in+Healthy+Volunteers&doi=10.1111%2Fdom.12681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers</span></div><div class="casAuthors">Pencek, R.; Marmon, T.; Roth, J. D.; Liberman, A.; Hooshmand-Rad, R.; Young, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">936-940</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The bile acid analog obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist in development for treatment of several chronic liver diseases.  FXR activation regulates lipoprotein homeostasis.  The effects of OCA on cholesterol and lipoprotein metab. in healthy individuals were assessed.  Two phase I studies were conducted to evaluate the effects of repeated oral doses of 5, 10 or 25 mg OCA on lipid variables after 14 or 20 days of consecutive administration in 68 healthy adults.  Changes in HDL and LDL cholesterol levels were examd., in addn. to NMR anal. of particle sizes and sub-fraction concns.  OCA elicited changes in circulating cholesterol and particle size of LDL and HDL.  OCA decreased HDL cholesterol and increased LDL cholesterol, independently of dose.  HDL particle concns. declined as a result of a redn. in medium and small HDL.  Total LDL particle concns. increased because of an increase in large LDL particles.  Changes in lipoprotein metab. attributable to OCA in healthy individuals were found to be consistent with previously reported changes in patients receiving OCA with non-alc. fatty liver disease or non-alc. steatohepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9crw5OdOUkLVg90H21EOLACvtfcHk0liVF40lv-dxOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOmsrzJ&md5=154e73d2b56a2b61ee5fe3bcbd8e2ad7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fdom.12681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12681%26sid%3Dliteratum%253Aachs%26aulast%3DPencek%26aufirst%3DR.%26aulast%3DMarmon%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DLiberman%26aufirst%3DA.%26aulast%3DHooshmand-Rad%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26atitle%3DEffects%2520of%2520Obeticholic%2520Acid%2520on%2520Lipoprotein%2520Metabolism%2520in%2520Healthy%2520Volunteers%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26spage%3D936%26epage%3D940%26doi%3D10.1111%2Fdom.12681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="ref14_1"><span><div class="note"><p class="first last">A Multipart, Double Blind Study to Assess Safety, Tolerability and Efficacy of LJN452 in PBC Patients. <a href="http://ClinicalTrials.gov" class="ext-link">ClinicalTrials.gov</a> Identifier: NCT02516605.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Multipart%2C+Double+Blind+Study+to+Assess+Safety%2C+Tolerability+and+Efficacy+of+LJN452+in+PBC+Patients.+ClinicalTrials.gov+Identifier%3A+NCT02516605."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref14_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><div class="note"><p class="first last">Safety, Tolerability and Efficacy Study of 12 Weeks LJN452 Treatment in NASH Patients (FLIGHT-FXR). <a href="http://ClinicalTrials.gov" class="ext-link">ClinicalTrials.gov</a> Identifier: NCT02855164.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety%2C+Tolerability+and+Efficacy+Study+of+12+Weeks+LJN452+Treatment+in+NASH+Patients+%28FLIGHT-FXR%29.+ClinicalTrials.gov+Identifier%3A+NCT02855164."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Maloney, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fivush, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plunket, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span> </span><span class="NLM_article-title">Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2971</span><span class="NLM_x">–</span> <span class="NLM_lpage">2974</span><span class="refDoi"> DOI: 10.1021/jm0002127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0002127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVSiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2971-2974&author=P.+R.+Maloneyauthor=D.+J.+Parksauthor=C.+D.+Haffnerauthor=A.+M.+Fivushauthor=G.+Chandraauthor=K.+D.+Plunketauthor=K.+L.+Creechauthor=L.+B.+Mooreauthor=J.+G.+Wilsonauthor=M.+C.+Lewisauthor=S.+A.+Jonesauthor=T.+M.+Willson&title=Identification+of+a+Chemical+Tool+for+the+Orphan+Nuclear+Receptor+FXR&doi=10.1021%2Fjm0002127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR</span></div><div class="casAuthors">Maloney, Patrick R.; Parks, Derek J.; Haffner, Curt D.; Fivush, Adam M.; Chandra, Gyan; Plunket, Kelli D.; Creech, Katrina L.; Moore, Linda B.; Wilson, Joan G.; Lewis, Michael C.; Jones, Stacey A.; Willson, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2971-2974</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors have identified the first high-affinity nonsteroidal FXR nuclear receptor agonist through use of high-throughput screening and combinatorial chem.  This agonist, GW4064, will be a valuable chem. tool for studying the role of FXR in mammalian physiol. and disease.  The data also establishes triglyceride lowering as a surrogate pharmacol. response to the activation of FXR receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry7sdXiiBvsLVg90H21EOLACvtfcHk0liVF40lv-dxOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVSiur0%253D&md5=111bd63144e2af62eee81b4d706a2672</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm0002127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0002127%26sid%3Dliteratum%253Aachs%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DHaffner%26aufirst%3DC.%2BD.%26aulast%3DFivush%26aufirst%3DA.%2BM.%26aulast%3DChandra%26aufirst%3DG.%26aulast%3DPlunket%26aufirst%3DK.%2BD.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26aulast%3DLewis%26aufirst%3DM.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26atitle%3DIdentification%2520of%2520a%2520Chemical%2520Tool%2520for%2520the%2520Orphan%2520Nuclear%2520Receptor%2520FXR%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2971%26epage%3D2974%26doi%3D10.1021%2Fjm0002127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Akwabi-Ameyaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spearing, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span> </span><span class="NLM_article-title">Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Alternative Replacements of the Stilbene</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6154</span><span class="NLM_x">–</span> <span class="NLM_lpage">6160</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.08.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2011.08.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=21890356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2qsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6154-6160&author=A.+Akwabi-Ameyawauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=A.+B.+Millerauthor=F.+Navasauthor=D.+J.+Parksauthor=P.+K.+Spearingauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Conformationally+Constrained+Farnesoid+X+Receptor+%28FXR%29+Agonists%3A+Alternative+Replacements+of+the+Stilbene&doi=10.1016%2Fj.bmcl.2011.08.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene</span></div><div class="casAuthors">Akwabi-Ameyaw, Adwoa; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Madauss, Kevin P.; Marr, Harry B.; Miller, Aaron B.; Navas, Frank, III; Parks, Derek J.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6154-6160</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To further explore the optimum placement of the acid moiety in conformationally constrained analogs of GW 4064, a series of stilbene replacements were prepd.  The benzothiophene I [X = S] and the indole I [X = NH] display the optimal orientation of the carboxylate for enhanced FXR agonist potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_-bx-WCdaVbVg90H21EOLACvtfcHk0lgtlaXLpyvL9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2qsr7E&md5=f0126e099a3c1d2abd52a2206979ce39</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.08.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.08.034%26sid%3Dliteratum%253Aachs%26aulast%3DAkwabi-Ameyaw%26aufirst%3DA.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DNavas%26aufirst%3DF.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DSpearing%26aufirst%3DP.%2BK.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DConformationally%2520Constrained%2520Farnesoid%2520X%2520Receptor%2520%2528FXR%2529%2520Agonists%253A%2520Alternative%2520Replacements%2520of%2520the%2520Stilbene%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6154%26epage%3D6160%26doi%3D10.1016%2Fj.bmcl.2011.08.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Bass, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFadyen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navas, F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, T. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spearing, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span> </span><span class="NLM_article-title">Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Heteroaryl Replacements of the Naphthalene</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1206</span><span class="NLM_x">–</span> <span class="NLM_lpage">1213</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2010.12.089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=21256005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1amt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1206-1213&author=J.+Y.+Bassauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=R.+B.+McFadyenauthor=A.+B.+Millerauthor=W.+Y.+Millsauthor=F.+Navasauthor=D.+J.+Parksauthor=T.+L.+Smalleyauthor=P.+K.+Spearingauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Conformationally+Constrained+Farnesoid+X+Receptor+%28FXR%29+Agonists%3A+Heteroaryl+Replacements+of+the+Naphthalene&doi=10.1016%2Fj.bmcl.2010.12.089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene</span></div><div class="casAuthors">Bass, Jonathan Y.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Mills, Wendy Y.; Navas, Frank, III; Parks, Derek J.; Smalley, Terrence L., Jr.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1206-1213</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To improve on the drug properties of GSK8062, a series of heteroaryl bicyclic naphthalene replacements were prepd.  The quinoline I was an equipotent FXR agonist with improved drug developability parameters relative to GSK8062.  In addn., I lowered body wt. gain and serum glucose in a DIO mouse model of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopkMv0ii-Ef7Vg90H21EOLACvtfcHk0lgtlaXLpyvL9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1amt74%253D&md5=7bff29efbc4421b1641fdd20eddcb064</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.089%26sid%3Dliteratum%253Aachs%26aulast%3DBass%26aufirst%3DJ.%2BY.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMcFadyen%26aufirst%3DR.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DMills%26aufirst%3DW.%2BY.%26aulast%3DNavas%26aufirst%3DF.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DSmalley%26aufirst%3DT.%2BL.%26aulast%3DSpearing%26aufirst%3DP.%2BK.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DConformationally%2520Constrained%2520Farnesoid%2520X%2520Receptor%2520%2528FXR%2529%2520Agonists%253A%2520Heteroaryl%2520Replacements%2520of%2520the%2520Naphthalene%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1206%26epage%3D1213%26doi%3D10.1016%2Fj.bmcl.2010.12.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Smalley, T. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span> </span><span class="NLM_article-title">Novel Heterocyclic Scaffolds of GW4064 as Farnesoid X Receptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2014.11.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25499883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWhsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=280-284&author=T.+L.+Smalleyauthor=S.+Boggsauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=I.+Kaldorauthor=D.+J.+Parks&title=Novel+Heterocyclic+Scaffolds+of+GW4064+as+Farnesoid+X+Receptor+Agonists&doi=10.1016%2Fj.bmcl.2014.11.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists</span></div><div class="casAuthors">Smalley, Terrence L., Jr.; Boggs, Sharon; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Kaldor, Istvan; Parks, Derek J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-284</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The farnesoid X receptor (FXR) may play a crucial role in a no. of metabolic diseases and, as such, could potentially serve as a target for the development of therapeutics as a treatment for those diseases.  Previous work has described GW4064 as an FXR agonist with an interesting activity profile.  This manuscript will describe the synthesis of novel analogs of GW4064, e.g. I, and the activity profile of those analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosZMu7uSERubVg90H21EOLACvtfcHk0lgtlaXLpyvL9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWhsL3N&md5=8ed3153fecf8c021d55618eb4bcdd97d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.050%26sid%3Dliteratum%253Aachs%26aulast%3DSmalley%26aufirst%3DT.%2BL.%26aulast%3DBoggs%26aufirst%3DS.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DKaldor%26aufirst%3DI.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26atitle%3DNovel%2520Heterocyclic%2520Scaffolds%2520of%2520GW4064%2520as%2520Farnesoid%2520X%2520Receptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D280%26epage%3D284%26doi%3D10.1016%2Fj.bmcl.2014.11.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Bass, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFadyen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span> </span><span class="NLM_article-title">Substituted Isoxazole Analogs of Farnesoid X Receptor (FXR) Agonist GW4064</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2969</span><span class="NLM_x">–</span> <span class="NLM_lpage">2973</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2009.04.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=19410460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVeku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2969-2973&author=J.+Y.+Bassauthor=R.+D.+Caldwellauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=R.+B.+McFadyenauthor=A.+B.+Millerauthor=D.+J.+Parksauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Substituted+Isoxazole+Analogs+of+Farnesoid+X+Receptor+%28FXR%29+Agonist+GW4064&doi=10.1016%2Fj.bmcl.2009.04.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064</span></div><div class="casAuthors">Bass, Jonathan Y.; Caldwell, Richard D.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Parks, Derek J.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2969-2973</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from the known FXR agonist GW 4064 (I) (R1 = i-Pr, R2 = 2,6-Cl2C6H3), a series of alternately 3,5-substituted isoxazoles was prepd.  A subset of this series, with a tether between the isoxazole ring and the 3-position aryl substituent, were equipotent FXR agonists to GW 4064, with the analog I (R1 = i-Pr, R2 = 2,6-Me2C6H3OCH2) having greater FRET FXR potency than GW 4064.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmilCrO1yO1LVg90H21EOLACvtfcHk0lgmP8kH7m_6ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVeku70%253D&md5=38b2a1b54be6ef8a3d58f6550a1ff16f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DBass%26aufirst%3DJ.%2BY.%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMcFadyen%26aufirst%3DR.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DSubstituted%2520Isoxazole%2520Analogs%2520of%2520Farnesoid%2520X%2520Receptor%2520%2528FXR%2529%2520Agonist%2520GW4064%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2969%26epage%3D2973%26doi%3D10.1016%2Fj.bmcl.2009.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Akwabi-Ameyaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFadyen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navas, F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spearing, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span> </span><span class="NLM_article-title">Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Naphthoic Acid-Based Analogs of GW 4064</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4339</span><span class="NLM_x">–</span> <span class="NLM_lpage">4343</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2008.06.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=18621523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVeqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4339-4343&author=A.+Akwabi-Ameyawauthor=J.+Y.+Bassauthor=R.+D.+Caldwellauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=S.+A.+Jonesauthor=I.+Kaldorauthor=Y.+Liuauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=R.+B.+McFadyenauthor=A.+B.+Millerauthor=F.+Navasauthor=D.+J.+Parksauthor=P.+K.+Spearingauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Conformationally+Constrained+Farnesoid+X+Receptor+%28FXR%29+Agonists%3A+Naphthoic+Acid-Based+Analogs+of+GW+4064&doi=10.1016%2Fj.bmcl.2008.06.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064</span></div><div class="casAuthors">Akwabi-Ameyaw, Adwoa; Bass, Jonathan Y.; Caldwell, Richard D.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Jones, Stacey A.; Kaldor, Istvan; Liu, Yaping; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Navas, Frank, III; Parks, Derek J.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4339-4343</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Starting from the known FXR agonist GW 4064 I, a series of stilbene replacements were prepd.  The 6-substituted 1-naphthoic acid II was an equipotent FXR agonist with improved developability parameters relative to I.  Analog II also reduced the severity of cholestasis in the ANIT acute cholestatic rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0IzFOXAysDrVg90H21EOLACvtfcHk0lgmP8kH7m_6ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVeqtbk%253D&md5=1007683ff89fa4257f063c63cd16481b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.073%26sid%3Dliteratum%253Aachs%26aulast%3DAkwabi-Ameyaw%26aufirst%3DA.%26aulast%3DBass%26aufirst%3DJ.%2BY.%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DKaldor%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMcFadyen%26aufirst%3DR.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DNavas%26aufirst%3DF.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DSpearing%26aufirst%3DP.%2BK.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DConformationally%2520Constrained%2520Farnesoid%2520X%2520Receptor%2520%2528FXR%2529%2520Agonists%253A%2520Naphthoic%2520Acid-Based%2520Analogs%2520of%2520GW%25204064%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4339%26epage%3D4343%26doi%3D10.1016%2Fj.bmcl.2008.06.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Abel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlüter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambruch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perović-Ottstadt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deuschle, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremoser, C.</span><span> </span><span class="NLM_article-title">Synthesis and Pharmacological Validation of a Novel Series of Non-Steroidal FXR Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4911</span><span class="NLM_x">–</span> <span class="NLM_lpage">4917</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2010.06.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=20638278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlans7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4911-4917&author=U.+Abelauthor=T.+Schl%C3%BCterauthor=A.+Schulzauthor=E.+Hambruchauthor=C.+Steeneckauthor=M.+Hornbergerauthor=T.+Hoffmannauthor=S.+Perovi%C4%87-Ottstadtauthor=O.+Kinzelauthor=M.+Burnetauthor=U.+Deuschleauthor=C.+Kremoser&title=Synthesis+and+Pharmacological+Validation+of+a+Novel+Series+of+Non-Steroidal+FXR+Agonists&doi=10.1016%2Fj.bmcl.2010.06.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists</span></div><div class="casAuthors">Abel, Ulrich; Schlueter, Thomas; Schulz, Andreas; Hambruch, Eva; Steeneck, Christoph; Hornberger, Martin; Hoffmann, Thomas; Perovic-Ottstadt, Sanja; Kinzel, Olaf; Burnet, Michael; Deuschle, Ulrich; Kremoser, Claus</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4911-4917</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To overcome the known liabilities of known farnesoid receptor agonist GW4064, a series of analogs was synthesized where the stilbene double bond was replaced by an oxymethylene or amino-methylene linker connecting a terminal benzoic acid with a substituted heteroaryl in the middle ring position.  Some compds., such as I (R = i-Pr, cyclopropyl), were found to have an increased potency in vitro that caused dose-dependent redn. of plasma triglycerides and cholesterol in db/db mice down to 2 × 1 mg/kg/day upon oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGx-787FlxpbVg90H21EOLACvtfcHk0lgmP8kH7m_6ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlans7k%253D&md5=26ea6a737e9d3844a7b32043e2b6a412</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.084%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DU.%26aulast%3DSchl%25C3%25BCter%26aufirst%3DT.%26aulast%3DSchulz%26aufirst%3DA.%26aulast%3DHambruch%26aufirst%3DE.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DHornberger%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DPerovi%25C4%2587-Ottstadt%26aufirst%3DS.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DBurnet%26aufirst%3DM.%26aulast%3DDeuschle%26aufirst%3DU.%26aulast%3DKremoser%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Validation%2520of%2520a%2520Novel%2520Series%2520of%2520Non-Steroidal%2520FXR%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4911%26epage%3D4917%26doi%3D10.1016%2Fj.bmcl.2010.06.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Gege, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremoser, C.</span><span> </span><span class="NLM_article-title">Knocking on FXR’s Door:The “Hammerhead”-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2158</span><span class="refDoi"> DOI: 10.2174/1568026614666141112094430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.2174%2F1568026614666141112094430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25388536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2rsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=2143-2158&author=C.+Gegeauthor=O.+Kinzelauthor=C.+Steeneckauthor=A.+Schulzauthor=C.+Kremoser&title=Knocking+on+FXR%E2%80%99s+Door%3AThe+%E2%80%9CHammerhead%E2%80%9D-Structure+Series+of+FXRs+Agonists+-+Amphiphilic+Isoxazoles+with+Potent+In+Vitro+and+In+Vivo+Activities&doi=10.2174%2F1568026614666141112094430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities</span></div><div class="casAuthors">Gege, Christian; Kinzel, Olaf; Steeneck, Christoph; Schulz, Andreas; Kremoser, Claus</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2143-2158</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The Farnesoid X Receptor (FXR) was recently validated in clin. studies using the bile acid analog Obeticholic Acid (OCA) as an attractive drug target for liver diseases such as Primary Biliary Cirrhosis (PBC) or Non-alc. Steatohepatitis (NASH).  OCA, however, turned out to induce cholesterol- related side effects upon prolonged treatment and it shows bile acid like pharmacokinetics.  The quest for synthetic non-steroidal FXR agonists with general drug likeliness and improved pharmacokinetic and - dynamic properties has started more than a decade ago: The first non-steroidal and selective FXR agonist with decent submicromolar potency, GW4064, was patented in 1998 and published in 2000.  Since then, many pharmaceutical companies have taken GW4064 as a structural template for their efforts in identifying novel patentable FXR agonists with the GW-derived trisubstituted isoxazole general structure.  However, so far only one compd. out of these different series has made it into the early stages of clin. development: The Px-102/Px-104 from Phenex is currently tested in a phase IIa study in patients with Non-Alc. Fatty Liver Disease (NAFLD).  In this review we try to summarize from the patent and scientific literature the attempts to improve the GW4064 structure into different directions.  Furthermore, we suggest directions for further improvements of this special class of synthetic FXR agonists which all display the typical "hammerhead"-conformation in the FXR ligand binding pocket that provides the basis for their impressive in vitro and in vivo potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAsJf5mf9ParVg90H21EOLACvtfcHk0lguOH10vsd7gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2rsLzE&md5=67e6c243603021ec6383f5e71b692b2e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F1568026614666141112094430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026614666141112094430%26sid%3Dliteratum%253Aachs%26aulast%3DGege%26aufirst%3DC.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DSchulz%26aufirst%3DA.%26aulast%3DKremoser%26aufirst%3DC.%26atitle%3DKnocking%2520on%2520FXR%25E2%2580%2599s%2520Door%253AThe%2520%25E2%2580%259CHammerhead%25E2%2580%259D-Structure%2520Series%2520of%2520FXRs%2520Agonists%2520-%2520Amphiphilic%2520Isoxazoles%2520with%2520Potent%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Activities%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26spage%3D2143%26epage%3D2158%26doi%3D10.2174%2F1568026614666141112094430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Xu, Y.</span><span> </span><span class="NLM_article-title">Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6553</span><span class="NLM_x">–</span> <span class="NLM_lpage">6579</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00342</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00342" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6553-6579&author=Y.+Xu&title=Recent+Progress+on+Bile+Acid+Receptor+Modulators+for+Treatment+of+Metabolic+Diseases&doi=10.1021%2Facs.jmedchem.5b00342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases</span></div><div class="casAuthors">Xu, Yanping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6553-6579</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bile acids are steroid-derived mols. synthesized in the liver, secreted from hepatocytes into the bile canaliculi, and subsequently stored in the gall bladder.  During the feeding, bile flows into the duodenum, where it contributes to the solubilization and digestion of lipid-sol. nutrients.  After a meal, bile-acid levels increase in the intestine, liver, and also in the systemic circulation.  Therefore, serum bile-acid levels serve as an important sensing mechanism for nutrient and energy.  Recent studies have described bile acids as versatile signaling mols. endowed with systemic endocrine functions.  Bile acids are ligands for G-protein coupled receptors (GPCRs) such as TGR5 (also known as GPBAR1, M-BAR, and BG37) and nuclear hormone receptors including farnesoid X receptor (FXR; also known as NR1H4).  Acting through these diverse signaling pathways, bile acids regulate triglyceride, cholesterol, glucose homeostasis, and energy expenditure.  These bile-acid-controlled signaling pathways have become the source of promising novel drug targets to treat common metabolic and hepatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGuPZaBpniNrVg90H21EOLACvtfcHk0lguOH10vsd7gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGntLc%253D&md5=6c31dcbb9eed8fb19ca78b6912b44e39</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00342%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26atitle%3DRecent%2520Progress%2520on%2520Bile%2520Acid%2520Receptor%2520Modulators%2520for%2520Treatment%2520of%2520Metabolic%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6553%26epage%3D6579%26doi%3D10.1021%2Facs.jmedchem.5b00342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Genin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bueno, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agejas Francisco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manninen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bocchinfuso, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montrose-Rafizadeh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannady, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stille, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reidy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, L. F.</span><span> </span><span class="NLM_article-title">Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-Dichlorophenyl)isoxazol-4-Yl]methoxy}piperidin-1-Yl)-1-Methyl-1H-Indole-3-Carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9768</span><span class="NLM_x">–</span> <span class="NLM_lpage">9772</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01161</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01161" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9768-9772&author=M.+J.+Geninauthor=A.+B.+Buenoauthor=J.+Agejas+Franciscoauthor=P.+R.+Manninenauthor=W.+P.+Bocchinfusoauthor=C.+Montrose-Rafizadehauthor=E.+A.+Cannadyauthor=T.+M.+Jonesauthor=J.+R.+Stilleauthor=E.+Raddadauthor=C.+Reidyauthor=A.+Coxauthor=M.+D.+Michaelauthor=L.+F.+Michael&title=Discovery+of+6-%284-%7B%5B5-Cyclopropyl-3-%282%2C6-Dichlorophenyl%29isoxazol-4-Yl%5Dmethoxy%7Dpiperidin-1-Yl%29-1-Methyl-1H-Indole-3-Carboxylic+Acid%3A+A+Novel+FXR+Agonist+for+the+Treatment+of+Dyslipidemia&doi=10.1021%2Facs.jmedchem.5b01161"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01161%26sid%3Dliteratum%253Aachs%26aulast%3DGenin%26aufirst%3DM.%2BJ.%26aulast%3DBueno%26aufirst%3DA.%2BB.%26aulast%3DAgejas%2BFrancisco%26aufirst%3DJ.%26aulast%3DManninen%26aufirst%3DP.%2BR.%26aulast%3DBocchinfuso%26aufirst%3DW.%2BP.%26aulast%3DMontrose-Rafizadeh%26aufirst%3DC.%26aulast%3DCannady%26aufirst%3DE.%2BA.%26aulast%3DJones%26aufirst%3DT.%2BM.%26aulast%3DStille%26aufirst%3DJ.%2BR.%26aulast%3DRaddad%26aufirst%3DE.%26aulast%3DReidy%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DA.%26aulast%3DMichael%26aufirst%3DM.%2BD.%26aulast%3DMichael%26aufirst%3DL.%2BF.%26atitle%3DDiscovery%2520of%25206-%25284-%257B%255B5-Cyclopropyl-3-%25282%252C6-Dichlorophenyl%2529isoxazol-4-Yl%255Dmethoxy%257Dpiperidin-1-Yl%2529-1-Methyl-1H-Indole-3-Carboxylic%2520Acid%253A%2520A%2520Novel%2520FXR%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Dyslipidemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9768%26epage%3D9772%26doi%3D10.1021%2Facs.jmedchem.5b01161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Tully, D. C.; Vidal, A.; Mutnick, D.; Alper, P. B.</span><span> </span><span class="NLM_article-title">Compositions and Methods for Modulating Farnesoid X Receptors</span>. WO 2012/087520 A1, June 28,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+C.+Tully&author=A.+Vidal&author=D.+Mutnick&author=P.+B.+Alper&title=Compositions+and+Methods+for+Modulating+Farnesoid+X+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTully%26aufirst%3DD.%2BC.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Modulating%2520Farnesoid%2520X%2520Receptors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Tully, D. C.; Rucker, P. V.; Alper, P. B.; Mutnick, D.; Chianelli, D.</span><span> </span><span class="NLM_article-title">Compositions and Methods for Modulating FXR</span>. WO 2012/087519 A1, June 28,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+C.+Tully&author=P.+V.+Rucker&author=P.+B.+Alper&author=D.+Mutnick&author=D.+Chianelli&title=Compositions+and+Methods+for+Modulating+FXR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTully%26aufirst%3DD.%2BC.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Modulating%2520FXR%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Alemi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattaruzza, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cevikbas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero-Alba, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez-Morales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottrell, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoonjans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnett, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvera, C. U.</span><span> </span><span class="NLM_article-title">The TGR5 Receptor Mediates Bile Acid–induced Itch and Analgesia</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1513</span><span class="NLM_x">–</span> <span class="NLM_lpage">1530</span><span class="refDoi"> DOI: 10.1172/JCI64551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1172%2FJCI64551" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=1513-1530&author=F.+Alemiauthor=E.+Kwonauthor=D.+P.+Pooleauthor=T.+Lieuauthor=V.+Lyoauthor=F.+Cattaruzzaauthor=F.+Cevikbasauthor=M.+Steinhoffauthor=R.+Nassiniauthor=S.+Materazziauthor=R.+Guerrero-Albaauthor=E.+Valdez-Moralesauthor=G.+S.+Cottrellauthor=K.+Schoonjansauthor=P.+Geppettiauthor=S.+J.+Vannerauthor=N.+W.+Bunnettauthor=C.+U.+Corvera&title=The+TGR5+Receptor+Mediates+Bile+Acid%E2%80%93induced+Itch+and+Analgesia&doi=10.1172%2FJCI64551"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1172%2FJCI64551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI64551%26sid%3Dliteratum%253Aachs%26aulast%3DAlemi%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DE.%26aulast%3DPoole%26aufirst%3DD.%2BP.%26aulast%3DLieu%26aufirst%3DT.%26aulast%3DLyo%26aufirst%3DV.%26aulast%3DCattaruzza%26aufirst%3DF.%26aulast%3DCevikbas%26aufirst%3DF.%26aulast%3DSteinhoff%26aufirst%3DM.%26aulast%3DNassini%26aufirst%3DR.%26aulast%3DMaterazzi%26aufirst%3DS.%26aulast%3DGuerrero-Alba%26aufirst%3DR.%26aulast%3DValdez-Morales%26aufirst%3DE.%26aulast%3DCottrell%26aufirst%3DG.%2BS.%26aulast%3DSchoonjans%26aufirst%3DK.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DVanner%26aufirst%3DS.%2BJ.%26aulast%3DBunnett%26aufirst%3DN.%2BW.%26aulast%3DCorvera%26aufirst%3DC.%2BU.%26atitle%3DThe%2520TGR5%2520Receptor%2520Mediates%2520Bile%2520Acid%25E2%2580%2593induced%2520Itch%2520and%2520Analgesia%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D1513%26epage%3D1530%26doi%3D10.1172%2FJCI64551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Lieu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaweera, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grace, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krappitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haerteis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korbmacher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhoff, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvera, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnett, N. W.</span><span> </span><span class="NLM_article-title">The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">1417</span><span class="NLM_x">–</span> <span class="NLM_lpage">1428</span><span class="refDoi"> DOI: 10.1053/j.gastro.2014.08.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1053%2Fj.gastro.2014.08.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25194674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOgsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2014&pages=1417-1428&author=T.+Lieuauthor=G.+Jayaweeraauthor=P.+Zhaoauthor=D.+P.+Pooleauthor=D.+Jensenauthor=M.+Graceauthor=P.+McIntyreauthor=R.+Bronauthor=Y.+M.+Wilsonauthor=M.+Krappitzauthor=S.+Haerteisauthor=C.+Korbmacherauthor=M.+S.+Steinhoffauthor=R.+Nassiniauthor=S.+Materazziauthor=P.+Geppettiauthor=C.+U.+Corveraauthor=N.+W.+Bunnett&title=The+Bile+Acid+Receptor+TGR5+Activates+the+TRPA1+Channel+to+Induce+Itch+in+Mice&doi=10.1053%2Fj.gastro.2014.08.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice</span></div><div class="casAuthors">Lieu, Tina Marie; Jayaweera, Gihan; Zhao, Peishen; Poole, Daniel P.; Jensen, Dane; Grace, Megan; McIntyre, Peter; Bron, Romke; Wilson, Yvette M.; Krappitz, Matteus; Haerteis, Silke; Korbmacher, Christoph; Steinhoff, Martin S.; Nassini, Romina; Materazzi, Serena; Geppetti, Pierangelo; Corvera, Carlos U.; Bunnett, Nigel W.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1417-1428</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Patients with cholestatic disease have increased systemic concns. of bile acids (BAs) and profound pruritus.  The G-protein-coupled BA receptor 1 TGR5 (encoded by GPBAR1) is expressed by primary sensory neurons; its activation induces neuronal hyperexcitability and scratching by unknown mechanisms.  We investigated whether the transient receptor potential ankyrin 1 (TRPA1) is involved in BA-evoked, TGR5-dependent pruritus in mice.  Co-expression of TGR5 and TRPA1 in cutaneous afferent neurons isolated from mice was analyzed by immunofluorescence, in situ hybridization, and single-cell polymerase chain reaction.  TGR5-induced activation of TRPA1 was studied in in HEK293 cells, Xenopus laevis oocytes, and primary sensory neurons by measuring Ca2+ signals.  The contribution of TRPA1 to TGR5-induced release of pruritogenic neuropeptides, activation of spinal neurons, and scratching behavior were studied using TRPA1 antagonists or Trpa1-/- mice.  TGR5 and TRPA1 protein and mRNA were expressed by cutaneous afferent neurons.  In HEK cells, oocytes, and neurons co-expressing TGR5 and TRPA1, BAs caused TGR5-dependent activation and sensitization of TRPA1 by mechanisms that required Gβγ, protein kinase C, and Ca2+.  Antagonists or deletion of TRPA1 prevented BA-stimulated release of the pruritogenic neuropeptides gastrin-releasing peptide and atrial natriuretic peptide B in the spinal cord.  Disruption of Trpa1 in mice blocked BA-induced expression of Fos in spinal neurons and prevented BA-stimulated scratching.  Spontaneous scratching was exacerbated in transgenic mice that overexpressed TRG5.  Administration of a TRPA1 antagonist or the BA sequestrant colestipol, which lowered circulating levels of BAs, prevented exacerbated spontaneous scratching in TGR5 overexpressing mice.  BAs induce pruritus in mice by co-activation of TGR5 and TRPA1.  Antagonists of TGR5 and TRPA1, or inhibitors of the signaling mechanism by which TGR5 activates TRPA1, might be developed for treatment of cholestatic pruritus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM4F6iy9XI9bVg90H21EOLACvtfcHk0li6ZBpOfA5ilw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOgsrzO&md5=3a77ab6ea2ee8f54d09e4f509167a67b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2014.08.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2014.08.042%26sid%3Dliteratum%253Aachs%26aulast%3DLieu%26aufirst%3DT.%26aulast%3DJayaweera%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DPoole%26aufirst%3DD.%2BP.%26aulast%3DJensen%26aufirst%3DD.%26aulast%3DGrace%26aufirst%3DM.%26aulast%3DMcIntyre%26aufirst%3DP.%26aulast%3DBron%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DY.%2BM.%26aulast%3DKrappitz%26aufirst%3DM.%26aulast%3DHaerteis%26aufirst%3DS.%26aulast%3DKorbmacher%26aufirst%3DC.%26aulast%3DSteinhoff%26aufirst%3DM.%2BS.%26aulast%3DNassini%26aufirst%3DR.%26aulast%3DMaterazzi%26aufirst%3DS.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DCorvera%26aufirst%3DC.%2BU.%26aulast%3DBunnett%26aufirst%3DN.%2BW.%26atitle%3DThe%2520Bile%2520Acid%2520Receptor%2520TGR5%2520Activates%2520the%2520TRPA1%2520Channel%2520to%2520Induce%2520Itch%2520in%2520Mice%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D147%26spage%3D1417%26epage%3D1428%26doi%3D10.1053%2Fj.gastro.2014.08.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Nevens, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreone, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strasser, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowlus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Invernizzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drenth, J. P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regula, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuers, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trauner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floreani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenester, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luketic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Erpecum, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirschfield, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindor, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marschall, H.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooshmand-Rad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheeron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pencek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacConell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruzanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D.</span><span> </span><span class="NLM_article-title">A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1056/NEJMoa1509840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1056%2FNEJMoa1509840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=27532829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=631-643&author=F.+Nevensauthor=P.+Andreoneauthor=G.+Mazzellaauthor=S.+I.+Strasserauthor=C.+Bowlusauthor=P.+Invernizziauthor=J.+P.+H.+Drenthauthor=P.+J.+Pockrosauthor=J.+Regulaauthor=U.+Beuersauthor=M.+Traunerauthor=D.+E.+Jonesauthor=A.+Floreaniauthor=S.+Hohenesterauthor=V.+Luketicauthor=M.+Shiffmanauthor=K.+J.+van+Erpecumauthor=V.+Vargasauthor=C.+Vincentauthor=G.+M.+Hirschfieldauthor=H.+Shahauthor=B.+Hansenauthor=K.+D.+Lindorauthor=H.-U.+Marschallauthor=K.+V.+Kowdleyauthor=R.+Hooshmand-Radauthor=T.+Marmonauthor=S.+Sheeronauthor=R.+Pencekauthor=L.+MacConellauthor=M.+Pruzanskiauthor=D.+Shapiro&title=A+Placebo-Controlled+Trial+of+Obeticholic+Acid+in+Primary+Biliary+Cholangitis&doi=10.1056%2FNEJMoa1509840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A placebo-controlled trial of obeticholic acid in primary biliary cholangitis</span></div><div class="casAuthors">Nevens, F.; Andreone, P.; Mazzella, G.; Strasser, S. I.; Bowlus, C.; Invernizzi, P.; Drenth, J. P. H.; Pockros, P. J.; Regula, J.; Beuers, U.; Trauner, M.; Jones, D. E.; Floreani, A.; Hohenester, S.; Luketic, V.; Shiffman, M.; van Erpecum, K. J.; Vargas, V.; Vincent, C.; Hirschfield, G. M.; Shah, H.; Hansen, B.; Lindor, K. D.; Marschall, H.-U.; Kowdley, K. V.; Hooshmand-Rad, R.; Marmon, T.; Sheeron, S.; Pencek, R.; MacConell, L.; Pruzanski, M.; Shapiro, D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-643</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy.  Alk. phosphatase and bilirubin levels correlate with the risk of liver transplantation or death.  Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients with this disease.  METHODS: In this 12-mo, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a dose of 10 mg (the 10-mg group), obeticholic acid at a dose of 5 mg with adjustment to 10 mg if applicable (the 5-10-mg group), or placebo.  The primary end point was an alk. phosphatase level of less than 1.67 times the upper limit of the normal range, with a redn. of at least 15% from baseline, and a normal total bilirubin level.  RESULTS: Of 216 patients who underwent randomization and received at least one dose of obeticholic acid or placebo, 93% received ursodiol as background therapy.  The primary end point occurred in more patients in the 5-10-mg group (46%) and the 10-mg group (47%) than in the placebo group (10%; P<0.001 for both comparisons).  Patients in the 5-10-mg group and those in the 10-mg group had greater decreases than those in the placebo group in the alk. phosphatase level (least-squares mean, -113 and -130 U per L, resp., vs. -14 U per L; P<0.001 for both comparisons) and total bilirubin level (-0.02 and -0.05 mg per dL [-0.3 and -0.9 μmol per L], resp., vs. 0.12 mg per dL [2.0 μmol per L]; P<0.001 for both comparisons).  Changes in noninvasive measures of liver fibrosis did not differ significantly between either treatment group and the placebo group at 12 mo.  Pruritus was more common with obeticholic acid than with placebo (56% of patients in the 5-10-mg group and 68% of those in the 10-mg group vs. 38% in the placebo group).  The rate of serious adverse events was 16% in the 5-10-mg group, 11% in the 10-mg group, and 4% in the placebo group.  CONCLUSIONS: Obeticholic acid administered with ursodiol or as monotherapy for 12 mo in patients with primary biliary cholangitis resulted in decreases from baseline in alk. phosphatase and total bilirubin levels that differed significantly from the changes obsd. with placebo.  There were more serious adverse events with obeticholic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovAIzzX9egK7Vg90H21EOLACvtfcHk0lhcuOstOTJ5zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7zE&md5=613ba0df3a84969560534d87de20420b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509840%26sid%3Dliteratum%253Aachs%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DAndreone%26aufirst%3DP.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DStrasser%26aufirst%3DS.%2BI.%26aulast%3DBowlus%26aufirst%3DC.%26aulast%3DInvernizzi%26aufirst%3DP.%26aulast%3DDrenth%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DRegula%26aufirst%3DJ.%26aulast%3DBeuers%26aufirst%3DU.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DD.%2BE.%26aulast%3DFloreani%26aufirst%3DA.%26aulast%3DHohenester%26aufirst%3DS.%26aulast%3DLuketic%26aufirst%3DV.%26aulast%3DShiffman%26aufirst%3DM.%26aulast%3Dvan%2BErpecum%26aufirst%3DK.%2BJ.%26aulast%3DVargas%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DC.%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DShah%26aufirst%3DH.%26aulast%3DHansen%26aufirst%3DB.%26aulast%3DLindor%26aufirst%3DK.%2BD.%26aulast%3DMarschall%26aufirst%3DH.-U.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DHooshmand-Rad%26aufirst%3DR.%26aulast%3DMarmon%26aufirst%3DT.%26aulast%3DSheeron%26aufirst%3DS.%26aulast%3DPencek%26aufirst%3DR.%26aulast%3DMacConell%26aufirst%3DL.%26aulast%3DPruzanski%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DD.%26atitle%3DA%2520Placebo-Controlled%2520Trial%2520of%2520Obeticholic%2520Acid%2520in%2520Primary%2520Biliary%2520Cholangitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D631%26epage%3D643%26doi%3D10.1056%2FNEJMoa1509840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span>Ocaliva Full Prescribing Information (US Package Insert for Commercial Use); <span class="NLM_publisher-name">US FDA</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ocaliva+Full+Prescribing+Information+%28US+Package+Insert+for+Commercial+Use%29%3B+US+FDA%3A+Silver+Spring%2C+MD%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dgov%26sid%3Dliteratum%253Aachs%26jtitle%3DOcaliva%2520Full%2520Prescribing%2520Information%2520%2528US%2520Package%2520Insert%2520for%2520Commercial%2520Use%2529%26pub%3DUS%2520FDA%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Badman, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laffitte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decristofaro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klickstein, L.</span><span> </span><span class="NLM_article-title">First-in-Human experience with LJN452, an orally available non-bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects. AASLD Abstracts, The Liver Meeting, Boston, MA. Nov 11–15, 2016</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">32</span><span class="refDoi"> DOI: 10.1002/hep.28796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1002%2Fhep.28796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=32&issue=1&author=M.+K.+Badmanauthor=S.+Desaiauthor=B.+Laffitteauthor=M.+Decristofaroauthor=T.+Linauthor=J.+Chenauthor=J.+F.+Reillyauthor=L.+Klickstein&title=First-in-Human+experience+with+LJN452%2C+an+orally+available+non-bile+acid+FXR+agonist%2C+demonstrates+potent+activation+of+FXR+in+healthy+subjects.+AASLD+Abstracts%2C+The+Liver+Meeting%2C+Boston%2C+MA.+Nov+11%E2%80%9315%2C+2016&doi=10.1002%2Fhep.28796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1002%2Fhep.28796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28796%26sid%3Dliteratum%253Aachs%26aulast%3DBadman%26aufirst%3DM.%2BK.%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DDecristofaro%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DKlickstein%26aufirst%3DL.%26atitle%3DFirst-in-Human%2520experience%2520with%2520LJN452%252C%2520an%2520orally%2520available%2520non-bile%2520acid%2520FXR%2520agonist%252C%2520demonstrates%2520potent%2520activation%2520of%2520FXR%2520in%2520healthy%2520subjects.%2520AASLD%2520Abstracts%252C%2520The%2520Liver%2520Meeting%252C%2520Boston%252C%2520MA.%2520Nov%252011%25E2%2580%259315%252C%25202016%26jtitle%3DHepatology%26date%3D2016%26volume%3D64%26issue%3D1%26spage%3D32%26doi%3D10.1002%2Fhep.28796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Laffitte, B.; Hernandez, E. D.; Zheng, L.; Kim, Y.; Liu, B.; Valdez, R. A.; Dietrich, W. F.; Rucker, P.; Chianelli, D.; Schmeits, J.; Bao, D.; Zoll, J.; Chen, L.; Joseph, S. B.; Klickstein, L. B.; Chen, J.; Xu, J.; Tully, D. C.; Molteni, V.; McNamara, P.; Badman, M. K.</span><span> </span><span class="NLM_article-title">Tropifexor (LJN452) Improves Cholestasis, Steatohepatitis and Hepatic Fibrosis in Rodents without Altering Plasma Lipids in Humans</span>. <div class="note"><p class="first last">Submitted for publication</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Laffitte%2C+B.%3B+Hernandez%2C+E.+D.%3B+Zheng%2C+L.%3B+Kim%2C+Y.%3B+Liu%2C+B.%3B+Valdez%2C+R.+A.%3B+Dietrich%2C+W.+F.%3B+Rucker%2C+P.%3B+Chianelli%2C+D.%3B+Schmeits%2C+J.%3B+Bao%2C+D.%3B+Zoll%2C+J.%3B+Chen%2C+L.%3B+Joseph%2C+S.+B.%3B+Klickstein%2C+L.+B.%3B+Chen%2C+J.%3B+Xu%2C+J.%3B+Tully%2C+D.+C.%3B+Molteni%2C+V.%3B+McNamara%2C+P.%3B+Badman%2C+M.+K.+Tropifexor+%28LJN452%29+Improves+Cholestasis%2C+Steatohepatitis+and+Hepatic+Fibrosis+in+Rodents+without+Altering+Plasma+Lipids+in+Humans.+Submitted+for+publication."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLaffitte%26aufirst%3DB.%26atitle%3DTropifexor%2520%2528LJN452%2529%2520Improves%2520Cholestasis%252C%2520Steatohepatitis%2520and%2520Hepatic%2520Fibrosis%2520in%2520Rodents%2520without%2520Altering%2520Plasma%2520Lipids%2520in%2520Humans" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['ref14_1'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 84 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Naoki Teno, Yusuke Iguchi, Keisuke Oda, Yukiko Yamashita, Arisa Masuda, Ko Fujimori, Mizuho Une, <span class="NLM_string-name hlFld-ContribAuthor">Keigo Gohda</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 420-425. <a href="https://doi.org/10.1021/acsmedchemlett.0c00640" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00640%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BOrally%252BActive%252Band%252BNonsteroidal%252BFarnesoid%252BX%252BReceptor%252B%252528FXR%252529%252BAntagonist%252Bwith%252BPropensity%252Bfor%252BAccumulation%252Band%252BResponsiveness%252Bin%252BIleum%26aulast%3DTeno%26aufirst%3DNaoki%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D06122020%26date%3D16022021%26date%3D24022021%26volume%3D12%26issue%3D3%26spage%3D420%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junyou Li, Mengqi Liu, Yazhou Li, Dan-dan Sun, Zhihao Shu, Qian Tan, Shimeng Guo, Rongrong Xie, Lixin Gao, Hongbo Ru, Yi Zang, Hong Liu, Jia Li, <span class="NLM_string-name hlFld-ContribAuthor">Yu Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12748-12772. <a href="https://doi.org/10.1021/acs.jmedchem.0c01065" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01065%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252BNon-bile%252BAcid%252BFXR%252BAgonists%252Bas%252BPreclinical%252BCandidates%252Bfor%252Bthe%252BTreatment%252Bof%252BNonalcoholic%252BSteatohepatitis%26aulast%3DLi%26aufirst%3DJunyou%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20062020%26date%3D13102020%26date%3D29092020%26volume%3D63%26issue%3D21%26spage%3D12748%26epage%3D12772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux, <span class="NLM_string-name hlFld-ContribAuthor">Randall L. Halcomb</span>. </span><span class="cited-content_cbyCitation_article-title">The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5031-5073. <a href="https://doi.org/10.1021/acs.jmedchem.9b01701" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01701%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BRace%252Bto%252BBash%252BNASH%25253A%252BEmerging%252BTargets%252Band%252BDrug%252BDevelopment%252Bin%252Ba%252BComplex%252BLiver%252BDisease%26aulast%3DRomero%26aufirst%3DF.%2BAnthony%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14102019%26date%3D29012020%26date%3D13012020%26volume%3D63%26issue%3D10%26spage%3D5031%26epage%3D5073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Donatella Chianelli, Paul V. Rucker, Jason Roland, David C. Tully, John Nelson, Xiaodong Liu, Badry Bursulaya, Eloy D. Hernandez, Jane Wu, Mahavir Prashad, Thierry Schlama, Yugang Liu, Alan Chu, James Schmeits, David J. Huang, Robert Hill, Dingjiu Bao, Jocelyn Zoll, Young Kim, Todd Groessl, Peter McNamara, Bo Liu, Wendy Richmond, Ignacio Sancho-Martinez, Andrew Phimister, H. Martin Seidel, Michael K. Badman, Sean B. Joseph, Bryan Laffitte, <span class="NLM_string-name hlFld-ContribAuthor">Valentina Molteni</span>. </span><span class="cited-content_cbyCitation_article-title">Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 3868-3880. <a href="https://doi.org/10.1021/acs.jmedchem.9b01621" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01621</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01621%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNidufexor%252B%252528LMB763%252529%25252C%252Ba%252BNovel%252BFXR%252BModulator%252Bfor%252Bthe%252BTreatment%252Bof%252BNonalcoholic%252BSteatohepatitis%26aulast%3DChianelli%26aufirst%3DDonatella%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D30092019%26date%3D05022020%26date%3D15012020%26volume%3D63%26issue%3D8%26spage%3D3868%26epage%3D3880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue Chen, Junhao Li, Zengrui Wu, Guixia Liu, Honglin Li, Yun Tang, <span class="NLM_string-name hlFld-ContribAuthor">Weihua Li</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Insight into the Allosteric Activation Mechanism of Farnesoid X Receptor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (3)
                                     , 1540-1550. <a href="https://doi.org/10.1021/acs.jcim.9b00914" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00914%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DComputational%252BInsight%252Binto%252Bthe%252BAllosteric%252BActivation%252BMechanism%252Bof%252BFarnesoid%252BX%252BReceptor%26aulast%3DChen%26aufirst%3DYue%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D01102019%26date%3D04032020%26date%3D25022020%26volume%3D60%26issue%3D3%26spage%3D1540%26epage%3D1550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Valentina Sepe, Silvia Marchianò, Claudia Finamore, Giuliana Baronissi, Francesco Saverio Di Leva, Adriana Carino, Michele Biagioli, Chiara Fiorucci, Chiara Cassiano, Maria Chiara Monti, Federica del Gaudio, Ettore Novellino, Vittorio Limongelli, Stefano Fiorucci, <span class="NLM_string-name hlFld-ContribAuthor">Angela Zampella</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (4)
                                     , 407-412. <a href="https://doi.org/10.1021/acsmedchemlett.8b00423" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00423%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252BIsoxazole%252BDerivatives%252Bwith%252BPotent%252BFXR%252BAgonistic%252BActivity%252BPrevent%252BAcetaminophen-Induced%252BLiver%252BInjury%26aulast%3DSepe%26aufirst%3DValentina%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D14092018%26date%3D06122018%26date%3D12122018%26date%3D06122018%26volume%3D10%26issue%3D4%26spage%3D407%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chaoran Li, Jingwen Yuan, Qian Zhang, Chitturi Bhujanga Rao, Rui Zhang, Yanning Zhao, Bicheng Deng, <span class="NLM_string-name hlFld-ContribAuthor">Dewen Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative Cyclization of β-Aminoacrylamides Mediated by PhIO: Chemoselective Synthesis of Isoxazoles and 2H-Azirines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (24)
                                     , 14999-15008. <a href="https://doi.org/10.1021/acs.joc.8b02132" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02132</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02132%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOxidative%252BCyclization%252Bof%252B%2525CE%2525B2-Aminoacrylamides%252BMediated%252Bby%252BPhIO%25253A%252BChemoselective%252BSynthesis%252Bof%252BIsoxazoles%252Band%252B2H-Azirines%26aulast%3DLi%26aufirst%3DChaoran%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D01092018%26date%3D30112018%26date%3D16112018%26volume%3D83%26issue%3D24%26spage%3D14999%26epage%3D15008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuehang  Tang</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Ning</span>, <span class="hlFld-ContribAuthor ">Yangliang  Ye</span>, <span class="hlFld-ContribAuthor ">Yipei  Gu</span>, <span class="hlFld-ContribAuthor ">Hongyi  Yan</span>, <span class="hlFld-ContribAuthor ">Ying  Leng</span>, <span class="hlFld-ContribAuthor ">Jianhua  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>43 </em>, 116280. <a href="https://doi.org/10.1016/j.bmc.2021.116280" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116280%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bketoxime%252Bether%252Bderivatives%252Bwith%252Bpotent%252BFXR%252Bagonistic%252Bactivity%25252C%252Boral%252Beffectiveness%252Band%252Bhigh%252Bliver%25252Fblood%252Bratio%26aulast%3DTang%26aufirst%3DXuehang%26date%3D2021%26volume%3D43%26spage%3D116280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Margaux  NAWROT</span>, <span class="hlFld-ContribAuthor ">Simon  PESCHARD</span>, <span class="hlFld-ContribAuthor ">Sophie  LESTAVEL</span>, <span class="hlFld-ContribAuthor ">Bart  STAELS</span>. </span><span class="cited-content_cbyCitation_article-title">Intestine-Liver Cross-talk in Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease. </span><span class="cited-content_cbyCitation_journal-name">Metabolism</span><span> <strong>2021,</strong> <em>12 </em>, 154844. <a href="https://doi.org/10.1016/j.metabol.2021.154844" title="DOI URL">https://doi.org/10.1016/j.metabol.2021.154844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.metabol.2021.154844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.metabol.2021.154844%26sid%3Dliteratum%253Aachs%26jtitle%3DMetabolism%26atitle%3DIntestine-Liver%252BCross-talk%252Bin%252BType%252B2%252BDiabetes%252Band%252BNon-Alcoholic%252BFatty%252BLiver%252BDisease%26aulast%3DNAWROT%26aufirst%3DMargaux%26date%3D2021%26volume%3D12%26spage%3D154844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Radun</span>, <span class="hlFld-ContribAuthor ">Michael  Trauner</span>. </span><span class="cited-content_cbyCitation_article-title">Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Liver Disease</span><span> <strong>2021,</strong> <em>64 </em><a href="https://doi.org/10.1055/s-0041-1731707" title="DOI URL">https://doi.org/10.1055/s-0041-1731707</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0041-1731707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0041-1731707%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Liver%2520Disease%26atitle%3DRole%252Bof%252BFXR%252Bin%252BBile%252BAcid%252Band%252BMetabolic%252BHomeostasis%252Bin%252BNASH%25253A%252BPathogenetic%252BConcepts%252Band%252BTherapeutic%252BOpportunities%26aulast%3DRadun%26aufirst%3DRichard%26date%3D2021%26date%3D2021%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amalia  Gastaldelli</span>, <span class="hlFld-ContribAuthor ">Norbert  Stefan</span>, <span class="hlFld-ContribAuthor ">Hans-Ulrich  Häring</span>. </span><span class="cited-content_cbyCitation_article-title">Liver-targeting drugs and their effect on blood glucose and hepatic lipids. </span><span class="cited-content_cbyCitation_journal-name">Diabetologia</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 1461-1479. <a href="https://doi.org/10.1007/s00125-021-05442-2" title="DOI URL">https://doi.org/10.1007/s00125-021-05442-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00125-021-05442-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00125-021-05442-2%26sid%3Dliteratum%253Aachs%26jtitle%3DDiabetologia%26atitle%3DLiver-targeting%252Bdrugs%252Band%252Btheir%252Beffect%252Bon%252Bblood%252Bglucose%252Band%252Bhepatic%252Blipids%26aulast%3DGastaldelli%26aufirst%3DAmalia%26date%3D2021%26date%3D2021%26volume%3D64%26issue%3D7%26spage%3D1461%26epage%3D1479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lydia  Wang-Lakshman</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Lai  Wang</span>, <span class="hlFld-ContribAuthor ">Helen  Gu</span>, <span class="hlFld-ContribAuthor ">Mark  Kagan</span>, <span class="hlFld-ContribAuthor ">Jessie  Gu</span>, <span class="hlFld-ContribAuthor ">Elizabeth  McNamara</span>, <span class="hlFld-ContribAuthor ">Markus  Walles</span>, <span class="hlFld-ContribAuthor ">Ralph  Woessner</span>, <span class="hlFld-ContribAuthor ">Gian  Camenisch</span>, <span class="hlFld-ContribAuthor ">Heidi J.  Einolf</span>, <span class="hlFld-ContribAuthor ">Jin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2021,</strong> <em>49 </em>
                                    (7)
                                     , 548-562. <a href="https://doi.org/10.1124/dmd.120.000349" title="DOI URL">https://doi.org/10.1124/dmd.120.000349</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.120.000349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.120.000349%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DEvaluation%252Bof%252Bthe%252BAbsorption%25252C%252BMetabolism%25252C%252Band%252BExcretion%252Bof%252Ba%252BSingle%252BOral%252B1-mg%252BDose%252Bof%252BTropifexor%252Bin%252BHealthy%252BMale%252BSubjects%252Band%252Bthe%252BConcentration%252BDependence%252Bof%252BTropifexor%252BMetabolism%26aulast%3DWang-Lakshman%26aufirst%3DLydia%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D7%26spage%3D548%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kyounghwa  Jung</span>, <span class="hlFld-ContribAuthor ">Minwook  Kim</span>, <span class="hlFld-ContribAuthor ">Juhoon  So</span>, <span class="hlFld-ContribAuthor ">Seung‐Hoon  Lee</span>, <span class="hlFld-ContribAuthor ">Sungjin  Ko</span>, <span class="hlFld-ContribAuthor ">Donghun  Shin</span>. </span><span class="cited-content_cbyCitation_article-title">Farnesoid
              X
              Receptor Activation Impairs Liver Progenitor Cell–Mediated Liver Regeneration via the
              PTEN‐PI3K‐AKT‐mTOR
              Axis in Zebrafish. </span><span class="cited-content_cbyCitation_journal-name">Hepatology</span><span> <strong>2021,</strong> <em>74 </em>
                                    (1)
                                     , 397-410. <a href="https://doi.org/10.1002/hep.31679" title="DOI URL">https://doi.org/10.1002/hep.31679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hep.31679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhep.31679%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatology%26atitle%3DFarnesoid%252BX%252BReceptor%252BActivation%252BImpairs%252BLiver%252BProgenitor%252BCell%2525E2%252580%252593Mediated%252BLiver%252BRegeneration%252Bvia%252Bthe%252BPTEN%2525E2%252580%252590PI3K%2525E2%252580%252590AKT%2525E2%252580%252590mTOR%252BAxis%252Bin%252BZebrafish%26aulast%3DJung%26aufirst%3DKyounghwa%26date%3D2021%26date%3D2021%26volume%3D74%26issue%3D1%26spage%3D397%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qianqian  Qiu</span>, <span class="hlFld-ContribAuthor ">Yanjuan  Wang</span>, <span class="hlFld-ContribAuthor ">Guolong  Gu</span>, <span class="hlFld-ContribAuthor ">Shichao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yining  Zhao</span>, <span class="hlFld-ContribAuthor ">Bai  Ling</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of novel FXR agonists based on auraptene. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>81 </em>, 105198. <a href="https://doi.org/10.1016/j.bioorg.2021.105198" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105198%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252BFXR%252Bagonists%252Bbased%252Bon%252Bauraptene%26aulast%3DQiu%26aufirst%3DQianqian%26date%3D2021%26volume%3D81%26spage%3D105198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virender  Kumar</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Xin</span>, <span class="hlFld-ContribAuthor ">Jingyi  Ma</span>, <span class="hlFld-ContribAuthor ">Chalet  Tan</span>, <span class="hlFld-ContribAuthor ">Natalia  Osna</span>, <span class="hlFld-ContribAuthor ">Ram I.  Mahato</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2021,</strong> <em>5 </em>, 113888. <a href="https://doi.org/10.1016/j.addr.2021.113888" title="DOI URL">https://doi.org/10.1016/j.addr.2021.113888</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2021.113888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2021.113888%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DTherapeutic%252Btargets%25252C%252Bnovel%252Bdrugs%25252C%252Band%252Bdelivery%252Bsystems%252Bfor%252Bdiabetes%252Bassociated%252BNAFLD%252Band%252Bliver%252Bfibrosis%26aulast%3DKumar%26aufirst%3DVirender%26date%3D2021%26volume%3D5%26spage%3D113888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katherine  Byrnes</span>, <span class="hlFld-ContribAuthor ">Sophia  Blessinger</span>, <span class="hlFld-ContribAuthor ">Niani  Bailey</span>, <span class="hlFld-ContribAuthor ">Russell  Scaife</span>, <span class="hlFld-ContribAuthor ">Gang  Liu</span>, <span class="hlFld-ContribAuthor ">Bilon  Khambu</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic regulation of autophagy in hepatic metabolism. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>20 </em><a href="https://doi.org/10.1016/j.apsb.2021.07.021" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.07.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.07.021%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DTherapeutic%252Bregulation%252Bof%252Bautophagy%252Bin%252Bhepatic%252Bmetabolism%26aulast%3DByrnes%26aufirst%3DKatherine%26date%3D2021%26volume%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert B. A.  Quinlan</span>, <span class="hlFld-ContribAuthor ">Paul E.  Brennan</span>. </span><span class="cited-content_cbyCitation_article-title">Chemogenomics for drug discovery: clinical molecules from open access chemical probes. </span><span class="cited-content_cbyCitation_journal-name">RSC Chemical Biology</span><span> <strong>2021,</strong> <em>2 </em>
                                    (3)
                                     , 759-795. <a href="https://doi.org/10.1039/D1CB00016K" title="DOI URL">https://doi.org/10.1039/D1CB00016K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CB00016K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CB00016K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Chemical%2520Biology%26atitle%3DChemogenomics%252Bfor%252Bdrug%252Bdiscovery%25253A%252Bclinical%252Bmolecules%252Bfrom%252Bopen%252Baccess%252Bchemical%252Bprobes%26aulast%3DQuinlan%26aufirst%3DRobert%2BB.%2BA.%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D3%26spage%3D759%26epage%3D795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keigo  Gohda</span>, <span class="hlFld-ContribAuthor ">Yusuke  Iguchi</span>, <span class="hlFld-ContribAuthor ">Arisa  Masuda</span>, <span class="hlFld-ContribAuthor ">Ko  Fujimori</span>, <span class="hlFld-ContribAuthor ">Yukiko  Yamashita</span>, <span class="hlFld-ContribAuthor ">Naoki  Teno</span>. </span><span class="cited-content_cbyCitation_article-title">Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure–activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>41 </em>, 128026. <a href="https://doi.org/10.1016/j.bmcl.2021.128026" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128026%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bidentification%252Bof%252Ba%252Bnew%252Bfarnesoid%2525C2%2525A0X%2525C2%2525A0receptor%252B%252528FXR%252529%252Bpartial%252Bagonist%252Bby%252Bcomputational%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Banalysis%25253A%252BLigand-induced%252BH8%252Bhelix%252Bfluctuation%252Bin%252Bthe%252Bligand-binding%252Bdomain%252Bof%252BFXR%252Bmay%252Blead%252Bto%252Bpartial%252Bagonism%26aulast%3DGohda%26aufirst%3DKeigo%26date%3D2021%26volume%3D41%26spage%3D128026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junxiao  Li</span>, <span class="hlFld-ContribAuthor ">Chuhe  Liu</span>, <span class="hlFld-ContribAuthor ">Zhenyu  Zhou</span>, <span class="hlFld-ContribAuthor ">Baokai  Dou</span>, <span class="hlFld-ContribAuthor ">Jinwen  Huang</span>, <span class="hlFld-ContribAuthor ">Leilei  Huang</span>, <span class="hlFld-ContribAuthor ">Peiyong  Zheng</span>, <span class="hlFld-ContribAuthor ">Shengjie  Fan</span>, <span class="hlFld-ContribAuthor ">Cheng  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via
              FXR
              agonism in mice. </span><span class="cited-content_cbyCitation_journal-name">Phytotherapy Research</span><span> <strong>2021,</strong> <em>35 </em>
                                    (6)
                                     , 3351-3364. <a href="https://doi.org/10.1002/ptr.7055" title="DOI URL">https://doi.org/10.1002/ptr.7055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ptr.7055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fptr.7055%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytotherapy%2520Research%26atitle%3DIsotschimgine%252Balleviates%252Bnonalcoholic%252Bsteatohepatitis%252Band%252Bfibrosis%252Bvia%252BFXR%252Bagonism%252Bin%252Bmice%26aulast%3DLi%26aufirst%3DJunxiao%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D6%26spage%3D3351%26epage%3D3364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Somaya A. M.  Albhaisi</span>, <span class="hlFld-ContribAuthor ">Arun J.  Sanyal</span>. </span><span class="cited-content_cbyCitation_article-title">New drugs for NASH. </span><span class="cited-content_cbyCitation_journal-name">Liver International</span><span> <strong>2021,</strong> <em>41 </em>
                                    (S1)
                                     , 112-118. <a href="https://doi.org/10.1111/liv.14844" title="DOI URL">https://doi.org/10.1111/liv.14844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/liv.14844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fliv.14844%26sid%3Dliteratum%253Aachs%26jtitle%3DLiver%2520International%26atitle%3DNew%252Bdrugs%252Bfor%252BNASH%26aulast%3DAlbhaisi%26aufirst%3DSomaya%2BA.%2BM.%26date%3D2021%26date%3D2021%26volume%3D41%26issue%3DS1%26spage%3D112%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongtao  Xiao</span>, <span class="hlFld-ContribAuthor ">Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Weipeng  Wang</span>, <span class="hlFld-ContribAuthor ">Xinbei  Tian</span>, <span class="hlFld-ContribAuthor ">Shanshan  Chen</span>, <span class="hlFld-ContribAuthor ">Ying  Lu</span>, <span class="hlFld-ContribAuthor ">Jun  Du</span>, <span class="hlFld-ContribAuthor ">Wei  Cai</span>, <span class="hlFld-ContribAuthor ">Isabelle  Leclercqv</span>. </span><span class="cited-content_cbyCitation_article-title">A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis. </span><span class="cited-content_cbyCitation_journal-name">Liver International</span><span> <strong>2021,</strong> <em>16 </em><a href="https://doi.org/10.1111/liv.14906" title="DOI URL">https://doi.org/10.1111/liv.14906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/liv.14906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fliv.14906%26sid%3Dliteratum%253Aachs%26jtitle%3DLiver%2520International%26atitle%3DA%252Bnonbile%252Bacid%252Bfarnesoid%252BX%252Breceptor%252Bagonist%252Btropifexor%252Bpotently%252Binhibits%252Bcholestatic%252Bliver%252Binjury%252Band%252Bfibrosis%252Bby%252Bmodulating%252Bthe%252Bgut%2525E2%252580%252593liver%252Baxis%26aulast%3DXiao%26aufirst%3DYongtao%26date%3D2021%26date%3D2021%26volume%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suchira  Gallage</span>, <span class="hlFld-ContribAuthor ">María  García-Beccaria</span>, <span class="hlFld-ContribAuthor ">Marta  Szydlowska</span>, <span class="hlFld-ContribAuthor ">Mohammad  Rahbari</span>, <span class="hlFld-ContribAuthor ">Raphael  Mohr</span>, <span class="hlFld-ContribAuthor ">Frank  Tacke</span>, <span class="hlFld-ContribAuthor ">Mathias  Heikenwalder</span>. </span><span class="cited-content_cbyCitation_article-title">The therapeutic landscape of hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Med</span><span> <strong>2021,</strong> <em>2 </em>
                                    (5)
                                     , 505-552. <a href="https://doi.org/10.1016/j.medj.2021.03.002" title="DOI URL">https://doi.org/10.1016/j.medj.2021.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.medj.2021.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.medj.2021.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DMed%26atitle%3DThe%252Btherapeutic%252Blandscape%252Bof%252Bhepatocellular%252Bcarcinoma%26aulast%3DGallage%26aufirst%3DSuchira%26date%3D2021%26volume%3D2%26issue%3D5%26spage%3D505%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuchang  Li</span>, <span class="hlFld-ContribAuthor ">Liting  Chen</span>, <span class="hlFld-ContribAuthor ">Lu  Li</span>, <span class="hlFld-ContribAuthor ">Chantal  Sottas</span>, <span class="hlFld-ContribAuthor ">Stephanie K.  Petrillo</span>, <span class="hlFld-ContribAuthor ">Anthoula  Lazaris</span>, <span class="hlFld-ContribAuthor ">Peter  Metrakos</span>, <span class="hlFld-ContribAuthor ">Hangyu  Wu</span>, <span class="hlFld-ContribAuthor ">Yuji  Ishida</span>, <span class="hlFld-ContribAuthor ">Takeshi  Saito</span>, <span class="hlFld-ContribAuthor ">Lucy  Golden-Mason</span>, <span class="hlFld-ContribAuthor ">Hugo R.  Rosen</span>, <span class="hlFld-ContribAuthor ">Jeremy J.  Wolff</span>, <span class="hlFld-ContribAuthor ">Cristina I.  Silvescu</span>, <span class="hlFld-ContribAuthor ">Samuel  Garza</span>, <span class="hlFld-ContribAuthor ">Garett  Cheung</span>, <span class="hlFld-ContribAuthor ">Tiffany  Huang</span>, <span class="hlFld-ContribAuthor ">Jinjiang  Fan</span>, <span class="hlFld-ContribAuthor ">Martine  Culty</span>, <span class="hlFld-ContribAuthor ">Bangyan  Stiles</span>, <span class="hlFld-ContribAuthor ">Kinji  Asahina</span>, <span class="hlFld-ContribAuthor ">Vassilios  Papadopoulos</span>. </span><span class="cited-content_cbyCitation_article-title">Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease. </span><span class="cited-content_cbyCitation_journal-name">iScience</span><span> <strong>2021,</strong> <em>24 </em>
                                    (5)
                                     , 102457. <a href="https://doi.org/10.1016/j.isci.2021.102457" title="DOI URL">https://doi.org/10.1016/j.isci.2021.102457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.isci.2021.102457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.isci.2021.102457%26sid%3Dliteratum%253Aachs%26jtitle%3DiScience%26atitle%3DCholesterol-binding%252Btranslocator%252Bprotein%252BTSPO%252Bregulates%252Bsteatosis%252Band%252Bbile%252Bacid%252Bsynthesis%252Bin%252Bnonalcoholic%252Bfatty%252Bliver%252Bdisease%26aulast%3DLi%26aufirst%3DYuchang%26date%3D2021%26volume%3D24%26issue%3D5%26spage%3D102457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ralf  Glatthar</span>, <span class="hlFld-ContribAuthor ">Robert H.  Arch</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Approaches for Nonalcoholic Steatohepatitis (
              NASH
              ). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-71. <a href="https://doi.org/10.1002/0471266949.bmc274" title="DOI URL">https://doi.org/10.1002/0471266949.bmc274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc274%26sid%3Dliteratum%253Aachs%26atitle%3DTherapeutic%252BApproaches%252Bfor%252BNonalcoholic%252BSteatohepatitis%252B%252528%252BNASH%252B%252529%26aulast%3DGlatthar%26aufirst%3DRalf%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D71%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Sebastian D.  Parlee</span>, <span class="hlFld-ContribAuthor ">Bin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. </span><span class="cited-content_cbyCitation_journal-name">Molecular Metabolism</span><span> <strong>2021,</strong> <em>46 </em>, 101153. <a href="https://doi.org/10.1016/j.molmet.2020.101153" title="DOI URL">https://doi.org/10.1016/j.molmet.2020.101153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molmet.2020.101153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molmet.2020.101153%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Metabolism%26atitle%3DNuclear%252Bhormone%252Band%252Bpeptide%252Bhormone%252Btherapeutics%252Bfor%252BNAFLD%252Band%252BNASH%26aulast%3DFinan%26aufirst%3DBrian%26date%3D2021%26volume%3D46%26spage%3D101153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessia  Perino</span>, <span class="hlFld-ContribAuthor ">Hadrien  Demagny</span>, <span class="hlFld-ContribAuthor ">Laura  Velazquez-Villegas</span>, <span class="hlFld-ContribAuthor ">Kristina  Schoonjans</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular physiology of bile acid signaling in health, disease, and aging. </span><span class="cited-content_cbyCitation_journal-name">Physiological Reviews</span><span> <strong>2021,</strong> <em>101 </em>
                                    (2)
                                     , 683-731. <a href="https://doi.org/10.1152/physrev.00049.2019" title="DOI URL">https://doi.org/10.1152/physrev.00049.2019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/physrev.00049.2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fphysrev.00049.2019%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysiological%2520Reviews%26atitle%3DMolecular%252Bphysiology%252Bof%252Bbile%252Bacid%252Bsignaling%252Bin%252Bhealth%25252C%252Bdisease%25252C%252Band%252Baging%26aulast%3DPerino%26aufirst%3DAlessia%26date%3D2021%26volume%3D101%26issue%3D2%26spage%3D683%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Felix F.  Lillich</span>, <span class="hlFld-ContribAuthor ">John D.  Imig</span>, <span class="hlFld-ContribAuthor ">Ewgenij  Proschak</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Target Approaches in Metabolic Syndrome. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.554961" title="DOI URL">https://doi.org/10.3389/fphar.2020.554961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.554961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.554961%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DMulti-Target%252BApproaches%252Bin%252BMetabolic%252BSyndrome%26aulast%3DLillich%26aufirst%3DFelix%2BF.%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raj  Vuppalanchi</span>, <span class="hlFld-ContribAuthor ">Mazen  Noureddin</span>, <span class="hlFld-ContribAuthor ">Naim  Alkhouri</span>, <span class="hlFld-ContribAuthor ">Arun J.  Sanyal</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic pipeline in nonalcoholic steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Gastroenterology & Hepatology</span><span> <strong>2021,</strong> <em>67 </em><a href="https://doi.org/10.1038/s41575-020-00408-y" title="DOI URL">https://doi.org/10.1038/s41575-020-00408-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41575-020-00408-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41575-020-00408-y%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DTherapeutic%252Bpipeline%252Bin%252Bnonalcoholic%252Bsteatohepatitis%26aulast%3DVuppalanchi%26aufirst%3DRaj%26date%3D2021%26date%3D2021%26volume%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lijun  Hu</span>, <span class="hlFld-ContribAuthor ">Qiang  Ren</span>, <span class="hlFld-ContribAuthor ">Liming  Deng</span>, <span class="hlFld-ContribAuthor ">Zongtao  Zhou</span>, <span class="hlFld-ContribAuthor ">Zongyu  Cai</span>, <span class="hlFld-ContribAuthor ">Bin  Wang</span>, <span class="hlFld-ContribAuthor ">Zheng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113106. <a href="https://doi.org/10.1016/j.ejmech.2020.113106" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113106%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bstudies%252Bof%252Bnovel%252B3-benzamidobenzoic%252Bacid%252Bderivatives%252Bas%252Bfarnesoid%252BX%252Breceptor%252Bpartial%252Bagonist%26aulast%3DHu%26aufirst%3DLijun%26date%3D2021%26volume%3D211%26spage%3D113106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shizhen  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenjing  Peng</span>, <span class="hlFld-ContribAuthor ">Xinping  Li</span>, <span class="hlFld-ContribAuthor ">Le  Wang</span>, <span class="hlFld-ContribAuthor ">Wenbo  Yin</span>, <span class="hlFld-ContribAuthor ">Yan-Dong  Wang</span>, <span class="hlFld-ContribAuthor ">Ruifang  Hou</span>, <span class="hlFld-ContribAuthor ">Wei-Dong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (4)
                                     , 2158-2166. <a href="https://doi.org/10.1039/D0RA09320C" title="DOI URL">https://doi.org/10.1039/D0RA09320C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA09320C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA09320C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DPharmacophore%252Bmodeling%252Band%252Bvirtual%252Bscreening%252Bstudies%252Bfor%252Bdiscovery%252Bof%252Bnovel%252Bfarnesoid%252BX%252Breceptor%252B%252528FXR%252529%252Bagonists%26aulast%3DZhao%26aufirst%3DShizhen%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D4%26spage%3D2158%26epage%3D2166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longying  Jiang</span>, <span class="hlFld-ContribAuthor ">Desheng  Xiao</span>, <span class="hlFld-ContribAuthor ">Yubin  Li</span>, <span class="hlFld-ContribAuthor ">Shuyan  Dai</span>, <span class="hlFld-ContribAuthor ">Lingzhi  Qu</span>, <span class="hlFld-ContribAuthor ">Xiaojuan  Chen</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Hudie  Wei</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2021,</strong> <em>534 </em>, 1047-1052. <a href="https://doi.org/10.1016/j.bbrc.2020.10.039" title="DOI URL">https://doi.org/10.1016/j.bbrc.2020.10.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2020.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2020.10.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DStructural%252Bbasis%252Bof%252Btropifexor%252Bas%252Ba%252Bpotent%252Band%252Bselective%252Bagonist%252Bof%252Bfarnesoid%252BX%252Breceptor%26aulast%3DJiang%26aufirst%3DLongying%26date%3D2021%26volume%3D534%26spage%3D1047%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guoshun  Luo</span>, <span class="hlFld-ContribAuthor ">Xin  Lin</span>, <span class="hlFld-ContribAuthor ">Zhenbang  Li</span>, <span class="hlFld-ContribAuthor ">Maoxu  Xiao</span>, <span class="hlFld-ContribAuthor ">Xinyu  Li</span>, <span class="hlFld-ContribAuthor ">Dayong  Zhang</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112910. <a href="https://doi.org/10.1016/j.ejmech.2020.112910" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112910</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112910%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-guided%252Bmodification%252Bof%252Bisoxazole-type%252BFXR%252Bagonists%25253A%252BIdentification%252Bof%252Ba%252Bpotent%252Band%252Borally%252Bbioavailable%252BFXR%252Bmodulator%26aulast%3DLuo%26aufirst%3DGuoshun%26date%3D2021%26volume%3D209%26spage%3D112910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longying  Jiang</span>, <span class="hlFld-ContribAuthor ">Huajun  Zhang</span>, <span class="hlFld-ContribAuthor ">Desheng  Xiao</span>, <span class="hlFld-ContribAuthor ">Hudie  Wei</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Farnesoid X receptor (FXR): Structures and ligands. </span><span class="cited-content_cbyCitation_journal-name">Computational and Structural Biotechnology Journal</span><span> <strong>2021,</strong> <em>19 </em>, 2148-2159. <a href="https://doi.org/10.1016/j.csbj.2021.04.029" title="DOI URL">https://doi.org/10.1016/j.csbj.2021.04.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.csbj.2021.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.csbj.2021.04.029%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520and%2520Structural%2520Biotechnology%2520Journal%26atitle%3DFarnesoid%252BX%252Breceptor%252B%252528FXR%252529%25253A%252BStructures%252Band%252Bligands%26aulast%3DJiang%26aufirst%3DLongying%26date%3D2021%26volume%3D19%26spage%3D2148%26epage%3D2159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanja  Stojsavljevic-Shapeski</span>, <span class="hlFld-ContribAuthor ">Marko  Duvnjak</span>, <span class="hlFld-ContribAuthor ">Lucija  Virovic-Jukic</span>, <span class="hlFld-ContribAuthor ">Davor  Hrabar</span>, <span class="hlFld-ContribAuthor ">Lea  Smircic Duvnjak</span>. </span><span class="cited-content_cbyCitation_article-title">New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical and Translational Hepatology</span><span> <strong>2020,</strong> <em>000 </em>
                                    (000)
                                     , 1-9. <a href="https://doi.org/10.14218/JCTH.2020.00057" title="DOI URL">https://doi.org/10.14218/JCTH.2020.00057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.14218/JCTH.2020.00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.14218%2FJCTH.2020.00057%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520and%2520Translational%2520Hepatology%26atitle%3DNew%252BDrugs%252Bon%252Bthe%252BBlock%2525E2%252580%252594Emerging%252BTreatments%252Bfor%252BNonalcoholic%252BSteatohepatitis%26aulast%3DStojsavljevic-Shapeski%26aufirst%3DSanja%26date%3D2020%26date%3D2020%26volume%3D000%26issue%3D000%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soung Won  Jeong</span>. </span><span class="cited-content_cbyCitation_article-title">Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. </span><span class="cited-content_cbyCitation_journal-name">Diabetes & Metabolism Journal</span><span> <strong>2020,</strong> <em>44 </em>
                                    (5)
                                     , 640-657. <a href="https://doi.org/10.4093/dmj.2020.0115" title="DOI URL">https://doi.org/10.4093/dmj.2020.0115</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4093/dmj.2020.0115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4093%2Fdmj.2020.0115%26sid%3Dliteratum%253Aachs%26jtitle%3DDiabetes%2520%2526%2520Metabolism%2520Journal%26atitle%3DNonalcoholic%252BFatty%252BLiver%252BDisease%25253A%252BA%252BDrug%252BRevolution%252BIs%252BComing%26aulast%3DJeong%26aufirst%3DSoung%2BWon%26date%3D2020%26volume%3D44%26issue%3D5%26spage%3D640%26epage%3D657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alejandro  Campos-Murguía</span>, <span class="hlFld-ContribAuthor ">Astrid  Ruiz-Margáin</span>, <span class="hlFld-ContribAuthor ">José A  González-Regueiro</span>, <span class="hlFld-ContribAuthor ">Ricardo U  Macías-Rodríguez</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Gastroenterology</span><span> <strong>2020,</strong> <em>26 </em>
                                    (39)
                                     , 5919-5943. <a href="https://doi.org/10.3748/wjg.v26.i39.5919" title="DOI URL">https://doi.org/10.3748/wjg.v26.i39.5919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3748/wjg.v26.i39.5919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3748%2Fwjg.v26.i39.5919%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26atitle%3DClinical%252Bassessment%252Band%252Bmanagement%252Bof%252Bliver%252Bfibrosis%252Bin%252Bnon-alcoholic%252Bfatty%252Bliver%252Bdisease%26aulast%3DCampos-Murgu%25C3%25ADa%26aufirst%3DAlejandro%26date%3D2020%26volume%3D26%26issue%3D39%26spage%3D5919%26epage%3D5943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lixia  Gao</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Elena  Woo</span>, <span class="hlFld-ContribAuthor ">XiaoSong  He</span>, <span class="hlFld-ContribAuthor ">GaoXiang  Yang</span>, <span class="hlFld-ContribAuthor ">Christopher  Bowlus</span>, <span class="hlFld-ContribAuthor ">Patrick S.C  Leung</span>, <span class="hlFld-ContribAuthor ">M. Eric  Gershwin</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends. </span><span class="cited-content_cbyCitation_journal-name">Clinical Reviews in Allergy & Immunology</span><span> <strong>2020,</strong> <em>59 </em>
                                    (2)
                                     , 175-194. <a href="https://doi.org/10.1007/s12016-019-08772-7" title="DOI URL">https://doi.org/10.1007/s12016-019-08772-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12016-019-08772-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12016-019-08772-7%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Reviews%2520in%2520Allergy%2520%2526%2520Immunology%26atitle%3DClinical%252BManagement%252Bof%252BPrimary%252BBiliary%252BCholangitis%2525E2%252580%252594Strategies%252Band%252BEvolving%252BTrends%26aulast%3DGao%26aufirst%3DLixia%26date%3D2020%26date%3D2019%26volume%3D59%26issue%3D2%26spage%3D175%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun Seok  Kim</span>, <span class="hlFld-ContribAuthor ">Sang Geon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Molecular Hepatology</span><span> <strong>2020,</strong> <em>26 </em>
                                    (4)
                                     , 715-727. <a href="https://doi.org/10.3350/cmh.2020.0173" title="DOI URL">https://doi.org/10.3350/cmh.2020.0173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3350/cmh.2020.0173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3350%2Fcmh.2020.0173%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Molecular%2520Hepatology%26atitle%3DEndoplasmic%252Breticulum%252Bstress%252Band%252Bautophagy%252Bdysregulation%252Bin%252Balcoholic%252Band%252Bnon-alcoholic%252Bliver%252Bdiseases%26aulast%3DKim%26aufirst%3DYun%2BSeok%26date%3D2020%26volume%3D26%26issue%3D4%26spage%3D715%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Camilleri</span>, <span class="hlFld-ContribAuthor ">Sara Linker  Nord</span>, <span class="hlFld-ContribAuthor ">Duane  Burton</span>, <span class="hlFld-ContribAuthor ">Ibironke  Oduyebo</span>, <span class="hlFld-ContribAuthor ">Yiming  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Chen</span>, <span class="hlFld-ContribAuthor ">Koeun  Im</span>, <span class="hlFld-ContribAuthor ">Prafulla  Bhad</span>, <span class="hlFld-ContribAuthor ">Michael K.  Badman</span>, <span class="hlFld-ContribAuthor ">David S.  Sanders</span>, <span class="hlFld-ContribAuthor ">Julian R. F.  Walters</span>. </span><span class="cited-content_cbyCitation_article-title">Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea. </span><span class="cited-content_cbyCitation_journal-name">Alimentary Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>52 </em>
                                    (5)
                                     , 808-820. <a href="https://doi.org/10.1111/apt.15967" title="DOI URL">https://doi.org/10.1111/apt.15967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/apt.15967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fapt.15967%26sid%3Dliteratum%253Aachs%26jtitle%3DAlimentary%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DRandomised%252Bclinical%252Btrial%25253A%252Bsignificant%252Bbiochemical%252Band%252Bcolonic%252Btransit%252Beffects%252Bof%252Bthe%252Bfarnesoid%252BX%252Breceptor%252Bagonist%252Btropifexor%252Bin%252Bpatients%252Bwith%252Bprimary%252Bbile%252Bacid%252Bdiarrhoea%26aulast%3DCamilleri%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D5%26spage%3D808%26epage%3D820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Yingzi  Qi</span>, <span class="hlFld-ContribAuthor ">Wenqing  Yang</span>, <span class="hlFld-ContribAuthor ">Yunlun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.01247" title="DOI URL">https://doi.org/10.3389/fphar.2020.01247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.01247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.01247%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DFarnesoid%252BX%252BReceptor%252BAgonists%252Bas%252BTherapeutic%252BTarget%252Bfor%252BCardiometabolic%252BDiseases%26aulast%3DLi%26aufirst%3DChao%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gianluca  Svegliati-Baroni</span>, <span class="hlFld-ContribAuthor ">Bárbara  Patrício</span>, <span class="hlFld-ContribAuthor ">Gessica  Lioci</span>, <span class="hlFld-ContribAuthor ">Maria Paula  Macedo</span>, <span class="hlFld-ContribAuthor ">Amalia  Gastaldelli</span>. </span><span class="cited-content_cbyCitation_article-title">Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (16)
                                     , 5820. <a href="https://doi.org/10.3390/ijms21165820" title="DOI URL">https://doi.org/10.3390/ijms21165820</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21165820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21165820%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DGut-Pancreas-Liver%252BAxis%252Bas%252Ba%252BTarget%252Bfor%252BTreatment%252Bof%252BNAFLD%25252FNASH%26aulast%3DSvegliati-Baroni%26aufirst%3DGianluca%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D16%26spage%3D5820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shizhang  Wei</span>, <span class="hlFld-ContribAuthor ">Xiao  Ma</span>, <span class="hlFld-ContribAuthor ">Yanling  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.01084" title="DOI URL">https://doi.org/10.3389/fphar.2020.01084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.01084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.01084%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DMechanism%252Bof%252BHydrophobic%252BBile%252BAcid-Induced%252BHepatocyte%252BInjury%252Band%252BDrug%252BDiscovery%26aulast%3DWei%26aufirst%3DShizhang%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arisa  Masuda</span>, <span class="hlFld-ContribAuthor ">Keigo  Gohda</span>, <span class="hlFld-ContribAuthor ">Yusuke  Iguchi</span>, <span class="hlFld-ContribAuthor ">Ko  Fujimori</span>, <span class="hlFld-ContribAuthor ">Yukiko  Yamashita</span>, <span class="hlFld-ContribAuthor ">Keisuke  Oda</span>, <span class="hlFld-ContribAuthor ">Mizuho  Une</span>, <span class="hlFld-ContribAuthor ">Naoki  Teno</span>. </span><span class="cited-content_cbyCitation_article-title">N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (14)
                                     , 115512. <a href="https://doi.org/10.1016/j.bmc.2020.115512" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115512%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DN1-Substituted%252Bbenzimidazole%252Bscaffold%252Bfor%252Bfarnesoid%2525C2%2525A0X%2525C2%2525A0receptor%252B%252528FXR%252529%252Bagonists%252Baccompanying%252Bprominent%252Bselectivity%252Bagainst%252Bvitamin%252BD%252Breceptor%252B%252528VDR%252529%26aulast%3DMasuda%26aufirst%3DArisa%26date%3D2020%26volume%3D28%26issue%3D14%26spage%3D115512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping  An</span>, <span class="hlFld-ContribAuthor ">Guangyan  Wei</span>, <span class="hlFld-ContribAuthor ">Pinzhu  Huang</span>, <span class="hlFld-ContribAuthor ">Wenda  Li</span>, <span class="hlFld-ContribAuthor ">Xiaolong  Qi</span>, <span class="hlFld-ContribAuthor ">Yi  Lin</span>, <span class="hlFld-ContribAuthor ">Kahini A.  Vaid</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Shucha  Zhang</span>, <span class="hlFld-ContribAuthor ">Yang  Li</span>, <span class="hlFld-ContribAuthor ">Yat Sun  Or</span>, <span class="hlFld-ContribAuthor ">Li‐Juan  Jiang</span>, <span class="hlFld-ContribAuthor ">Yury V.  Popov</span>. </span><span class="cited-content_cbyCitation_article-title">A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. </span><span class="cited-content_cbyCitation_journal-name">Liver International</span><span> <strong>2020,</strong> <em>40 </em>
                                    (7)
                                     , 1655-1669. <a href="https://doi.org/10.1111/liv.14490" title="DOI URL">https://doi.org/10.1111/liv.14490</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/liv.14490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fliv.14490%26sid%3Dliteratum%253Aachs%26jtitle%3DLiver%2520International%26atitle%3DA%252Bnovel%252Bnon%2525E2%252580%252590bile%252Bacid%252BFXR%252Bagonist%252BEDP%2525E2%252580%252590305%252Bpotently%252Bsuppresses%252Bliver%252Binjury%252Band%252Bfibrosis%252Bwithout%252Bworsening%252Bof%252Bductular%252Breaction%26aulast%3DAn%26aufirst%3DPing%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D7%26spage%3D1655%26epage%3D1669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mette  Vesterhus</span>, <span class="hlFld-ContribAuthor ">Tom Hemming  Karlsen</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Gastroenterology</span><span> <strong>2020,</strong> <em>55 </em>
                                    (6)
                                     , 588-614. <a href="https://doi.org/10.1007/s00535-020-01681-z" title="DOI URL">https://doi.org/10.1007/s00535-020-01681-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00535-020-01681-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00535-020-01681-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Gastroenterology%26atitle%3DEmerging%252Btherapies%252Bin%252Bprimary%252Bsclerosing%252Bcholangitis%25253A%252Bpathophysiological%252Bbasis%252Band%252Bclinical%252Bopportunities%26aulast%3DVesterhus%26aufirst%3DMette%26date%3D2020%26date%3D2020%26volume%3D55%26issue%3D6%26spage%3D588%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ludovico  Abenavoli</span>, <span class="hlFld-ContribAuthor ">Anna Caterina  Procopio</span>, <span class="hlFld-ContribAuthor ">Sharmila  Fagoonee</span>, <span class="hlFld-ContribAuthor ">Rinaldo  Pellicano</span>, <span class="hlFld-ContribAuthor ">Marco  Carbone</span>, <span class="hlFld-ContribAuthor ">Francesco  Luzza</span>, <span class="hlFld-ContribAuthor ">Pietro  Invernizzi</span>. </span><span class="cited-content_cbyCitation_article-title">Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. </span><span class="cited-content_cbyCitation_journal-name">Diseases</span><span> <strong>2020,</strong> <em>8 </em>
                                    (2)
                                     , 20. <a href="https://doi.org/10.3390/diseases8020020" title="DOI URL">https://doi.org/10.3390/diseases8020020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/diseases8020020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fdiseases8020020%26sid%3Dliteratum%253Aachs%26jtitle%3DDiseases%26atitle%3DPrimary%252BBiliary%252BCholangitis%252Band%252BBile%252BAcid%252BFarnesoid%252BX%252BReceptor%252BAgonists%26aulast%3DAbenavoli%26aufirst%3DLudovico%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D2%26spage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshio  Sumida</span>, <span class="hlFld-ContribAuthor ">Masato  Yoneda</span>, <span class="hlFld-ContribAuthor ">Yuji  Ogawa</span>, <span class="hlFld-ContribAuthor ">Masashi  Yoneda</span>, <span class="hlFld-ContribAuthor ">Takeshi  Okanoue</span>, <span class="hlFld-ContribAuthor ">Atsushi  Nakajima</span>. </span><span class="cited-content_cbyCitation_article-title">Current and new pharmacotherapy options for non-alcoholic steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2020,</strong> <em>21 </em>
                                    (8)
                                     , 953-967. <a href="https://doi.org/10.1080/14656566.2020.1744564" title="DOI URL">https://doi.org/10.1080/14656566.2020.1744564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2020.1744564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2020.1744564%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DCurrent%252Band%252Bnew%252Bpharmacotherapy%252Boptions%252Bfor%252Bnon-alcoholic%252Bsteatohepatitis%26aulast%3DSumida%26aufirst%3DYoshio%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D8%26spage%3D953%26epage%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanlin  Zhu</span>, <span class="hlFld-ContribAuthor ">Shuangshuang  Xu</span>, <span class="hlFld-ContribAuthor ">Yi  Lu</span>, <span class="hlFld-ContribAuthor ">Yijuan  Wei</span>, <span class="hlFld-ContribAuthor ">Benqiang  Yao</span>, <span class="hlFld-ContribAuthor ">Fusheng  Guo</span>, <span class="hlFld-ContribAuthor ">Xing  Zheng</span>, <span class="hlFld-ContribAuthor ">Yumeng  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  He</span>, <span class="hlFld-ContribAuthor ">Lihua  Jin</span>, <span class="hlFld-ContribAuthor ">Yong  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00590" title="DOI URL">https://doi.org/10.3389/fphar.2020.00590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00590%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DRepositioning%252Ban%252BImmunomodulatory%252BDrug%252BVidofludimus%252Bas%252Ba%252BFarnesoid%252BX%252BReceptor%252BModulator%252BWith%252BTherapeutic%252BEffects%252Bon%252BNAFLD%26aulast%3DZhu%26aufirst%3DYanlin%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alyssa  Kriegermeier</span>, <span class="hlFld-ContribAuthor ">Richard  Green</span>. </span><span class="cited-content_cbyCitation_article-title">Pediatric Cholestatic Liver Disease: Review of Bile Acid Metabolism and Discussion of Current and Emerging Therapies. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Medicine</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmed.2020.00149" title="DOI URL">https://doi.org/10.3389/fmed.2020.00149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmed.2020.00149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmed.2020.00149%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Medicine%26atitle%3DPediatric%252BCholestatic%252BLiver%252BDisease%25253A%252BReview%252Bof%252BBile%252BAcid%252BMetabolism%252Band%252BDiscussion%252Bof%252BCurrent%252Band%252BEmerging%252BTherapies%26aulast%3DKriegermeier%26aufirst%3DAlyssa%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael K.  Badman</span>, <span class="hlFld-ContribAuthor ">Jin  Chen</span>, <span class="hlFld-ContribAuthor ">Sachin  Desai</span>, <span class="hlFld-ContribAuthor ">Soniya  Vaidya</span>, <span class="hlFld-ContribAuthor ">Srikanth  Neelakantham</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu  Gan</span>, <span class="hlFld-ContribAuthor ">Kate  Danis</span>, <span class="hlFld-ContribAuthor ">Bryan  Laffitte</span>, <span class="hlFld-ContribAuthor ">Lloyd B.  Klickstein</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology in Drug Development</span><span> <strong>2020,</strong> <em>9 </em>
                                    (3)
                                     , 395-410. <a href="https://doi.org/10.1002/cpdd.762" title="DOI URL">https://doi.org/10.1002/cpdd.762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpdd.762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpdd.762%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520in%2520Drug%2520Development%26atitle%3DSafety%25252C%252BTolerability%25252C%252BPharmacokinetics%25252C%252Band%252BPharmacodynamics%252Bof%252Bthe%252BNovel%252BNon%2525E2%252580%252593Bile%252BAcid%252BFXR%252BAgonist%252BTropifexor%252B%252528LJN452%252529%252Bin%252BHealthy%252BVolunteers%26aulast%3DBadman%26aufirst%3DMichael%2BK.%26date%3D2020%26volume%3D9%26issue%3D3%26spage%3D395%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James Philip G.  Esteban</span>, <span class="hlFld-ContribAuthor ">Amon  Asgharpour</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Gastroenterology Clinics of North America</span><span> <strong>2020,</strong> <em>49 </em>
                                    (1)
                                     , 105-121. <a href="https://doi.org/10.1016/j.gtc.2019.10.003" title="DOI URL">https://doi.org/10.1016/j.gtc.2019.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.gtc.2019.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.gtc.2019.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DGastroenterology%2520Clinics%2520of%2520North%2520America%26atitle%3DPharmacologic%252BTreatment%252BStrategies%252Bfor%252BNonalcoholic%252BSteatohepatitis%26aulast%3DEsteban%26aufirst%3DJames%2BPhilip%2BG.%26date%3D2020%26volume%3D49%26issue%3D1%26spage%3D105%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John Y. L.  Chiang</span>, <span class="hlFld-ContribAuthor ">Jessica M.  Ferrell</span>. </span><span class="cited-content_cbyCitation_article-title">Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Physiology-Gastrointestinal and Liver Physiology</span><span> <strong>2020,</strong> <em>318 </em>
                                    (3)
                                     , G554-G573. <a href="https://doi.org/10.1152/ajpgi.00223.2019" title="DOI URL">https://doi.org/10.1152/ajpgi.00223.2019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/ajpgi.00223.2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fajpgi.00223.2019%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Gastrointestinal%2520and%2520Liver%2520Physiology%26atitle%3DBile%252Bacid%252Breceptors%252BFXR%252Band%252BTGR5%252Bsignaling%252Bin%252Bfatty%252Bliver%252Bdiseases%252Band%252Btherapy%26aulast%3DChiang%26aufirst%3DJohn%2BY.%2BL.%26date%3D2020%26volume%3D318%26issue%3D3%26spage%3DG554%26epage%3DG573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiming  Hu</span>, <span class="hlFld-ContribAuthor ">Aizhen  Lin</span>, <span class="hlFld-ContribAuthor ">Mingwang  Kong</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Yao</span>, <span class="hlFld-ContribAuthor ">Mingzhu  Yin</span>, <span class="hlFld-ContribAuthor ">Hui  Xia</span>, <span class="hlFld-ContribAuthor ">Jun  Ma</span>, <span class="hlFld-ContribAuthor ">Hongtao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Gastroenterology</span><span> <strong>2020,</strong> <em>55 </em>
                                    (2)
                                     , 142-158. <a href="https://doi.org/10.1007/s00535-019-01649-8" title="DOI URL">https://doi.org/10.1007/s00535-019-01649-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00535-019-01649-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00535-019-01649-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Gastroenterology%26atitle%3DIntestinal%252Bmicrobiome%252Band%252BNAFLD%25253A%252Bmolecular%252Binsights%252Band%252Btherapeutic%252Bperspectives%26aulast%3DHu%26aufirst%3DHaiming%26date%3D2020%26date%3D2019%26volume%3D55%26issue%3D2%26spage%3D142%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana‐Carolina  Cardoso</span>, <span class="hlFld-ContribAuthor ">Claudio  Figueiredo‐Mendes</span>, <span class="hlFld-ContribAuthor ">Cristiane  A. Villela‐Nogueira</span>, <span class="hlFld-ContribAuthor ">Arun J.  Sanyal</span>. </span><span class="cited-content_cbyCitation_article-title">New drugs for non‐alcoholic steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Liver International</span><span> <strong>2020,</strong> <em>40 </em>
                                    (S1)
                                     , 96-101. <a href="https://doi.org/10.1111/liv.14354" title="DOI URL">https://doi.org/10.1111/liv.14354</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/liv.14354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fliv.14354%26sid%3Dliteratum%253Aachs%26jtitle%3DLiver%2520International%26atitle%3DNew%252Bdrugs%252Bfor%252Bnon%2525E2%252580%252590alcoholic%252Bsteatohepatitis%26aulast%3DCardoso%26aufirst%3DAna%25E2%2580%2590Carolina%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3DS1%26spage%3D96%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Wagner</span>, <span class="hlFld-ContribAuthor ">Peter  Fickert</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Therapies for Chronic Cholestatic Liver Diseases. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Pharmacology and Toxicology</span><span> <strong>2020,</strong> <em>60 </em>
                                    (1)
                                     , 503-527. <a href="https://doi.org/10.1146/annurev-pharmtox-010818-021059" title="DOI URL">https://doi.org/10.1146/annurev-pharmtox-010818-021059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-pharmtox-010818-021059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-pharmtox-010818-021059%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Pharmacology%2520and%2520Toxicology%26atitle%3DDrug%252BTherapies%252Bfor%252BChronic%252BCholestatic%252BLiver%252BDiseases%26aulast%3DWagner%26aufirst%3DMartin%26date%3D2020%26volume%3D60%26issue%3D1%26spage%3D503%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Berangere  Gapp</span>, <span class="hlFld-ContribAuthor ">Marie  Jourdain</span>, <span class="hlFld-ContribAuthor ">Pauline  Bringer</span>, <span class="hlFld-ContribAuthor ">Benjamin  Kueng</span>, <span class="hlFld-ContribAuthor ">Delphine  Weber</span>, <span class="hlFld-ContribAuthor ">Arnaud  Osmont</span>, <span class="hlFld-ContribAuthor ">Stefan  Zurbruegg</span>, <span class="hlFld-ContribAuthor ">Judith  Knehr</span>, <span class="hlFld-ContribAuthor ">Rocco  Falchetto</span>, <span class="hlFld-ContribAuthor ">Guglielmo  Roma</span>, <span class="hlFld-ContribAuthor ">William  Dietrich</span>, <span class="hlFld-ContribAuthor ">Reginald  Valdez</span>, <span class="hlFld-ContribAuthor ">Nicolau  Beckmann</span>, <span class="hlFld-ContribAuthor ">Florian  Nigsch</span>, <span class="hlFld-ContribAuthor ">Arun J.  Sanyal</span>, <span class="hlFld-ContribAuthor ">Iwona  Ksiazek</span>. </span><span class="cited-content_cbyCitation_article-title">Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of
              De Novo
              Lipogenesis in a Murine NASH Model. </span><span class="cited-content_cbyCitation_journal-name">Hepatology Communications</span><span> <strong>2020,</strong> <em>4 </em>
                                    (1)
                                     , 109-125. <a href="https://doi.org/10.1002/hep4.1443" title="DOI URL">https://doi.org/10.1002/hep4.1443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hep4.1443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhep4.1443%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatology%2520Communications%26atitle%3DFarnesoid%252BX%252BReceptor%252BAgonism%25252C%252BAcetyl%2525E2%252580%252590Coenzyme%252BA%252BCarboxylase%252BInhibition%25252C%252Band%252BBack%252BTranslation%252Bof%252BClinically%252BObserved%252BEndpoints%252Bof%252BDe%252BNovo%252BLipogenesis%252Bin%252Ba%252BMurine%252BNASH%252BModel%26aulast%3DGapp%26aufirst%3DBerangere%26date%3D2020%26date%3D2019%26volume%3D4%26issue%3D1%26spage%3D109%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katharina C.  Reimer</span>, <span class="hlFld-ContribAuthor ">Alexander  Wree</span>, <span class="hlFld-ContribAuthor ">Christoph  Roderburg</span>, <span class="hlFld-ContribAuthor ">Frank  Tacke</span>. </span><span class="cited-content_cbyCitation_article-title">New drugs for NAFLD: lessons from basic models to the clinic. </span><span class="cited-content_cbyCitation_journal-name">Hepatology International</span><span> <strong>2020,</strong> <em>14 </em>
                                    (1)
                                     , 8-23. <a href="https://doi.org/10.1007/s12072-019-10001-4" title="DOI URL">https://doi.org/10.1007/s12072-019-10001-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12072-019-10001-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12072-019-10001-4%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatology%2520International%26atitle%3DNew%252Bdrugs%252Bfor%252BNAFLD%25253A%252Blessons%252Bfrom%252Bbasic%252Bmodels%252Bto%252Bthe%252Bclinic%26aulast%3DReimer%26aufirst%3DKatharina%2BC.%26date%3D2020%26date%3D2019%26volume%3D14%26issue%3D1%26spage%3D8%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  Gerussi</span>, <span class="hlFld-ContribAuthor ">Daphne  D’Amato</span>, <span class="hlFld-ContribAuthor ">Laura  Cristoferi</span>, <span class="hlFld-ContribAuthor ">Sarah Elizabeth  O’Donnell</span>, <span class="hlFld-ContribAuthor ">Marco  Carbone</span>, <span class="hlFld-ContribAuthor ">Pietro  Invernizzi</span>. </span><span class="cited-content_cbyCitation_article-title">Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. </span><span class="cited-content_cbyCitation_journal-name">Annals of Hepatology</span><span> <strong>2020,</strong> <em>19 </em>
                                    (1)
                                     , 5-16. <a href="https://doi.org/10.1016/j.aohep.2019.09.009" title="DOI URL">https://doi.org/10.1016/j.aohep.2019.09.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.aohep.2019.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.aohep.2019.09.009%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Hepatology%26atitle%3DMultiple%252Btherapeutic%252Btargets%252Bin%252Brare%252Bcholestatic%252Bliver%252Bdiseases%25253A%252BTime%252Bto%252Bredefine%252Btreatment%252Bstrategies%26aulast%3DGerussi%26aufirst%3DAlessio%26date%3D2020%26volume%3D19%26issue%3D1%26spage%3D5%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcos  Pedrosa</span>, <span class="hlFld-ContribAuthor ">Star  Seyedkazemi</span>, <span class="hlFld-ContribAuthor ">Sven  Francque</span>, <span class="hlFld-ContribAuthor ">Arun  Sanyal</span>, <span class="hlFld-ContribAuthor ">Mary  Rinella</span>, <span class="hlFld-ContribAuthor ">Michael  Charlton</span>, <span class="hlFld-ContribAuthor ">Rohit  Loomba</span>, <span class="hlFld-ContribAuthor ">Vlad  Ratziu</span>, <span class="hlFld-ContribAuthor ">Jossy  Kochuparampil</span>, <span class="hlFld-ContribAuthor ">Laurent  Fischer</span>, <span class="hlFld-ContribAuthor ">Sujata  Vaidyanathan</span>, <span class="hlFld-ContribAuthor ">Quentin M.  Anstee</span>. </span><span class="cited-content_cbyCitation_article-title">A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. </span><span class="cited-content_cbyCitation_journal-name">Contemporary Clinical Trials</span><span> <strong>2020,</strong> <em>88 </em>, 105889. <a href="https://doi.org/10.1016/j.cct.2019.105889" title="DOI URL">https://doi.org/10.1016/j.cct.2019.105889</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cct.2019.105889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cct.2019.105889%26sid%3Dliteratum%253Aachs%26jtitle%3DContemporary%2520Clinical%2520Trials%26atitle%3DA%252Brandomized%25252C%252Bdouble-blind%25252C%252Bmulticenter%25252C%252Bphase%252B2b%252Bstudy%252Bto%252Bevaluate%252Bthe%252Bsafety%252Band%252Befficacy%252Bof%252Ba%252Bcombination%252Bof%252Btropifexor%252Band%252Bcenicriviroc%252Bin%252Bpatients%252Bwith%252Bnonalcoholic%252Bsteatohepatitis%252Band%252Bliver%252Bfibrosis%25253A%252BStudy%252Bdesign%252Bof%252Bthe%252BTANDEM%252Btrial%26aulast%3DPedrosa%26aufirst%3DMarcos%26date%3D2020%26volume%3D88%26spage%3D105889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Paula  Diaz Soto</span>, <span class="hlFld-ContribAuthor ">Joseph K  Lim</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data</p>. </span><span class="cited-content_cbyCitation_journal-name">Hepatic Medicine: Evidence and Research</span><span> <strong>2020,</strong> <em>Volume 12 </em>, 115-123. <a href="https://doi.org/10.2147/HMER.S230613" title="DOI URL">https://doi.org/10.2147/HMER.S230613</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/HMER.S230613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FHMER.S230613%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatic%2520Medicine%253A%2520Evidence%2520and%2520Research%26atitle%3D%25253Cp%25253EEvaluating%252Bthe%252BTherapeutic%252BPotential%252Bof%252BCenicriviroc%252Bin%252Bthe%252BTreatment%252Bof%252BNonalcoholic%252BSteatohepatitis%252Bwith%252BFibrosis%25253A%252BA%252BBrief%252BReport%252Bon%252BEmerging%252BData%25253C%25252Fp%25253E%26aulast%3DDiaz%2BSoto%26aufirst%3DMaria%2BPaula%26date%3D2020%26date%3D2020%26volume%3DVolume%252012%26spage%3D115%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annarosa  Floreani</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis</p>. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental Pharmacology</span><span> <strong>2020,</strong> <em>Volume 12 </em>, 643-652. <a href="https://doi.org/10.2147/JEP.S267375" title="DOI URL">https://doi.org/10.2147/JEP.S267375</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/JEP.S267375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FJEP.S267375%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520Pharmacology%26atitle%3D%25253Cp%25253EExperimental%252BPharmacological%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BPrimary%252BBiliary%252BCholangitis%25253C%25252Fp%25253E%26aulast%3DFloreani%26aufirst%3DAnnarosa%26date%3D2020%26date%3D2020%26volume%3DVolume%252012%26spage%3D643%26epage%3D652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Zhao</span>, <span class="hlFld-ContribAuthor ">Chien-Yu  Lin</span>, <span class="hlFld-ContribAuthor ">Kun  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">siRNA- and miRNA-based therapeutics for liver fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Translational Research</span><span> <strong>2019,</strong> <em>214 </em>, 17-29. <a href="https://doi.org/10.1016/j.trsl.2019.07.007" title="DOI URL">https://doi.org/10.1016/j.trsl.2019.07.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.trsl.2019.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.trsl.2019.07.007%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Research%26atitle%3DsiRNA-%252Band%252BmiRNA-based%252Btherapeutics%252Bfor%252Bliver%252Bfibrosis%26aulast%3DZhao%26aufirst%3DZhen%26date%3D2019%26volume%3D214%26spage%3D17%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Lin  Luan</span>, <span class="hlFld-ContribAuthor ">Xiao-Kui  Huo</span>, <span class="hlFld-ContribAuthor ">Pei-Pei  Dong</span>, <span class="hlFld-ContribAuthor ">Xiang-Ge  Tian</span>, <span class="hlFld-ContribAuthor ">Cheng-Peng  Sun</span>, <span class="hlFld-ContribAuthor ">Xia  Lv</span>, <span class="hlFld-ContribAuthor ">Lei  Feng</span>, <span class="hlFld-ContribAuthor ">Jing  Ning</span>, <span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Bao-Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Chi  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111652. <a href="https://doi.org/10.1016/j.ejmech.2019.111652" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111652%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252Bpotent%252Bnon-steroidal%252BFXR%252Bagonists%252Bprotostane-type%252Btriterpenoids%25253A%252BStructure-activity%252Brelationship%252Band%252Bmechanism%26aulast%3DLuan%26aufirst%3DZhi-Lin%26date%3D2019%26volume%3D182%26spage%3D111652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ko  Fujimori</span>, <span class="hlFld-ContribAuthor ">Yusuke  Iguchi</span>, <span class="hlFld-ContribAuthor ">Yukiko  Yamashita</span>, <span class="hlFld-ContribAuthor ">Keigo  Gohda</span>, <span class="hlFld-ContribAuthor ">Naoki  Teno</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (22)
                                     , 4155. <a href="https://doi.org/10.3390/molecules24224155" title="DOI URL">https://doi.org/10.3390/molecules24224155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24224155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24224155%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Bof%252BNovel%252BFarnesoid%252BX%252BReceptor%252BAgonists%252Band%252BValidation%252Bof%252BTheir%252BEfficacy%252Bin%252BActivating%252BDifferentiation%252Bof%252BMouse%252BBone%252BMarrow-Derived%252BMesenchymal%252BStem%252BCells%252Binto%252BOsteoblasts%26aulast%3DFujimori%26aufirst%3DKo%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D22%26spage%3D4155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tim  van Zutphen</span>, <span class="hlFld-ContribAuthor ">Johanna H.M.  Stroeve</span>, <span class="hlFld-ContribAuthor ">Jiufang  Yang</span>, <span class="hlFld-ContribAuthor ">Vincent W.  Bloks</span>, <span class="hlFld-ContribAuthor ">Angelika  Jurdzinski</span>, <span class="hlFld-ContribAuthor ">Han  Roelofsen</span>, <span class="hlFld-ContribAuthor ">Nicolette C.A.  Huijkman</span>, <span class="hlFld-ContribAuthor ">Theo H.  van Dijk</span>, <span class="hlFld-ContribAuthor ">Roel J.  Vonk</span>, <span class="hlFld-ContribAuthor ">Jan  van Deursen</span>, <span class="hlFld-ContribAuthor ">Bart  Staels</span>, <span class="hlFld-ContribAuthor ">Albert K.  Groen</span>, <span class="hlFld-ContribAuthor ">Folkert  Kuipers</span>. </span><span class="cited-content_cbyCitation_article-title">FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements. </span><span class="cited-content_cbyCitation_journal-name">Journal of Lipid Research</span><span> <strong>2019,</strong> <em>60 </em>
                                    (9)
                                     , 1547-1561. <a href="https://doi.org/10.1194/jlr.M094508" title="DOI URL">https://doi.org/10.1194/jlr.M094508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1194/jlr.M094508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1194%2Fjlr.M094508%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Lipid%2520Research%26atitle%3DFXR%252Boverexpression%252Balters%252Badipose%252Btissue%252Barchitecture%252Bin%252Bmice%252Band%252Blimits%252Bits%252Bstorage%252Bcapacity%252Bleading%252Bto%252Bmetabolic%252Bderangements%26aulast%3Dvan%2BZutphen%26aufirst%3DTim%26date%3D2019%26volume%3D60%26issue%3D9%26spage%3D1547%26epage%3D1561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanqing  Wu</span>, <span class="hlFld-ContribAuthor ">Can  Li</span>, <span class="hlFld-ContribAuthor ">Fei  Zhou</span>, <span class="hlFld-ContribAuthor ">Jianxiao  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Xu</span>, <span class="hlFld-ContribAuthor ">Huanfeng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of
              β
              ‐Isoxazole Carbonyl Derivatives and their Analogues
              via
              Palladium‐Catalyzed Sequential C(
              sp
              2
              )−O/C(
              sp
              2
              )−C(
              sp
              3
              ) Bond Formations. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (16)
                                     , 3813-3823. <a href="https://doi.org/10.1002/adsc.201900391" title="DOI URL">https://doi.org/10.1002/adsc.201900391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201900391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201900391%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DSynthesis%252Bof%252B%2525CE%2525B2%252B%2525E2%252580%252590Isoxazole%252BCarbonyl%252BDerivatives%252Band%252Btheir%252BAnalogues%252Bvia%252BPalladium%2525E2%252580%252590Catalyzed%252BSequential%252BC%252528%252Bsp%252B2%252B%252529%2525E2%252588%252592O%25252FC%252528%252Bsp%252B2%252B%252529%2525E2%252588%252592C%252528%252Bsp%252B3%252B%252529%252BBond%252BFormations%26aulast%3DWu%26aufirst%3DWanqing%26date%3D2019%26date%3D2019%26volume%3D361%26issue%3D16%26spage%3D3813%26epage%3D3823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eloy D.  Hernandez</span>, <span class="hlFld-ContribAuthor ">Lianxing  Zheng</span>, <span class="hlFld-ContribAuthor ">Young  Kim</span>, <span class="hlFld-ContribAuthor ">Bin  Fang</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Reginald A.  Valdez</span>, <span class="hlFld-ContribAuthor ">William F.  Dietrich</span>, <span class="hlFld-ContribAuthor ">Paul V.  Rucker</span>, <span class="hlFld-ContribAuthor ">Donatella  Chianelli</span>, <span class="hlFld-ContribAuthor ">James  Schmeits</span>, <span class="hlFld-ContribAuthor ">Dingjiu  Bao</span>, <span class="hlFld-ContribAuthor ">Jocelyn  Zoll</span>, <span class="hlFld-ContribAuthor ">Claire  Dubois</span>, <span class="hlFld-ContribAuthor ">Glenn C.  Federe</span>, <span class="hlFld-ContribAuthor ">Lihao  Chen</span>, <span class="hlFld-ContribAuthor ">Sean B.  Joseph</span>, <span class="hlFld-ContribAuthor ">Lloyd B.  Klickstein</span>, <span class="hlFld-ContribAuthor ">John  Walker</span>, <span class="hlFld-ContribAuthor ">Valentina  Molteni</span>, <span class="hlFld-ContribAuthor ">Peter  McNamara</span>, <span class="hlFld-ContribAuthor ">Shelly  Meeusen</span>, <span class="hlFld-ContribAuthor ">David C.  Tully</span>, <span class="hlFld-ContribAuthor ">Michael K.  Badman</span>, <span class="hlFld-ContribAuthor ">Jie  Xu</span>, <span class="hlFld-ContribAuthor ">Bryan  Laffitte</span>. </span><span class="cited-content_cbyCitation_article-title">Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. </span><span class="cited-content_cbyCitation_journal-name">Hepatology Communications</span><span> <strong>2019,</strong> <em>3 </em>
                                    (8)
                                     , 1085-1097. <a href="https://doi.org/10.1002/hep4.1368" title="DOI URL">https://doi.org/10.1002/hep4.1368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hep4.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhep4.1368%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatology%2520Communications%26atitle%3DTropifexor%2525E2%252580%252590Mediated%252BAbrogation%252Bof%252BSteatohepatitis%252Band%252BFibrosis%252BIs%252BAssociated%252BWith%252Bthe%252BAntioxidative%252BGene%252BExpression%252BProfile%252Bin%252BRodents%26aulast%3DHernandez%26aufirst%3DEloy%2BD.%26date%3D2019%26date%3D2019%26volume%3D3%26issue%3D8%26spage%3D1085%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reenam S.  Khan</span>, <span class="hlFld-ContribAuthor ">Fernando  Bril</span>, <span class="hlFld-ContribAuthor ">Kenneth  Cusi</span>, <span class="hlFld-ContribAuthor ">Philip N.  Newsome</span>. </span><span class="cited-content_cbyCitation_article-title">Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. </span><span class="cited-content_cbyCitation_journal-name">Hepatology</span><span> <strong>2019,</strong> <em>61 </em><a href="https://doi.org/10.1002/hep.30429" title="DOI URL">https://doi.org/10.1002/hep.30429</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hep.30429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhep.30429%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatology%26atitle%3DModulation%252Bof%252BInsulin%252BResistance%252Bin%252BNonalcoholic%252BFatty%252BLiver%252BDisease%26aulast%3DKhan%26aufirst%3DReenam%2BS.%26date%3D2019%26date%3D2019%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Manka</span>, <span class="hlFld-ContribAuthor ">Amos  Zeller</span>, <span class="hlFld-ContribAuthor ">Wing-Kin  Syn</span>. </span><span class="cited-content_cbyCitation_article-title">Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2019,</strong> <em>79 </em>
                                    (9)
                                     , 903-927. <a href="https://doi.org/10.1007/s40265-019-01126-9" title="DOI URL">https://doi.org/10.1007/s40265-019-01126-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-019-01126-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-019-01126-9%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DFibrosis%252Bin%252BChronic%252BLiver%252BDisease%25253A%252BAn%252BUpdate%252Bon%252BDiagnostic%252Band%252BTreatment%252BModalities%26aulast%3DManka%26aufirst%3DPaul%26date%3D2019%26date%3D2019%26volume%3D79%26issue%3D9%26spage%3D903%26epage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naoki  Teno</span>, <span class="hlFld-ContribAuthor ">Yukiko  Yamashita</span>, <span class="hlFld-ContribAuthor ">Arisa  Masuda</span>, <span class="hlFld-ContribAuthor ">Yusuke  Iguchi</span>, <span class="hlFld-ContribAuthor ">Keisuke  Oda</span>, <span class="hlFld-ContribAuthor ">Ko  Fujimori</span>, <span class="hlFld-ContribAuthor ">Takie  Hiramoto</span>, <span class="hlFld-ContribAuthor ">Tomoko  Nishimaki-Mogami</span>, <span class="hlFld-ContribAuthor ">Mizuho  Une</span>, <span class="hlFld-ContribAuthor ">Keigo  Gohda</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (11)
                                     , 2220-2227. <a href="https://doi.org/10.1016/j.bmc.2019.04.029" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.04.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.04.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bpotent%252Bfarnesoid%252BX%252Breceptor%252B%252528FXR%252529%252Bantagonist%252Bshowing%252Bfavorable%252BPK%252Bprofile%252Band%252Bdistribution%252Btoward%252Btarget%252Btissues%25253A%252BComprehensive%252Bunderstanding%252Bof%252Bstructure-activity%252Brelationship%252Bof%252BFXR%252Bantagonists%26aulast%3DTeno%26aufirst%3DNaoki%26date%3D2019%26volume%3D27%26issue%3D11%26spage%3D2220%26epage%3D2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuji  Ogawa</span>, <span class="hlFld-ContribAuthor ">Masato  Yoneda</span>, <span class="hlFld-ContribAuthor ">Takashi  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Yasushi  Honda</span>, <span class="hlFld-ContribAuthor ">Takaomi  Kessoku</span>, <span class="hlFld-ContribAuthor ">Kento  Imajo</span>, <span class="hlFld-ContribAuthor ">Satoru  Saito</span>, <span class="hlFld-ContribAuthor ">Atsushi  Nakajima</span>. </span><span class="cited-content_cbyCitation_article-title">Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2019,</strong> <em>20 </em>
                                    (1)
                                     , 69-82. <a href="https://doi.org/10.1080/14656566.2018.1543403" title="DOI URL">https://doi.org/10.1080/14656566.2018.1543403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2018.1543403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2018.1543403%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DPresent%252Band%252Bemerging%252Bpharmacotherapies%252Bfor%252Bnon-alcoholic%252Bsteatohepatitis%252Bin%252Badults%26aulast%3DOgawa%26aufirst%3DYuji%26date%3D2019%26date%3D2018%26volume%3D20%26issue%3D1%26spage%3D69%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Verena  Keitel</span>, <span class="hlFld-ContribAuthor ">Carola  Dröge</span>, <span class="hlFld-ContribAuthor ">Dieter  Häussinger</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting FXR in Cholestasis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 299-324. <a href="https://doi.org/10.1007/164_2019_231" title="DOI URL">https://doi.org/10.1007/164_2019_231</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/164_2019_231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F164_2019_231%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252BFXR%252Bin%252BCholestasis%26aulast%3DKeitel%26aufirst%3DVerena%26date%3D2019%26date%3D2019%26spage%3D299%26epage%3D324%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DBile%252BAcids%252Band%252BTheir%252BReceptors%26aulast%3DFiorucci%26aufirst%3DStefano%26date%3D2019%26volume%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Gege</span>, <span class="hlFld-ContribAuthor ">Eva  Hambruch</span>, <span class="hlFld-ContribAuthor ">Nina  Hambruch</span>, <span class="hlFld-ContribAuthor ">Olaf  Kinzel</span>, <span class="hlFld-ContribAuthor ">Claus  Kremoser</span>. </span><span class="cited-content_cbyCitation_article-title">Nonsteroidal FXR Ligands: Current Status and Clinical Applications. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 167-205. <a href="https://doi.org/10.1007/164_2019_232" title="DOI URL">https://doi.org/10.1007/164_2019_232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/164_2019_232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F164_2019_232%26sid%3Dliteratum%253Aachs%26atitle%3DNonsteroidal%252BFXR%252BLigands%25253A%252BCurrent%252BStatus%252Band%252BClinical%252BApplications%26aulast%3DGege%26aufirst%3DChristian%26date%3D2019%26date%3D2019%26spage%3D167%26epage%3D205%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DBile%252BAcids%252Band%252BTheir%252BReceptors%26aulast%3DFiorucci%26aufirst%3DStefano%26date%3D2019%26volume%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simona  De Marino</span>, <span class="hlFld-ContribAuthor ">Carmen  Festa</span>, <span class="hlFld-ContribAuthor ">Valentina  Sepe</span>, <span class="hlFld-ContribAuthor ">Angela  Zampella</span>. </span><span class="cited-content_cbyCitation_article-title">Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 137-165. <a href="https://doi.org/10.1007/164_2019_237" title="DOI URL">https://doi.org/10.1007/164_2019_237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/164_2019_237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F164_2019_237%26sid%3Dliteratum%253Aachs%26atitle%3DChemistry%252Band%252BPharmacology%252Bof%252BGPBAR1%252Band%252BFXR%252BSelective%252BAgonists%25252C%252BDual%252BAgonists%25252C%252Band%252BAntagonists%26aulast%3DDe%2BMarino%26aufirst%3DSimona%26date%3D2019%26date%3D2019%26spage%3D137%26epage%3D165%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DBile%252BAcids%252Band%252BTheir%252BReceptors%26aulast%3DFiorucci%26aufirst%3DStefano%26date%3D2019%26volume%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Yang</span>, <span class="hlFld-ContribAuthor ">Ghulam Jilany  Khan</span>, <span class="hlFld-ContribAuthor ">Ziteng  Wu</span>, <span class="hlFld-ContribAuthor ">Xue  Wang</span>, <span class="hlFld-ContribAuthor ">Luyong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenzhou  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (1)
                                     , 112-128. <a href="https://doi.org/10.1016/j.drudis.2018.09.007" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.09.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.09.007%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DBile%252Bacid%252Bhomeostasis%252Bparadigm%252Band%252Bits%252Bconnotation%252Bwith%252Bcholestatic%252Bliver%252Bdiseases%26aulast%3DYang%26aufirst%3DTingting%26date%3D2019%26volume%3D24%26issue%3D1%26spage%3D112%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Schierle</span>, <span class="hlFld-ContribAuthor ">Jurema  Schmidt</span>, <span class="hlFld-ContribAuthor ">Astrid  Kaiser</span>, <span class="hlFld-ContribAuthor ">Daniel  Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (23)
                                     , 2530-2545. <a href="https://doi.org/10.1002/cmdc.201800549" title="DOI URL">https://doi.org/10.1002/cmdc.201800549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800549%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSelective%252BOptimization%252Bof%252BPranlukast%252Bto%252BFarnesoid%2525E2%252580%252585X%252BReceptor%252BModulators%26aulast%3DSchierle%26aufirst%3DSimone%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D23%26spage%3D2530%26epage%3D2545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian N.  Finck</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. </span><span class="cited-content_cbyCitation_journal-name">Diabetes</span><span> <strong>2018,</strong> <em>67 </em>
                                    (12)
                                     , 2485-2493. <a href="https://doi.org/10.2337/dbi18-0024" title="DOI URL">https://doi.org/10.2337/dbi18-0024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2337/dbi18-0024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2337%2Fdbi18-0024%26sid%3Dliteratum%253Aachs%26jtitle%3DDiabetes%26atitle%3DTargeting%252BMetabolism%25252C%252BInsulin%252BResistance%25252C%252Band%252BDiabetes%252Bto%252BTreat%252BNonalcoholic%252BSteatohepatitis%26aulast%3DFinck%26aufirst%3DBrian%2BN.%26date%3D2018%26date%3D2018%26volume%3D67%26issue%3D12%26spage%3D2485%26epage%3D2493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Wang</span>, <span class="hlFld-ContribAuthor ">Qingxian  He</span>, <span class="hlFld-ContribAuthor ">Guangji  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Xu</span>, <span class="hlFld-ContribAuthor ">Haiping  Hao</span>. </span><span class="cited-content_cbyCitation_article-title">FXR modulators for enterohepatic and metabolic diseases. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2018,</strong> <em>28 </em>
                                    (11)
                                     , 765-782. <a href="https://doi.org/10.1080/13543776.2018.1527906" title="DOI URL">https://doi.org/10.1080/13543776.2018.1527906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2018.1527906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2018.1527906%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DFXR%252Bmodulators%252Bfor%252Benterohepatic%252Band%252Bmetabolic%252Bdiseases%26aulast%3DWang%26aufirst%3DHong%26date%3D2018%26date%3D2018%26volume%3D28%26issue%3D11%26spage%3D765%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jurema  Schmidt</span>, <span class="hlFld-ContribAuthor ">Simone  Schierle</span>, <span class="hlFld-ContribAuthor ">Leonie  Gellrich</span>, <span class="hlFld-ContribAuthor ">Astrid  Kaiser</span>, <span class="hlFld-ContribAuthor ">Daniel  Merk</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (14)
                                     , 4240-4253. <a href="https://doi.org/10.1016/j.bmc.2018.07.017" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.07.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.07.017%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Band%252Bin%252Bvitro%252Bprofiling%252Bof%252BN-phenylbenzamide-based%252Bfarnesoid%252BX%252Breceptor%252Bantagonists%26aulast%3DSchmidt%26aufirst%3DJurema%26date%3D2018%26volume%3D26%26issue%3D14%26spage%3D4240%26epage%3D4253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gwilym J.  Webb</span>, <span class="hlFld-ContribAuthor ">Gideon M.  Hirschfield</span>. </span><span class="cited-content_cbyCitation_article-title">Work in Progress. </span><span class="cited-content_cbyCitation_journal-name">Clinics in Liver Disease</span><span> <strong>2018,</strong> <em>22 </em>
                                    (3)
                                     , 501-515. <a href="https://doi.org/10.1016/j.cld.2018.03.004" title="DOI URL">https://doi.org/10.1016/j.cld.2018.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cld.2018.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cld.2018.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DClinics%2520in%2520Liver%2520Disease%26atitle%3DWork%252Bin%252BProgress%26aulast%3DWebb%26aufirst%3DGwilym%2BJ.%26date%3D2018%26volume%3D22%26issue%3D3%26spage%3D501%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chang  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Update on FXR Biology: Promising Therapeutic Target?. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (7)
                                     , 2069. <a href="https://doi.org/10.3390/ijms19072069" title="DOI URL">https://doi.org/10.3390/ijms19072069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19072069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19072069%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DUpdate%252Bon%252BFXR%252BBiology%25253A%252BPromising%252BTherapeutic%252BTarget%25253F%26aulast%3DHan%26aufirst%3DChang%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D7%26spage%3D2069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan Freark  de Boer</span>, <span class="hlFld-ContribAuthor ">Vincent W.  Bloks</span>, <span class="hlFld-ContribAuthor ">Esther  Verkade</span>, <span class="hlFld-ContribAuthor ">M. Rebecca  Heiner-Fokkema</span>, <span class="hlFld-ContribAuthor ">Folkert  Kuipers</span>. </span><span class="cited-content_cbyCitation_article-title">New insights in the multiple roles of bile acids and their signaling pathways in metabolic control. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Lipidology</span><span> <strong>2018,</strong> <em>29 </em>
                                    (3)
                                     , 194-202. <a href="https://doi.org/10.1097/MOL.0000000000000508" title="DOI URL">https://doi.org/10.1097/MOL.0000000000000508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MOL.0000000000000508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMOL.0000000000000508%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Lipidology%26atitle%3DNew%252Binsights%252Bin%252Bthe%252Bmultiple%252Broles%252Bof%252Bbile%252Bacids%252Band%252Btheir%252Bsignaling%252Bpathways%252Bin%252Bmetabolic%252Bcontrol%26aulast%3Dde%2BBoer%26aufirst%3DJan%2BFreark%26date%3D2018%26volume%3D29%26issue%3D3%26spage%3D194%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong-Jin  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Five-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 243-262. <a href="https://doi.org/10.1016/B978-0-08-102788-2.00009-X" title="DOI URL">https://doi.org/10.1016/B978-0-08-102788-2.00009-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102788-2.00009-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102788-2.00009-X%26sid%3Dliteratum%253Aachs%26atitle%3DFive-Membered%252BRing%252BSystems%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2018%26spage%3D243%26epage%3D262%26pub%3DElsevier%26date%3D2018%26volume%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of FXR agonists reported in the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Model of <b>1</b> docked into FXR ligand binding domain from X-ray structure of PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DCT">3DCT</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Induction of FXR target genes BSEP and SHP in vitro in rat primary hepatocytes by compound <b>1</b>. Primary rat hepatocytes were treated for 24 h with compound <b>1</b> or vehicle only, and gene expression was determined by real-time quantitative PCR. *<i>p</i> ≤ 0.01, **<i>p</i> ≤ 0.001, and ***<i>p</i> ≤ 0.0001 compared to vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Induction of FXR target genes SHP and BSEP in rat liver by compounds <b>1</b> and <b>16</b> following single oral dose. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. *<i>p</i> ≤ 0.01 versus vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Induction of FXR target genes SHP and FGF15 in rat ileum by compounds <b>1</b> and <b>16</b> following single oral dose. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. #<i>p</i> ≤ 0.05 and *<i>p</i> ≤ 0.01 vs vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Induction of FXR target genes SHP, BSEP, and CYP8B1 in rat liver following oral administration of compound <b>1</b> once daily for 14 days. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. *<i>p</i> ≤ 0.01 and **<i>p</i> ≤ 0.001 versus vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Induction of FXR target genes SHP and FGF15 in rat liver following oral administration of compound <b>1</b> once daily for 14 days. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. *<i>p</i> ≤ 0.01 and **<i>p</i> ≤ 0.001 versus vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Plasma FGF15 levels on day 14, at 1, 7, and 24 h following oral administration of compound <b>1</b> once daily for 14 days. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Serum triglycerides on day 15, at 24 h following oral administration of compound <b>1</b> once daily for 14 days. Dose in mg/kg; vehicle 0.5% methylcellulose, 0.5% Tween80, 99% water, suspension. *<i>p</i> ≤ 0.01 and **<i>p</i> ≤ 0.001 versus vehicle by one-way ANOVA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Steady state pharmacokinetics (day 11) of compound <b>1</b>; mean total plasma concentration versus time profiles (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/medium/jm-2017-00907n_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b00907/20171221/images/large/jm-2017-00907n_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00907&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) NH<sub>2</sub>OH·HCl, H<sub>2</sub>O, 10 min, 0 °C, 83%; (b) NCS, DMF, 1 h, 25 °C, 99%; (c) K<sub>2</sub>CO<sub>3</sub>, methyl 3-cyclopropyl-3-oxopropanoate, THF, −5 to 35 °C, 52%; (d) LiAlH<sub>4</sub>, THF, −10 °C, 30 min, 93%; (e) CBr<sub>4</sub>, PPh<sub>3</sub>, THF, 1 h, rt, 87%; (f) <i>N</i>-Boc nortropine, 18-crown-6, THF, potassium <i>tert</i>-butoxide, 18 h, rt, 69%; (g) TFA, DCM, 1 h, rt, 94%; (h) <b>25a</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 1 h, rt to 60 °C, 75%; (i) KOH, MeOH, THF, 1 h, 70 °C, 91%; (l) NaSCN, AcOH, Br<sub>2</sub>, 0 to 30 °C over 48 h 66%; (m) CuBr<sub>2</sub>, MeCN, <i>t</i>-BuONO, 0 to 30 °C, 48 h, 24%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Chiang, J. Y. L.</span><span> </span><span class="NLM_article-title">Bile Acids: Regulation of Synthesis</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1955</span><span class="NLM_x">–</span> <span class="NLM_lpage">1966</span><span class="refDoi"> DOI: 10.1194/jlr.R900010-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1194%2Fjlr.R900010-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=19346330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2qsLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1955-1966&author=J.+Y.+L.+Chiang&title=Bile+Acids%3A+Regulation+of+Synthesis&doi=10.1194%2Fjlr.R900010-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acids: regulation of synthesis</span></div><div class="casAuthors">Chiang, John Y. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1955-1966</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Bile acids are physiol. detergents that generate bile flow and facilitate intestinal absorption and transport of lipids, nutrients, and vitamins.  Bile acids also are signaling mols. and inflammatory agents that rapidly activate nuclear receptors and cell signaling pathways that regulate lipid, glucose, and energy metab.  The enterohepatic circulation of bile acids exerts important physiol. functions not only in feedback inhibition of bile acid biosynthesis but also in control of whole-body lipid homeostasis.  In the liver, bile acids activate a nuclear receptor, farnesoid X receptor (FXR), that induces an atypical nuclear receptor small heterodimer partner, which subsequently inhibits nuclear receptors, liver-related homolog-1, and hepatocyte nuclear factor 4α and results in inhibiting transcription of the crit. regulatory gene in bile acid biosynthesis, cholesterol 7α-hydroxylase (cytochrome P 450 7A1; CYP7A1).  In the intestine, FXR induces an intestinal hormone, fibroblast growth factor 15 (FGF15; or FGF19 in humans), which activates hepatic FGF receptor 4 (FGFR4) signaling to inhibit bile acid biosynthesis.  However, the mechanism by which FXR/FGF19/FGFR4 signaling inhibits CYP7A1 remains unknown.  Bile acids are able to induce FGF19 in human hepatocytes, and the FGF19 autocrine pathway may exist in the human livers.  Bile acids and bile acid receptors are therapeutic targets for development of drugs for treatment of cholestatic liver diseases, fatty liver diseases, diabetes, obesity, and metabolic syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzJA-wyOlA7Vg90H21EOLACvtfcHk0lgT9Xs54jW0uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2qsLjL&md5=5868a2630c5625dfb63b9ebf9b35d45c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R900010-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R900010-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DJ.%2BY.%2BL.%26atitle%3DBile%2520Acids%253A%2520Regulation%2520of%2520Synthesis%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2009%26volume%3D50%26spage%3D1955%26epage%3D1966%26doi%3D10.1194%2Fjlr.R900010-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Calkin, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontonoz, P.</span><span> </span><span class="NLM_article-title">Transcriptional Integration of Metabolism by the Nuclear Sterol-Activated Receptors LXR and FXR</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span><span class="refDoi"> DOI: 10.1038/nrm3312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1038%2Fnrm3312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=22414897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjslelurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=213-224&author=A.+C.+Calkinauthor=P.+Tontonoz&title=Transcriptional+Integration+of+Metabolism+by+the+Nuclear+Sterol-Activated+Receptors+LXR+and+FXR&doi=10.1038%2Fnrm3312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR</span></div><div class="casAuthors">Calkin, Anna C.; Tontonoz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-224</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nuclear receptors are integrators of hormonal and nutritional signals, mediating changes to metabolic pathways within the body.  Given that modulation of lipid and glucose metab. has been linked to diseases including type 2 diabetes, obesity and atherosclerosis, a greater understanding of pathways that regulate metab. in physiol. and disease is crucial.  The liver X receptors (LXRs) and the farnesoid X receptors (FXRs) are activated by oxysterols and bile acids, resp.  Mounting evidence indicates that these nuclear receptors have essential roles, not only in the regulation of cholesterol and bile acid metab. but also in the integration of sterol, fatty acid and glucose metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomZtKGuHssqbVg90H21EOLACvtfcHk0ljYb0a_rZkcag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjslelurs%253D&md5=07454f4951b0af4c1efa251e23cfa264</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm3312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3312%26sid%3Dliteratum%253Aachs%26aulast%3DCalkin%26aufirst%3DA.%2BC.%26aulast%3DTontonoz%26aufirst%3DP.%26atitle%3DTranscriptional%2520Integration%2520of%2520Metabolism%2520by%2520the%2520Nuclear%2520Sterol-Activated%2520Receptors%2520LXR%2520and%2520FXR%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D13%26spage%3D213%26epage%3D224%26doi%3D10.1038%2Fnrm3312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Goodwin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galardi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliewer, S. A.</span><span> </span><span class="NLM_article-title">A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1016/S1097-2765(00)00051-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2FS1097-2765%2800%2900051-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=11030332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntVyhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=517-526&author=B.+Goodwinauthor=S.+A.+Jonesauthor=R.+R.+Priceauthor=M.+A.+Watsonauthor=D.+D.+McKeeauthor=L.+B.+Mooreauthor=C.+Galardiauthor=J.+G.+Wilsonauthor=M.+C.+Lewisauthor=M.+E.+Rothauthor=P.+R.+Maloneyauthor=T.+M.+Willsonauthor=S.+A.+Kliewer&title=A+Regulatory+Cascade+of+the+Nuclear+Receptors+FXR%2C+SHP-1%2C+and+LRH-1+Represses+Bile+Acid+Biosynthesis&doi=10.1016%2FS1097-2765%2800%2900051-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis</span></div><div class="casAuthors">Goodwin, Bryan; Jones, Stacey A.; Price, Roger R.; Watson, Michael A.; McKee, David D.; Moore, Linda B.; Galardi, Cristin; Wilson, Joan G.; Lewis, Michael C.; Roth, Matthew E.; Maloney, Patrick R.; Willson, Timothy M.; Kliewer, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">517-526</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Bile acids repress the transcription of cytochrome P 450 7A1 (CYP7A1), which catalyzes the rate-limiting step in bile acid biosynthesis.  Although bile acids activate the farnesoid X receptor (FXR), the mechanism underlying bile acid-mediated repression of CYP7A1 remained unclear.  We have used a potent, nonsteroidal FXR ligand to show that FXR induces expression of small heterodimer partner 1 (SHP-1), an atypical member of the nuclear receptor family that lacks a DNA-binding domain.  SHP-1 represses expression of CYP7A1 by inhibiting the activity of of liver receptor homolog 1 (LRH-1), an orphan nuclear receptor that is known to regulate CYP7A1 expression pos.  This bile acid-activated regulatory cascade provides a mol. basis for the coordinate suppression of CYP7A1 and other genes involved in bile acid biosynthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUMa4HDRxLWrVg90H21EOLACvtfcHk0ljYb0a_rZkcag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntVyhs7o%253D&md5=a2fe31512a56ba5747b1aa8c89b93713</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2900051-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252900051-4%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DPrice%26aufirst%3DR.%2BR.%26aulast%3DWatson%26aufirst%3DM.%2BA.%26aulast%3DMcKee%26aufirst%3DD.%2BD.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DGalardi%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26aulast%3DLewis%26aufirst%3DM.%2BC.%26aulast%3DRoth%26aufirst%3DM.%2BE.%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26atitle%3DA%2520Regulatory%2520Cascade%2520of%2520the%2520Nuclear%2520Receptors%2520FXR%252C%2520SHP-1%252C%2520and%2520LRH-1%2520Represses%2520Bile%2520Acid%2520Biosynthesis%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D517%26epage%3D526%26doi%3D10.1016%2FS1097-2765%2800%2900051-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Schaap, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trauner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, P. L. M.</span><span> </span><span class="NLM_article-title">Bile Acid Receptors as Targets for Drug Development</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1038/nrgastro.2013.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1038%2Fnrgastro.2013.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=23982684" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=55-67&author=F.+G.+Schaapauthor=M.+Traunerauthor=P.+L.+M.+Jansen&title=Bile+Acid+Receptors+as+Targets+for+Drug+Development&doi=10.1038%2Fnrgastro.2013.151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.151%26sid%3Dliteratum%253Aachs%26aulast%3DSchaap%26aufirst%3DF.%2BG.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DP.%2BL.%2BM.%26atitle%3DBile%2520Acid%2520Receptors%2520as%2520Targets%2520for%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2013%26volume%3D11%26spage%3D55%26epage%3D67%26doi%3D10.1038%2Fnrgastro.2013.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Dyson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirschfield, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuers, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindor, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. E. J.</span><span> </span><span class="NLM_article-title">Novel Therapeutic Targets in Primary Biliary Cirrhosis</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.1038/nrgastro.2015.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1038%2Fnrgastro.2015.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25645973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFCntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=147-158&author=J.+K.+Dysonauthor=G.+M.+Hirschfieldauthor=D.+H.+Adamsauthor=U.+Beuersauthor=D.+A.+Mannauthor=K.+D.+Lindorauthor=D.+E.+J.+Jones&title=Novel+Therapeutic+Targets+in+Primary+Biliary+Cirrhosis&doi=10.1038%2Fnrgastro.2015.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel therapeutic targets in primary biliary cirrhosis</span></div><div class="casAuthors">Dyson, Jessica K.; Hirschfield, Gideon M.; Adams, David H.; Beuers, Ulrich; Mann, Derek A.; Lindor, Keith D.; Jones, David E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">147-158</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Primary biliary cirrhosis (PBC) is a chronic immune-mediated liver disease characterized by progressive cholestasis, biliary fibrosis and eventually cirrhosis.  It results in characteristic symptoms with marked effects on life quality.  The advent of large patient cohorts has challenged the view of PBC as a benign condition treated effectively by the single licensed therapy-ursodeoxycholic acid (UDCA).  UDCA nonresponse or under-response has a major bearing on outcome, substantially increasing the likelihood that liver transplantation will be required or that patients will die of the disease.  In patients with high-risk, treatment-unresponsive or highly symptomatic disease the need for new treatment approaches is clear.  Evolution in our understanding of disease mechanisms is rapidly leading to the advent of new and re-purposed therapeutic agents targeting key processes.  Notable opportunities are offered by targeting what could be considered as the 'upstream' immune response, 'midstream' biliary injury and 'downstream' fibrotic processes.  Combination therapy targeting several pathways or the development of novel agents addressing multiple components of the disease pathway might be required.  Ultimately, PBC therapeutics will require a stratified approach to be adopted in practice.  This Review provides a current perspective on potential approaches to PBC treatment, and highlights the challenges faced in evaluating and implementing those treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulgGBl_f3-rVg90H21EOLACvtfcHk0ljYVQiTPoDmAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFCntLs%253D&md5=8cef843d9d9818aca9bbb4a55c8743ce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2015.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2015.12%26sid%3Dliteratum%253Aachs%26aulast%3DDyson%26aufirst%3DJ.%2BK.%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DAdams%26aufirst%3DD.%2BH.%26aulast%3DBeuers%26aufirst%3DU.%26aulast%3DMann%26aufirst%3DD.%2BA.%26aulast%3DLindor%26aufirst%3DK.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BE.%2BJ.%26atitle%3DNovel%2520Therapeutic%2520Targets%2520in%2520Primary%2520Biliary%2520Cirrhosis%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D12%26spage%3D147%26epage%3D158%26doi%3D10.1038%2Fnrgastro.2015.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Srivastava, A.</span><span> </span><span class="NLM_article-title">Progressive Familial Intrahepatic Cholestasis</span> <span class="citation_source-journal">J. Clin. Exp. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1016/j.jceh.2013.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.jceh.2013.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25755532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A280%3ADC%252BC2MnislGmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=25-36&author=A.+Srivastava&title=Progressive+Familial+Intrahepatic+Cholestasis&doi=10.1016%2Fj.jceh.2013.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Progressive familial intrahepatic cholestasis</span></div><div class="casAuthors">Srivastava Anshu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and experimental hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>
        ISSN:<span class="NLM_cas:issn">0973-6883</span>.
    </div><div class="casAbstract">Progressive familial intrahepatic cholestasis (PFIC) is a group of rare disorders which are caused by defect in bile secretion and present with intrahepatic cholestasis, usually in infancy and childhood.  These are autosomal recessive in inheritance.  The estimated incidence is about 1 per 50,000 to 1 per 100,000 births, although exact prevalence is not known.  These diseases affect both the genders equally and have been reported from all geographical areas.  Based on clinical presentation, laboratory findings, liver histology and genetic defect, these are broadly divided into three types-PFIC type 1, PFIC type 2 and PFIC type 3.  The defect is in ATP8B1 gene encoding the FIC1 protein, ABCB 11 gene encoding BSEP protein and ABCB4 gene encoding MDR3 protein in PFIC1, 2 and 3 respectively.  The basic defect is impaired bile salt secretion in PFIC1/2 whereas in PFIC3, it is reduced biliary phospholipid secretion.  The main clinical presentation is in the form of cholestatic jaundice and pruritus.  Serum gamma glutamyl transpeptidase (GGT) is normal in patients with PFIC1/2 while it is raised in patients with PFIC3.  Treatment includes nutritional support (adequate calories, supplementation of fat soluble vitamins and medium chain triglycerides) and use of medications to relieve pruritus as initial therapy followed by biliary diversion procedures in selected patients.  Ultimately liver transplantation is needed in most patients as they develop progressive liver fibrosis, cirrhosis and end stage liver disease.  Due to the high risk of developing liver tumors in PFIC2 patients, monitoring is recommended from infancy.  Mutation targeted pharmacotherapy, gene therapy and hepatocyte transplantation are being explored as future therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnmBqw7L9yv4xhnOQkIHOxfW6udTcc2eZ1YpmZ88JQmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnislGmuw%253D%253D&md5=7d62a527b62fc7972e61dfa10603ba1f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.jceh.2013.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jceh.2013.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DA.%26atitle%3DProgressive%2520Familial%2520Intrahepatic%2520Cholestasis%26jtitle%3DJ.%2520Clin.%2520Exp.%2520Hepatol.%26date%3D2014%26volume%3D4%26spage%3D25%26epage%3D36%26doi%3D10.1016%2Fj.jceh.2013.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Chen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthanarayanan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neimark, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knisely, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strautnieks, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magid, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchy, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shneider, B. L.</span><span> </span><span class="NLM_article-title">Progressive Familial Intrahepatic Cholestasis, Type 1, Is Associated with Decreased Farnesoid X Receptor Activity</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">764</span><span class="refDoi"> DOI: 10.1053/j.gastro.2003.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1053%2Fj.gastro.2003.12.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=756-764&author=F.+Chenauthor=M.+Ananthanarayananauthor=S.+Emreauthor=E.+Neimarkauthor=L.+N.+Bullauthor=A.+S.+Kniselyauthor=S.+S.+Strautnieksauthor=R.+J.+Thompsonauthor=M.+S.+Magidauthor=R.+Gordonauthor=N.+Balasubramanianauthor=F.+J.+Suchyauthor=B.+L.+Shneider&title=Progressive+Familial+Intrahepatic+Cholestasis%2C+Type+1%2C+Is+Associated+with+Decreased+Farnesoid+X+Receptor+Activity&doi=10.1053%2Fj.gastro.2003.12.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2003.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2003.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26aulast%3DAnanthanarayanan%26aufirst%3DM.%26aulast%3DEmre%26aufirst%3DS.%26aulast%3DNeimark%26aufirst%3DE.%26aulast%3DBull%26aufirst%3DL.%2BN.%26aulast%3DKnisely%26aufirst%3DA.%2BS.%26aulast%3DStrautnieks%26aufirst%3DS.%2BS.%26aulast%3DThompson%26aufirst%3DR.%2BJ.%26aulast%3DMagid%26aufirst%3DM.%2BS.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DBalasubramanian%26aufirst%3DN.%26aulast%3DSuchy%26aufirst%3DF.%2BJ.%26aulast%3DShneider%26aufirst%3DB.%2BL.%26atitle%3DProgressive%2520Familial%2520Intrahepatic%2520Cholestasis%252C%2520Type%25201%252C%2520Is%2520Associated%2520with%2520Decreased%2520Farnesoid%2520X%2520Receptor%2520Activity%26jtitle%3DGastroenterology%26date%3D2004%26volume%3D126%26spage%3D756%26epage%3D764%26doi%3D10.1053%2Fj.gastro.2003.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Gomez-Ospina, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manickam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shneider, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picarsic, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knisely, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finegold, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzny, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerwinkle, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupski, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plon, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washington, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porteus, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berquist, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kambham, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enns, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, D. D.</span><span> </span><span class="NLM_article-title">Mutations in the Nuclear Bile Acid Receptor FXR Cause Progressive Familial Intrahepatic Cholestasis</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">10713</span><span class="refDoi"> DOI: 10.1038/ncomms10713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1038%2Fncomms10713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=26888176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislylu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10713&author=N.+Gomez-Ospinaauthor=C.+J.+Potterauthor=R.+Xiaoauthor=K.+Manickamauthor=M.-S.+Kimauthor=K.+H.+Kimauthor=B.+L.+Shneiderauthor=J.+L.+Picarsicauthor=T.+A.+Jacobsonauthor=J.+Zhangauthor=W.+Heauthor=P.+Liuauthor=A.+S.+Kniselyauthor=M.+J.+Finegoldauthor=D.+M.+Muznyauthor=E.+Boerwinkleauthor=J.+R.+Lupskiauthor=S.+E.+Plonauthor=R.+A.+Gibbsauthor=C.+M.+Engauthor=Y.+Yangauthor=G.+C.+Washingtonauthor=M.+H.+Porteusauthor=W.+E.+Berquistauthor=N.+Kambhamauthor=R.+J.+Singhauthor=F.+Xiaauthor=G.+M.+Ennsauthor=D.+D.+Moore&title=Mutations+in+the+Nuclear+Bile+Acid+Receptor+FXR+Cause+Progressive+Familial+Intrahepatic+Cholestasis&doi=10.1038%2Fncomms10713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis</span></div><div class="casAuthors">Gomez-Ospina, Natalia; Potter, Carol J.; Xiao, Rui; Manickam, Kandamurugu; Kim, Mi-Sun; Kim, Kang Ho; Shneider, Benjamin L.; Picarsic, Jennifer L.; Jacobson, Theodora A.; Zhang, Jing; He, Weimin; Liu, Pengfei; Knisely, A. S.; Finegold, Milton J.; Muzny, Donna M.; Boerwinkle, Eric; Lupski, James R.; Plon, Sharon E.; Gibbs, Richard A.; Eng, Christine M.; Yang, Yaping; Washington, Gabriel C.; Porteus, Matthew H.; Berquist, William E.; Kambham, Neeraja; Singh, Ravinder J.; Xia, Fan; Enns, Gregory M.; Moore, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10713</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neonatal cholestasis is a potentially life-threatening condition requiring prompt diagnosis.  Mutations in several different genes can cause progressive familial intrahepatic cholestasis, but known genes cannot account for all familial cases.  Here we report four individuals from two unrelated families with neonatal cholestasis and mutations in NR1H4, which encodes the farnesoid X receptor (FXR), a bile acid-activated nuclear hormone receptor that regulates bile acid metab.  Clin. features of severe, persistent NR1H4-related cholestasis include neonatal onset with rapid progression to end-stage liver disease, vitamin K-independent coagulopathy, low-to-normal serum gamma-glutamyl transferase activity, elevated serum alpha-fetoprotein and undetectable liver bile salt export pump (ABCB11) expression.  Our findings demonstrate a pivotal function for FXR in bile acid homeostasis and liver protection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8Z3Xkz9YRIrVg90H21EOLACvtfcHk0lgdBtO0-dLbwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislylu7k%253D&md5=9a9da92cbe59e519a1031b7826c5ede8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fncomms10713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10713%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Ospina%26aufirst%3DN.%26aulast%3DPotter%26aufirst%3DC.%2BJ.%26aulast%3DXiao%26aufirst%3DR.%26aulast%3DManickam%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DM.-S.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DShneider%26aufirst%3DB.%2BL.%26aulast%3DPicarsic%26aufirst%3DJ.%2BL.%26aulast%3DJacobson%26aufirst%3DT.%2BA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DKnisely%26aufirst%3DA.%2BS.%26aulast%3DFinegold%26aufirst%3DM.%2BJ.%26aulast%3DMuzny%26aufirst%3DD.%2BM.%26aulast%3DBoerwinkle%26aufirst%3DE.%26aulast%3DLupski%26aufirst%3DJ.%2BR.%26aulast%3DPlon%26aufirst%3DS.%2BE.%26aulast%3DGibbs%26aufirst%3DR.%2BA.%26aulast%3DEng%26aufirst%3DC.%2BM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWashington%26aufirst%3DG.%2BC.%26aulast%3DPorteus%26aufirst%3DM.%2BH.%26aulast%3DBerquist%26aufirst%3DW.%2BE.%26aulast%3DKambham%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26aulast%3DXia%26aufirst%3DF.%26aulast%3DEnns%26aufirst%3DG.%2BM.%26aulast%3DMoore%26aufirst%3DD.%2BD.%26atitle%3DMutations%2520in%2520the%2520Nuclear%2520Bile%2520Acid%2520Receptor%2520FXR%2520Cause%2520Progressive%2520Familial%2520Intrahepatic%2520Cholestasis%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10713%26doi%3D10.1038%2Fncomms10713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ali, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindor, K. D.</span><span> </span><span class="NLM_article-title">Recent Advances in the Development of Farnesoid X Receptor Agonists</span> <span class="citation_source-journal">Ann. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">5</span><span class="refDoi"> DOI: 10.3978/j.issn.2305-5839.2014.12.06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.3978%2Fj.issn.2305-5839.2014.12.06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25705637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlGrsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=5&issue=1&author=A.+H.+Aliauthor=E.+J.+Careyauthor=K.+D.+Lindor&title=Recent+Advances+in+the+Development+of+Farnesoid+X+Receptor+Agonists&doi=10.3978%2Fj.issn.2305-5839.2014.12.06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of farnesoid X receptor agonists</span></div><div class="casAuthors">Ali, Ahmad H.; Carey, Elizabeth J.; Lindor, Keith D.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5/1-5/16</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">Farnesoid X receptors (FXRs) are nuclear hormone receptors expressed in high amts. in body tissues that participate in bilirubin metab. including the liver, intestines, and kidneys.  Bile acids (BAs) are the natural ligands of the FXRs.  FXRs regulate the expression of the gene encoding for cholesterol 7 alpha-hydroxylase, which is the rate-limiting enzyme in BA synthesis.  In addn., FXRs play a crit. role in carbohydrate and lipid metab. and regulation of insulin sensitivity.  FXRs also modulate live growth and regeneration during liver injury.  Preclin. studies have shown that FXR activation protects against cholestasis-induced liver injury.  Moreover, FXR activation protects against fatty liver injury in animal models of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and improved hyperlipidemia, glucose intolerance, and insulin sensitivity.  Obeticholic acid (OCA), a 6α-Et deriv. of the natural human BA chenodeoxycholic acid (CDCA) is the first-in-class selective FXR agonist that is ∼100-fold more potent than CDCA.  Preliminary human clin. trials have shown that OCA is safe and effective.  In a phase II clin. trial, administration of OCA was well-tolerated, increased insulin sensitivity and reduced markers of liver inflammation and fibrosis in patients with type II diabetes mellitus and NAFLD.  In two clin. trials of OCA in patients with primary biliary cirrhosis (PBC), a progressive cholestatic liver disease, OCA significantly reduced serum alk. phosphatase (ALP) levels, an important disease marker that correlates well with clin. outcomes of patients with PBC.  Together, these studies suggest that FXR agonists could potentially be used as therapeutic tools in patients suffering from nonalcoholic fatty and cholestatic liver diseases.  Larger and Longer-term studies are currently ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ7xVIB1gg47Vg90H21EOLACvtfcHk0lg_bl_uV7eIkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlGrsbjN&md5=5fb87bbd5d25a4b63c615c710884b05b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2305-5839.2014.12.06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2305-5839.2014.12.06%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DA.%2BH.%26aulast%3DCarey%26aufirst%3DE.%2BJ.%26aulast%3DLindor%26aufirst%3DK.%2BD.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Development%2520of%2520Farnesoid%2520X%2520Receptor%2520Agonists%26jtitle%3DAnn.%2520Transl.%2520Med.%26date%3D2015%26volume%3D3%26issue%3D1%26spage%3D5%26doi%3D10.3978%2Fj.issn.2305-5839.2014.12.06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Neuschwander-Tetri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loomba, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanyal, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavine, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Natta, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdelmalek, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalasani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dasarathy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hameed, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCullough, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrault, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonascia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunt, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doo, E.</span><span> </span><span class="NLM_article-title">Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicenter, Randomized, Placebo-Controlled Trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">9972</span><span class="NLM_x">–</span> <span class="NLM_lpage">0065</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61933-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2FS0140-6736%2814%2961933-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=9972-0065&author=B.+A.+Neuschwander-Tetriauthor=R.+Loombaauthor=A.+J.+Sanyalauthor=J.+E.+Lavineauthor=M.+L.+Van+Nattaauthor=M.+F.+Abdelmalekauthor=N.+Chalasaniauthor=S.+Dasarathyauthor=A.+M.+Diehlauthor=B.+Hameedauthor=K.+V.+Kowdleyauthor=A.+McCulloughauthor=N.+Terraultauthor=J.+M.+Clarkauthor=J.+Tonasciaauthor=E.+M.+Bruntauthor=D.+E.+Kleinerauthor=E.+Doo&title=Farnesoid+X+Nuclear+Receptor+Ligand+Obeticholic+Acid+for+Non-Cirrhotic%2C+Non-Alcoholic+Steatohepatitis+%28FLINT%29%3A+A+Multicenter%2C+Randomized%2C+Placebo-Controlled+Trial&doi=10.1016%2FS0140-6736%2814%2961933-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961933-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961933-4%26sid%3Dliteratum%253Aachs%26aulast%3DNeuschwander-Tetri%26aufirst%3DB.%2BA.%26aulast%3DLoomba%26aufirst%3DR.%26aulast%3DSanyal%26aufirst%3DA.%2BJ.%26aulast%3DLavine%26aufirst%3DJ.%2BE.%26aulast%3DVan%2BNatta%26aufirst%3DM.%2BL.%26aulast%3DAbdelmalek%26aufirst%3DM.%2BF.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DDasarathy%26aufirst%3DS.%26aulast%3DDiehl%26aufirst%3DA.%2BM.%26aulast%3DHameed%26aufirst%3DB.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DMcCullough%26aufirst%3DA.%26aulast%3DTerrault%26aufirst%3DN.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DTonascia%26aufirst%3DJ.%26aulast%3DBrunt%26aufirst%3DE.%2BM.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DDoo%26aufirst%3DE.%26atitle%3DFarnesoid%2520X%2520Nuclear%2520Receptor%2520Ligand%2520Obeticholic%2520Acid%2520for%2520Non-Cirrhotic%252C%2520Non-Alcoholic%2520Steatohepatitis%2520%2528FLINT%2529%253A%2520A%2520Multicenter%252C%2520Randomized%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D9972%26epage%3D0065%26doi%3D10.1016%2FS0140-6736%2814%2961933-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Hirschfield, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luketic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodhenheimer, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parés, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trauner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marschall, H.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adorini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beecher-Jones, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelloe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böhm, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D.</span><span> </span><span class="NLM_article-title">Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">–</span> <span class="NLM_lpage">761</span><span class="refDoi"> DOI: 10.1053/j.gastro.2014.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1053%2Fj.gastro.2014.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25500425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFGmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=751-761&author=G.+M.+Hirschfieldauthor=A.+Masonauthor=V.+Luketicauthor=K.+Lindorauthor=S.+C.+Gordonauthor=M.+Mayoauthor=K.+V.+Kowdleyauthor=C.+Vincentauthor=H.+C.+Bodhenheimerauthor=A.+Par%C3%A9sauthor=M.+Traunerauthor=H.-U.+Marschallauthor=L.+Adoriniauthor=C.+Sciaccaauthor=T.+Beecher-Jonesauthor=E.+Castelloeauthor=O.+B%C3%B6hmauthor=D.+Shapiro&title=Efficacy+of+Obeticholic+Acid+in+Patients+With+Primary+Biliary+Cirrhosis+and+Inadequate+Response+to+Ursodeoxycholic+Acid&doi=10.1053%2Fj.gastro.2014.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid</span></div><div class="casAuthors">Hirschfield, Gideon M.; Mason, Andrew; Luketic, Velimir; Lindor, Keith; Gordon, Stuart C.; Mayo, Marlyn; Kowdley, Kris V.; Vincent, Catherine; Bodhenheimer, Henry C., Jr.; Pares, Albert; Trauner, Michael; Marschall, Hanns-Ulrich; Adorini, Luciano; Sciacca, Cathi; Beecher-Jones, Tessa; Castelloe, Erin; Bohm, Olaf; Shapiro, David</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">751-761.e8</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We evaluated the efficacy and safety of obeticholic acid (OCA, α-ethylchenodeoxycholic acid) in a randomized controlled trial of patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid therapy.  We performed a double-blind study of 165 patients with primary biliary cirrhosis (95% women) and levels of alk. phosphatase (ALP) 1.5- to 10-fold the upper limit of normal.  Patients were randomly assigned to groups given 10 mg, 25 mg, or 50 mg doses of OCA or placebo, once daily for 3 mo.  Patients maintained their existing dose of ursodeoxycholic acid throughout the study.  The primary outcome was change in level of ALP from baseline (day 0) until the end of the study (day 85 or early termination).  We also performed an open-label extension of the trial in which 78 patients were enrolled and 61 completed the first year.  OCA was superior to placebo in achieving the primary end point.  Subjects given OCA had statistically significant relative redns. in mean ALP from baseline to the end of the study (P < .0001 all OCA groups vs placebo).  Levels of ALP decreased 21%-25% on av. from baseline in the OCA groups and 3% in the placebo group.  Sixty-nine percent (68 of 99) of patients given OCA had at least a 20% redn. in ALP compared with 8% (3 of 37) of patients given placebo (P < .0003).  Among secondary end points, levels of γ-glutamyl transpeptidase decreased 48%-63%, on av., among subjects given OCA, vs a 7% decrease in the group given placebo; levels of alanine aminotransferase decreased 21%-35% on av. among subjects given OCA vs none of the patients given placebo.  Pruritus was the principal adverse event; incidence values in the OCA 10 mg, 25 mg, and 50 mg groups were 47% (not significantly different), 87% (P < .0003), and 80% (P < .006), resp., vs 50% in the placebo group.  In the extension study, levels of ALP continued to decrease to a mean level of 202 ± 11 U/L after 12 mo vs 285 ± 15 U/L at baseline.  Daily doses of OCA, ranging from 10 to 50 mg, significantly reduced levels of ALP, γ-glutamyl transpeptidase, and alanine aminotransferase, compared with placebo, in patients with primary biliary cirrhosis who had inadequate responses to ursodeoxycholic acid.  The incidence and severity of pruritus were lowest among patients who received 10 mg/d OCA.  Biochem. responses to OCA were maintained in a 12-mo open-label extension trial.  ClinicalTrials.gov ID: NCT00550862.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEVC_XNJt84bVg90H21EOLACvtfcHk0lg_bl_uV7eIkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFGmtbc%253D&md5=88ad43649d1dec228af49f4570247523</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2014.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2014.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DMason%26aufirst%3DA.%26aulast%3DLuketic%26aufirst%3DV.%26aulast%3DLindor%26aufirst%3DK.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DMayo%26aufirst%3DM.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DVincent%26aufirst%3DC.%26aulast%3DBodhenheimer%26aufirst%3DH.%2BC.%26aulast%3DPar%25C3%25A9s%26aufirst%3DA.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DMarschall%26aufirst%3DH.-U.%26aulast%3DAdorini%26aufirst%3DL.%26aulast%3DSciacca%26aufirst%3DC.%26aulast%3DBeecher-Jones%26aufirst%3DT.%26aulast%3DCastelloe%26aufirst%3DE.%26aulast%3DB%25C3%25B6hm%26aufirst%3DO.%26aulast%3DShapiro%26aufirst%3DD.%26atitle%3DEfficacy%2520of%2520Obeticholic%2520Acid%2520in%2520Patients%2520With%2520Primary%2520Biliary%2520Cirrhosis%2520and%2520Inadequate%2520Response%2520to%2520Ursodeoxycholic%2520Acid%26jtitle%3DGastroenterology%26date%3D2015%26volume%3D148%26spage%3D751%26epage%3D761%26doi%3D10.1053%2Fj.gastro.2014.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Bowlus, C.</span><span> </span><span class="NLM_article-title">Obeticholic Acid for the Treatment of Primary Biliary Cholangitis in Adult Patients: Clinical Utility and Patient Selection</span> <span class="citation_source-journal">Hepatic Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.2147/HMER.S91709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.2147%2FHMER.S91709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=27621676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A280%3ADC%252BC2svgtVKjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=89-95&author=C.+Bowlus&title=Obeticholic+Acid+for+the+Treatment+of+Primary+Biliary+Cholangitis+in+Adult+Patients%3A+Clinical+Utility+and+Patient+Selection&doi=10.2147%2FHMER.S91709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection</span></div><div class="casAuthors">Bowlus Christopher L</div><div class="citationInfo"><span class="NLM_cas:title">Hepatic medicine : evidence and research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-95</span>
        ISSN:<span class="NLM_cas:issn">1179-1535</span>.
    </div><div class="casAbstract">Primary biliary cholangitis (PBC), previously known as primary biliary "cirrhosis", is a rare autoimmune liver disease characterized by the hallmark autoantibodies to mitochondrial antigens and immune-mediated destruction of small bile duct epithelial cells leading to cholestasis and cirrhosis.  Surprisingly, while immune modulators have not been effective in the treatment of PBC, supplementation with the hydrophilic bile acid (BA) ursodeoxycholic acid (UDCA) has been demonstrated to slow the disease progression.  However, a significant minority of PBC patients do not have a complete response to UDCA and remain at risk of continued disease progression.  Although the mechanisms of action are not well understood, UDCA provided proof of concept for BA therapy in PBC.  Obeticholic acid (OCA), a novel derivative of the human BA chenodeoxycholic acid, is a potent agonist of the nuclear hormone receptor farnesoid X receptor, which regulates BA synthesis and transport.  A series of clinical trials of OCA in PBC, primarily in combination with UDCA, have established that OCA leads to significant reductions in serum alkaline phosphatase that are predicted to lead to improved clinical outcomes, while dose-dependent pruritus has been the most common adverse effect.  On the basis of these studies, OCA was given conditional approval by the US Food and Drug Administration with plans to establish the long-term clinical efficacy of OCA in patients with advanced PBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrtYKwZhE3_sULxIEhxUjPfW6udTcc2eZXqsplKKW5rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svgtVKjtg%253D%253D&md5=aae2c3b5bce3ace0442a0e85b925200d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2147%2FHMER.S91709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FHMER.S91709%26sid%3Dliteratum%253Aachs%26aulast%3DBowlus%26aufirst%3DC.%26atitle%3DObeticholic%2520Acid%2520for%2520the%2520Treatment%2520of%2520Primary%2520Biliary%2520Cholangitis%2520in%2520Adult%2520Patients%253A%2520Clinical%2520Utility%2520and%2520Patient%2520Selection%26jtitle%3DHepatic%2520Med.%26date%3D2016%26volume%3D8%26spage%3D89%26epage%3D95%26doi%3D10.2147%2FHMER.S91709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pencek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liberman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooshmand-Rad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. A.</span><span> </span><span class="NLM_article-title">Effects of Obeticholic Acid on Lipoprotein Metabolism in Healthy Volunteers</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">936</span><span class="NLM_x">–</span> <span class="NLM_lpage">940</span><span class="refDoi"> DOI: 10.1111/dom.12681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1111%2Fdom.12681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=27109453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOmsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=936-940&author=R.+Pencekauthor=T.+Marmonauthor=J.+D.+Rothauthor=A.+Libermanauthor=R.+Hooshmand-Radauthor=M.+A.+Young&title=Effects+of+Obeticholic+Acid+on+Lipoprotein+Metabolism+in+Healthy+Volunteers&doi=10.1111%2Fdom.12681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers</span></div><div class="casAuthors">Pencek, R.; Marmon, T.; Roth, J. D.; Liberman, A.; Hooshmand-Rad, R.; Young, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">936-940</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The bile acid analog obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist in development for treatment of several chronic liver diseases.  FXR activation regulates lipoprotein homeostasis.  The effects of OCA on cholesterol and lipoprotein metab. in healthy individuals were assessed.  Two phase I studies were conducted to evaluate the effects of repeated oral doses of 5, 10 or 25 mg OCA on lipid variables after 14 or 20 days of consecutive administration in 68 healthy adults.  Changes in HDL and LDL cholesterol levels were examd., in addn. to NMR anal. of particle sizes and sub-fraction concns.  OCA elicited changes in circulating cholesterol and particle size of LDL and HDL.  OCA decreased HDL cholesterol and increased LDL cholesterol, independently of dose.  HDL particle concns. declined as a result of a redn. in medium and small HDL.  Total LDL particle concns. increased because of an increase in large LDL particles.  Changes in lipoprotein metab. attributable to OCA in healthy individuals were found to be consistent with previously reported changes in patients receiving OCA with non-alc. fatty liver disease or non-alc. steatohepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9crw5OdOUkLVg90H21EOLACvtfcHk0li1x7yj9AIJEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOmsrzJ&md5=154e73d2b56a2b61ee5fe3bcbd8e2ad7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fdom.12681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12681%26sid%3Dliteratum%253Aachs%26aulast%3DPencek%26aufirst%3DR.%26aulast%3DMarmon%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DLiberman%26aufirst%3DA.%26aulast%3DHooshmand-Rad%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26atitle%3DEffects%2520of%2520Obeticholic%2520Acid%2520on%2520Lipoprotein%2520Metabolism%2520in%2520Healthy%2520Volunteers%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26spage%3D936%26epage%3D940%26doi%3D10.1111%2Fdom.12681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-ref14_1"><span><div class="note"><p class="first last">A Multipart, Double Blind Study to Assess Safety, Tolerability and Efficacy of LJN452 in PBC Patients. <a href="http://ClinicalTrials.gov" class="ext-link">ClinicalTrials.gov</a> Identifier: NCT02516605.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Multipart%2C+Double+Blind+Study+to+Assess+Safety%2C+Tolerability+and+Efficacy+of+LJN452+in+PBC+Patients.+ClinicalTrials.gov+Identifier%3A+NCT02516605."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref14_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><div class="note"><p class="first last">Safety, Tolerability and Efficacy Study of 12 Weeks LJN452 Treatment in NASH Patients (FLIGHT-FXR). <a href="http://ClinicalTrials.gov" class="ext-link">ClinicalTrials.gov</a> Identifier: NCT02855164.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety%2C+Tolerability+and+Efficacy+Study+of+12+Weeks+LJN452+Treatment+in+NASH+Patients+%28FLIGHT-FXR%29.+ClinicalTrials.gov+Identifier%3A+NCT02855164."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Maloney, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fivush, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plunket, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, T. M.</span><span> </span><span class="NLM_article-title">Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2971</span><span class="NLM_x">–</span> <span class="NLM_lpage">2974</span><span class="refDoi"> DOI: 10.1021/jm0002127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0002127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVSiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2971-2974&author=P.+R.+Maloneyauthor=D.+J.+Parksauthor=C.+D.+Haffnerauthor=A.+M.+Fivushauthor=G.+Chandraauthor=K.+D.+Plunketauthor=K.+L.+Creechauthor=L.+B.+Mooreauthor=J.+G.+Wilsonauthor=M.+C.+Lewisauthor=S.+A.+Jonesauthor=T.+M.+Willson&title=Identification+of+a+Chemical+Tool+for+the+Orphan+Nuclear+Receptor+FXR&doi=10.1021%2Fjm0002127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR</span></div><div class="casAuthors">Maloney, Patrick R.; Parks, Derek J.; Haffner, Curt D.; Fivush, Adam M.; Chandra, Gyan; Plunket, Kelli D.; Creech, Katrina L.; Moore, Linda B.; Wilson, Joan G.; Lewis, Michael C.; Jones, Stacey A.; Willson, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2971-2974</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors have identified the first high-affinity nonsteroidal FXR nuclear receptor agonist through use of high-throughput screening and combinatorial chem.  This agonist, GW4064, will be a valuable chem. tool for studying the role of FXR in mammalian physiol. and disease.  The data also establishes triglyceride lowering as a surrogate pharmacol. response to the activation of FXR receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry7sdXiiBvsLVg90H21EOLACvtfcHk0lg98uo8jj12cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVSiur0%253D&md5=111bd63144e2af62eee81b4d706a2672</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm0002127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0002127%26sid%3Dliteratum%253Aachs%26aulast%3DMaloney%26aufirst%3DP.%2BR.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DHaffner%26aufirst%3DC.%2BD.%26aulast%3DFivush%26aufirst%3DA.%2BM.%26aulast%3DChandra%26aufirst%3DG.%26aulast%3DPlunket%26aufirst%3DK.%2BD.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26aulast%3DLewis%26aufirst%3DM.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26atitle%3DIdentification%2520of%2520a%2520Chemical%2520Tool%2520for%2520the%2520Orphan%2520Nuclear%2520Receptor%2520FXR%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2971%26epage%3D2974%26doi%3D10.1021%2Fjm0002127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Akwabi-Ameyaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spearing, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span> </span><span class="NLM_article-title">Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Alternative Replacements of the Stilbene</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6154</span><span class="NLM_x">–</span> <span class="NLM_lpage">6160</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.08.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2011.08.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=21890356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2qsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6154-6160&author=A.+Akwabi-Ameyawauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=A.+B.+Millerauthor=F.+Navasauthor=D.+J.+Parksauthor=P.+K.+Spearingauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Conformationally+Constrained+Farnesoid+X+Receptor+%28FXR%29+Agonists%3A+Alternative+Replacements+of+the+Stilbene&doi=10.1016%2Fj.bmcl.2011.08.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene</span></div><div class="casAuthors">Akwabi-Ameyaw, Adwoa; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Madauss, Kevin P.; Marr, Harry B.; Miller, Aaron B.; Navas, Frank, III; Parks, Derek J.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6154-6160</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To further explore the optimum placement of the acid moiety in conformationally constrained analogs of GW 4064, a series of stilbene replacements were prepd.  The benzothiophene I [X = S] and the indole I [X = NH] display the optimal orientation of the carboxylate for enhanced FXR agonist potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_-bx-WCdaVbVg90H21EOLACvtfcHk0lg98uo8jj12cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2qsr7E&md5=f0126e099a3c1d2abd52a2206979ce39</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.08.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.08.034%26sid%3Dliteratum%253Aachs%26aulast%3DAkwabi-Ameyaw%26aufirst%3DA.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DNavas%26aufirst%3DF.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DSpearing%26aufirst%3DP.%2BK.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DConformationally%2520Constrained%2520Farnesoid%2520X%2520Receptor%2520%2528FXR%2529%2520Agonists%253A%2520Alternative%2520Replacements%2520of%2520the%2520Stilbene%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6154%26epage%3D6160%26doi%3D10.1016%2Fj.bmcl.2011.08.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Bass, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFadyen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navas, F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, T. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spearing, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span> </span><span class="NLM_article-title">Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Heteroaryl Replacements of the Naphthalene</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1206</span><span class="NLM_x">–</span> <span class="NLM_lpage">1213</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2010.12.089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=21256005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1amt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1206-1213&author=J.+Y.+Bassauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=R.+B.+McFadyenauthor=A.+B.+Millerauthor=W.+Y.+Millsauthor=F.+Navasauthor=D.+J.+Parksauthor=T.+L.+Smalleyauthor=P.+K.+Spearingauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Conformationally+Constrained+Farnesoid+X+Receptor+%28FXR%29+Agonists%3A+Heteroaryl+Replacements+of+the+Naphthalene&doi=10.1016%2Fj.bmcl.2010.12.089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene</span></div><div class="casAuthors">Bass, Jonathan Y.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Mills, Wendy Y.; Navas, Frank, III; Parks, Derek J.; Smalley, Terrence L., Jr.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1206-1213</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To improve on the drug properties of GSK8062, a series of heteroaryl bicyclic naphthalene replacements were prepd.  The quinoline I was an equipotent FXR agonist with improved drug developability parameters relative to GSK8062.  In addn., I lowered body wt. gain and serum glucose in a DIO mouse model of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopkMv0ii-Ef7Vg90H21EOLACvtfcHk0liEtmSGkOIYig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1amt74%253D&md5=7bff29efbc4421b1641fdd20eddcb064</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.089%26sid%3Dliteratum%253Aachs%26aulast%3DBass%26aufirst%3DJ.%2BY.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMcFadyen%26aufirst%3DR.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DMills%26aufirst%3DW.%2BY.%26aulast%3DNavas%26aufirst%3DF.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DSmalley%26aufirst%3DT.%2BL.%26aulast%3DSpearing%26aufirst%3DP.%2BK.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DConformationally%2520Constrained%2520Farnesoid%2520X%2520Receptor%2520%2528FXR%2529%2520Agonists%253A%2520Heteroaryl%2520Replacements%2520of%2520the%2520Naphthalene%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1206%26epage%3D1213%26doi%3D10.1016%2Fj.bmcl.2010.12.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Smalley, T. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span> </span><span class="NLM_article-title">Novel Heterocyclic Scaffolds of GW4064 as Farnesoid X Receptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2014.11.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25499883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWhsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=280-284&author=T.+L.+Smalleyauthor=S.+Boggsauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=I.+Kaldorauthor=D.+J.+Parks&title=Novel+Heterocyclic+Scaffolds+of+GW4064+as+Farnesoid+X+Receptor+Agonists&doi=10.1016%2Fj.bmcl.2014.11.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists</span></div><div class="casAuthors">Smalley, Terrence L., Jr.; Boggs, Sharon; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Kaldor, Istvan; Parks, Derek J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-284</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The farnesoid X receptor (FXR) may play a crucial role in a no. of metabolic diseases and, as such, could potentially serve as a target for the development of therapeutics as a treatment for those diseases.  Previous work has described GW4064 as an FXR agonist with an interesting activity profile.  This manuscript will describe the synthesis of novel analogs of GW4064, e.g. I, and the activity profile of those analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosZMu7uSERubVg90H21EOLACvtfcHk0liEtmSGkOIYig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWhsL3N&md5=8ed3153fecf8c021d55618eb4bcdd97d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.050%26sid%3Dliteratum%253Aachs%26aulast%3DSmalley%26aufirst%3DT.%2BL.%26aulast%3DBoggs%26aufirst%3DS.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DKaldor%26aufirst%3DI.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26atitle%3DNovel%2520Heterocyclic%2520Scaffolds%2520of%2520GW4064%2520as%2520Farnesoid%2520X%2520Receptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D280%26epage%3D284%26doi%3D10.1016%2Fj.bmcl.2014.11.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Bass, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFadyen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span> </span><span class="NLM_article-title">Substituted Isoxazole Analogs of Farnesoid X Receptor (FXR) Agonist GW4064</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2969</span><span class="NLM_x">–</span> <span class="NLM_lpage">2973</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2009.04.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=19410460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVeku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2969-2973&author=J.+Y.+Bassauthor=R.+D.+Caldwellauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=R.+B.+McFadyenauthor=A.+B.+Millerauthor=D.+J.+Parksauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Substituted+Isoxazole+Analogs+of+Farnesoid+X+Receptor+%28FXR%29+Agonist+GW4064&doi=10.1016%2Fj.bmcl.2009.04.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064</span></div><div class="casAuthors">Bass, Jonathan Y.; Caldwell, Richard D.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Parks, Derek J.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2969-2973</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from the known FXR agonist GW 4064 (I) (R1 = i-Pr, R2 = 2,6-Cl2C6H3), a series of alternately 3,5-substituted isoxazoles was prepd.  A subset of this series, with a tether between the isoxazole ring and the 3-position aryl substituent, were equipotent FXR agonists to GW 4064, with the analog I (R1 = i-Pr, R2 = 2,6-Me2C6H3OCH2) having greater FRET FXR potency than GW 4064.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmilCrO1yO1LVg90H21EOLACvtfcHk0lhA_hzAEOGnHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVeku70%253D&md5=38b2a1b54be6ef8a3d58f6550a1ff16f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DBass%26aufirst%3DJ.%2BY.%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMcFadyen%26aufirst%3DR.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DSubstituted%2520Isoxazole%2520Analogs%2520of%2520Farnesoid%2520X%2520Receptor%2520%2528FXR%2529%2520Agonist%2520GW4064%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2969%26epage%3D2973%26doi%3D10.1016%2Fj.bmcl.2009.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Akwabi-Ameyaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bass, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravella, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creech, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deaton, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFadyen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navas, F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spearing, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisely, G. B.</span><span> </span><span class="NLM_article-title">Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Naphthoic Acid-Based Analogs of GW 4064</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4339</span><span class="NLM_x">–</span> <span class="NLM_lpage">4343</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2008.06.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=18621523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVeqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4339-4343&author=A.+Akwabi-Ameyawauthor=J.+Y.+Bassauthor=R.+D.+Caldwellauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=S.+A.+Jonesauthor=I.+Kaldorauthor=Y.+Liuauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=R.+B.+McFadyenauthor=A.+B.+Millerauthor=F.+Navasauthor=D.+J.+Parksauthor=P.+K.+Spearingauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Conformationally+Constrained+Farnesoid+X+Receptor+%28FXR%29+Agonists%3A+Naphthoic+Acid-Based+Analogs+of+GW+4064&doi=10.1016%2Fj.bmcl.2008.06.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064</span></div><div class="casAuthors">Akwabi-Ameyaw, Adwoa; Bass, Jonathan Y.; Caldwell, Richard D.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Jones, Stacey A.; Kaldor, Istvan; Liu, Yaping; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Navas, Frank, III; Parks, Derek J.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4339-4343</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Starting from the known FXR agonist GW 4064 I, a series of stilbene replacements were prepd.  The 6-substituted 1-naphthoic acid II was an equipotent FXR agonist with improved developability parameters relative to I.  Analog II also reduced the severity of cholestasis in the ANIT acute cholestatic rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0IzFOXAysDrVg90H21EOLACvtfcHk0lhA_hzAEOGnHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVeqtbk%253D&md5=1007683ff89fa4257f063c63cd16481b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.073%26sid%3Dliteratum%253Aachs%26aulast%3DAkwabi-Ameyaw%26aufirst%3DA.%26aulast%3DBass%26aufirst%3DJ.%2BY.%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DKaldor%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMcFadyen%26aufirst%3DR.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DNavas%26aufirst%3DF.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DSpearing%26aufirst%3DP.%2BK.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DConformationally%2520Constrained%2520Farnesoid%2520X%2520Receptor%2520%2528FXR%2529%2520Agonists%253A%2520Naphthoic%2520Acid-Based%2520Analogs%2520of%2520GW%25204064%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4339%26epage%3D4343%26doi%3D10.1016%2Fj.bmcl.2008.06.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Abel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlüter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambruch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perović-Ottstadt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deuschle, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremoser, C.</span><span> </span><span class="NLM_article-title">Synthesis and Pharmacological Validation of a Novel Series of Non-Steroidal FXR Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4911</span><span class="NLM_x">–</span> <span class="NLM_lpage">4917</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1016%2Fj.bmcl.2010.06.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=20638278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlans7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4911-4917&author=U.+Abelauthor=T.+Schl%C3%BCterauthor=A.+Schulzauthor=E.+Hambruchauthor=C.+Steeneckauthor=M.+Hornbergerauthor=T.+Hoffmannauthor=S.+Perovi%C4%87-Ottstadtauthor=O.+Kinzelauthor=M.+Burnetauthor=U.+Deuschleauthor=C.+Kremoser&title=Synthesis+and+Pharmacological+Validation+of+a+Novel+Series+of+Non-Steroidal+FXR+Agonists&doi=10.1016%2Fj.bmcl.2010.06.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists</span></div><div class="casAuthors">Abel, Ulrich; Schlueter, Thomas; Schulz, Andreas; Hambruch, Eva; Steeneck, Christoph; Hornberger, Martin; Hoffmann, Thomas; Perovic-Ottstadt, Sanja; Kinzel, Olaf; Burnet, Michael; Deuschle, Ulrich; Kremoser, Claus</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4911-4917</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To overcome the known liabilities of known farnesoid receptor agonist GW4064, a series of analogs was synthesized where the stilbene double bond was replaced by an oxymethylene or amino-methylene linker connecting a terminal benzoic acid with a substituted heteroaryl in the middle ring position.  Some compds., such as I (R = i-Pr, cyclopropyl), were found to have an increased potency in vitro that caused dose-dependent redn. of plasma triglycerides and cholesterol in db/db mice down to 2 × 1 mg/kg/day upon oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGx-787FlxpbVg90H21EOLACvtfcHk0lhXBXQ-TwOYBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlans7k%253D&md5=26ea6a737e9d3844a7b32043e2b6a412</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.084%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DU.%26aulast%3DSchl%25C3%25BCter%26aufirst%3DT.%26aulast%3DSchulz%26aufirst%3DA.%26aulast%3DHambruch%26aufirst%3DE.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DHornberger%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DT.%26aulast%3DPerovi%25C4%2587-Ottstadt%26aufirst%3DS.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DBurnet%26aufirst%3DM.%26aulast%3DDeuschle%26aufirst%3DU.%26aulast%3DKremoser%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Validation%2520of%2520a%2520Novel%2520Series%2520of%2520Non-Steroidal%2520FXR%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4911%26epage%3D4917%26doi%3D10.1016%2Fj.bmcl.2010.06.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Gege, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremoser, C.</span><span> </span><span class="NLM_article-title">Knocking on FXR’s Door:The “Hammerhead”-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2158</span><span class="refDoi"> DOI: 10.2174/1568026614666141112094430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.2174%2F1568026614666141112094430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25388536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2rsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=2143-2158&author=C.+Gegeauthor=O.+Kinzelauthor=C.+Steeneckauthor=A.+Schulzauthor=C.+Kremoser&title=Knocking+on+FXR%E2%80%99s+Door%3AThe+%E2%80%9CHammerhead%E2%80%9D-Structure+Series+of+FXRs+Agonists+-+Amphiphilic+Isoxazoles+with+Potent+In+Vitro+and+In+Vivo+Activities&doi=10.2174%2F1568026614666141112094430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities</span></div><div class="casAuthors">Gege, Christian; Kinzel, Olaf; Steeneck, Christoph; Schulz, Andreas; Kremoser, Claus</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2143-2158</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The Farnesoid X Receptor (FXR) was recently validated in clin. studies using the bile acid analog Obeticholic Acid (OCA) as an attractive drug target for liver diseases such as Primary Biliary Cirrhosis (PBC) or Non-alc. Steatohepatitis (NASH).  OCA, however, turned out to induce cholesterol- related side effects upon prolonged treatment and it shows bile acid like pharmacokinetics.  The quest for synthetic non-steroidal FXR agonists with general drug likeliness and improved pharmacokinetic and - dynamic properties has started more than a decade ago: The first non-steroidal and selective FXR agonist with decent submicromolar potency, GW4064, was patented in 1998 and published in 2000.  Since then, many pharmaceutical companies have taken GW4064 as a structural template for their efforts in identifying novel patentable FXR agonists with the GW-derived trisubstituted isoxazole general structure.  However, so far only one compd. out of these different series has made it into the early stages of clin. development: The Px-102/Px-104 from Phenex is currently tested in a phase IIa study in patients with Non-Alc. Fatty Liver Disease (NAFLD).  In this review we try to summarize from the patent and scientific literature the attempts to improve the GW4064 structure into different directions.  Furthermore, we suggest directions for further improvements of this special class of synthetic FXR agonists which all display the typical "hammerhead"-conformation in the FXR ligand binding pocket that provides the basis for their impressive in vitro and in vivo potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAsJf5mf9ParVg90H21EOLACvtfcHk0lhXBXQ-TwOYBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2rsLzE&md5=67e6c243603021ec6383f5e71b692b2e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F1568026614666141112094430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026614666141112094430%26sid%3Dliteratum%253Aachs%26aulast%3DGege%26aufirst%3DC.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DSchulz%26aufirst%3DA.%26aulast%3DKremoser%26aufirst%3DC.%26atitle%3DKnocking%2520on%2520FXR%25E2%2580%2599s%2520Door%253AThe%2520%25E2%2580%259CHammerhead%25E2%2580%259D-Structure%2520Series%2520of%2520FXRs%2520Agonists%2520-%2520Amphiphilic%2520Isoxazoles%2520with%2520Potent%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Activities%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26spage%3D2143%26epage%3D2158%26doi%3D10.2174%2F1568026614666141112094430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Xu, Y.</span><span> </span><span class="NLM_article-title">Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">6553</span><span class="NLM_x">–</span> <span class="NLM_lpage">6579</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00342</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00342" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6553-6579&author=Y.+Xu&title=Recent+Progress+on+Bile+Acid+Receptor+Modulators+for+Treatment+of+Metabolic+Diseases&doi=10.1021%2Facs.jmedchem.5b00342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases</span></div><div class="casAuthors">Xu, Yanping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6553-6579</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bile acids are steroid-derived mols. synthesized in the liver, secreted from hepatocytes into the bile canaliculi, and subsequently stored in the gall bladder.  During the feeding, bile flows into the duodenum, where it contributes to the solubilization and digestion of lipid-sol. nutrients.  After a meal, bile-acid levels increase in the intestine, liver, and also in the systemic circulation.  Therefore, serum bile-acid levels serve as an important sensing mechanism for nutrient and energy.  Recent studies have described bile acids as versatile signaling mols. endowed with systemic endocrine functions.  Bile acids are ligands for G-protein coupled receptors (GPCRs) such as TGR5 (also known as GPBAR1, M-BAR, and BG37) and nuclear hormone receptors including farnesoid X receptor (FXR; also known as NR1H4).  Acting through these diverse signaling pathways, bile acids regulate triglyceride, cholesterol, glucose homeostasis, and energy expenditure.  These bile-acid-controlled signaling pathways have become the source of promising novel drug targets to treat common metabolic and hepatic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGuPZaBpniNrVg90H21EOLACvtfcHk0ljgCQgp0YBKJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGntLc%253D&md5=6c31dcbb9eed8fb19ca78b6912b44e39</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00342%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26atitle%3DRecent%2520Progress%2520on%2520Bile%2520Acid%2520Receptor%2520Modulators%2520for%2520Treatment%2520of%2520Metabolic%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6553%26epage%3D6579%26doi%3D10.1021%2Facs.jmedchem.5b00342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Genin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bueno, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agejas Francisco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manninen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bocchinfuso, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montrose-Rafizadeh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannady, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stille, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reidy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, L. F.</span><span> </span><span class="NLM_article-title">Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-Dichlorophenyl)isoxazol-4-Yl]methoxy}piperidin-1-Yl)-1-Methyl-1H-Indole-3-Carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9768</span><span class="NLM_x">–</span> <span class="NLM_lpage">9772</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01161</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01161" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9768-9772&author=M.+J.+Geninauthor=A.+B.+Buenoauthor=J.+Agejas+Franciscoauthor=P.+R.+Manninenauthor=W.+P.+Bocchinfusoauthor=C.+Montrose-Rafizadehauthor=E.+A.+Cannadyauthor=T.+M.+Jonesauthor=J.+R.+Stilleauthor=E.+Raddadauthor=C.+Reidyauthor=A.+Coxauthor=M.+D.+Michaelauthor=L.+F.+Michael&title=Discovery+of+6-%284-%7B%5B5-Cyclopropyl-3-%282%2C6-Dichlorophenyl%29isoxazol-4-Yl%5Dmethoxy%7Dpiperidin-1-Yl%29-1-Methyl-1H-Indole-3-Carboxylic+Acid%3A+A+Novel+FXR+Agonist+for+the+Treatment+of+Dyslipidemia&doi=10.1021%2Facs.jmedchem.5b01161"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01161%26sid%3Dliteratum%253Aachs%26aulast%3DGenin%26aufirst%3DM.%2BJ.%26aulast%3DBueno%26aufirst%3DA.%2BB.%26aulast%3DAgejas%2BFrancisco%26aufirst%3DJ.%26aulast%3DManninen%26aufirst%3DP.%2BR.%26aulast%3DBocchinfuso%26aufirst%3DW.%2BP.%26aulast%3DMontrose-Rafizadeh%26aufirst%3DC.%26aulast%3DCannady%26aufirst%3DE.%2BA.%26aulast%3DJones%26aufirst%3DT.%2BM.%26aulast%3DStille%26aufirst%3DJ.%2BR.%26aulast%3DRaddad%26aufirst%3DE.%26aulast%3DReidy%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DA.%26aulast%3DMichael%26aufirst%3DM.%2BD.%26aulast%3DMichael%26aufirst%3DL.%2BF.%26atitle%3DDiscovery%2520of%25206-%25284-%257B%255B5-Cyclopropyl-3-%25282%252C6-Dichlorophenyl%2529isoxazol-4-Yl%255Dmethoxy%257Dpiperidin-1-Yl%2529-1-Methyl-1H-Indole-3-Carboxylic%2520Acid%253A%2520A%2520Novel%2520FXR%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Dyslipidemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9768%26epage%3D9772%26doi%3D10.1021%2Facs.jmedchem.5b01161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Tully, D. C.; Vidal, A.; Mutnick, D.; Alper, P. B.</span><span> </span><span class="NLM_article-title">Compositions and Methods for Modulating Farnesoid X Receptors</span>. WO 2012/087520 A1, June 28,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+C.+Tully&author=A.+Vidal&author=D.+Mutnick&author=P.+B.+Alper&title=Compositions+and+Methods+for+Modulating+Farnesoid+X+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTully%26aufirst%3DD.%2BC.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Modulating%2520Farnesoid%2520X%2520Receptors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Tully, D. C.; Rucker, P. V.; Alper, P. B.; Mutnick, D.; Chianelli, D.</span><span> </span><span class="NLM_article-title">Compositions and Methods for Modulating FXR</span>. WO 2012/087519 A1, June 28,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+C.+Tully&author=P.+V.+Rucker&author=P.+B.+Alper&author=D.+Mutnick&author=D.+Chianelli&title=Compositions+and+Methods+for+Modulating+FXR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTully%26aufirst%3DD.%2BC.%26atitle%3DCompositions%2520and%2520Methods%2520for%2520Modulating%2520FXR%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Alemi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattaruzza, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cevikbas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero-Alba, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez-Morales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottrell, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoonjans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnett, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvera, C. U.</span><span> </span><span class="NLM_article-title">The TGR5 Receptor Mediates Bile Acid–induced Itch and Analgesia</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1513</span><span class="NLM_x">–</span> <span class="NLM_lpage">1530</span><span class="refDoi"> DOI: 10.1172/JCI64551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1172%2FJCI64551" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=1513-1530&author=F.+Alemiauthor=E.+Kwonauthor=D.+P.+Pooleauthor=T.+Lieuauthor=V.+Lyoauthor=F.+Cattaruzzaauthor=F.+Cevikbasauthor=M.+Steinhoffauthor=R.+Nassiniauthor=S.+Materazziauthor=R.+Guerrero-Albaauthor=E.+Valdez-Moralesauthor=G.+S.+Cottrellauthor=K.+Schoonjansauthor=P.+Geppettiauthor=S.+J.+Vannerauthor=N.+W.+Bunnettauthor=C.+U.+Corvera&title=The+TGR5+Receptor+Mediates+Bile+Acid%E2%80%93induced+Itch+and+Analgesia&doi=10.1172%2FJCI64551"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1172%2FJCI64551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI64551%26sid%3Dliteratum%253Aachs%26aulast%3DAlemi%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DE.%26aulast%3DPoole%26aufirst%3DD.%2BP.%26aulast%3DLieu%26aufirst%3DT.%26aulast%3DLyo%26aufirst%3DV.%26aulast%3DCattaruzza%26aufirst%3DF.%26aulast%3DCevikbas%26aufirst%3DF.%26aulast%3DSteinhoff%26aufirst%3DM.%26aulast%3DNassini%26aufirst%3DR.%26aulast%3DMaterazzi%26aufirst%3DS.%26aulast%3DGuerrero-Alba%26aufirst%3DR.%26aulast%3DValdez-Morales%26aufirst%3DE.%26aulast%3DCottrell%26aufirst%3DG.%2BS.%26aulast%3DSchoonjans%26aufirst%3DK.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DVanner%26aufirst%3DS.%2BJ.%26aulast%3DBunnett%26aufirst%3DN.%2BW.%26aulast%3DCorvera%26aufirst%3DC.%2BU.%26atitle%3DThe%2520TGR5%2520Receptor%2520Mediates%2520Bile%2520Acid%25E2%2580%2593induced%2520Itch%2520and%2520Analgesia%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D1513%26epage%3D1530%26doi%3D10.1172%2FJCI64551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Lieu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaweera, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grace, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krappitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haerteis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korbmacher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhoff, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvera, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnett, N. W.</span><span> </span><span class="NLM_article-title">The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">1417</span><span class="NLM_x">–</span> <span class="NLM_lpage">1428</span><span class="refDoi"> DOI: 10.1053/j.gastro.2014.08.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1053%2Fj.gastro.2014.08.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=25194674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOgsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2014&pages=1417-1428&author=T.+Lieuauthor=G.+Jayaweeraauthor=P.+Zhaoauthor=D.+P.+Pooleauthor=D.+Jensenauthor=M.+Graceauthor=P.+McIntyreauthor=R.+Bronauthor=Y.+M.+Wilsonauthor=M.+Krappitzauthor=S.+Haerteisauthor=C.+Korbmacherauthor=M.+S.+Steinhoffauthor=R.+Nassiniauthor=S.+Materazziauthor=P.+Geppettiauthor=C.+U.+Corveraauthor=N.+W.+Bunnett&title=The+Bile+Acid+Receptor+TGR5+Activates+the+TRPA1+Channel+to+Induce+Itch+in+Mice&doi=10.1053%2Fj.gastro.2014.08.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice</span></div><div class="casAuthors">Lieu, Tina Marie; Jayaweera, Gihan; Zhao, Peishen; Poole, Daniel P.; Jensen, Dane; Grace, Megan; McIntyre, Peter; Bron, Romke; Wilson, Yvette M.; Krappitz, Matteus; Haerteis, Silke; Korbmacher, Christoph; Steinhoff, Martin S.; Nassini, Romina; Materazzi, Serena; Geppetti, Pierangelo; Corvera, Carlos U.; Bunnett, Nigel W.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1417-1428</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Patients with cholestatic disease have increased systemic concns. of bile acids (BAs) and profound pruritus.  The G-protein-coupled BA receptor 1 TGR5 (encoded by GPBAR1) is expressed by primary sensory neurons; its activation induces neuronal hyperexcitability and scratching by unknown mechanisms.  We investigated whether the transient receptor potential ankyrin 1 (TRPA1) is involved in BA-evoked, TGR5-dependent pruritus in mice.  Co-expression of TGR5 and TRPA1 in cutaneous afferent neurons isolated from mice was analyzed by immunofluorescence, in situ hybridization, and single-cell polymerase chain reaction.  TGR5-induced activation of TRPA1 was studied in in HEK293 cells, Xenopus laevis oocytes, and primary sensory neurons by measuring Ca2+ signals.  The contribution of TRPA1 to TGR5-induced release of pruritogenic neuropeptides, activation of spinal neurons, and scratching behavior were studied using TRPA1 antagonists or Trpa1-/- mice.  TGR5 and TRPA1 protein and mRNA were expressed by cutaneous afferent neurons.  In HEK cells, oocytes, and neurons co-expressing TGR5 and TRPA1, BAs caused TGR5-dependent activation and sensitization of TRPA1 by mechanisms that required Gβγ, protein kinase C, and Ca2+.  Antagonists or deletion of TRPA1 prevented BA-stimulated release of the pruritogenic neuropeptides gastrin-releasing peptide and atrial natriuretic peptide B in the spinal cord.  Disruption of Trpa1 in mice blocked BA-induced expression of Fos in spinal neurons and prevented BA-stimulated scratching.  Spontaneous scratching was exacerbated in transgenic mice that overexpressed TRG5.  Administration of a TRPA1 antagonist or the BA sequestrant colestipol, which lowered circulating levels of BAs, prevented exacerbated spontaneous scratching in TGR5 overexpressing mice.  BAs induce pruritus in mice by co-activation of TGR5 and TRPA1.  Antagonists of TGR5 and TRPA1, or inhibitors of the signaling mechanism by which TGR5 activates TRPA1, might be developed for treatment of cholestatic pruritus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM4F6iy9XI9bVg90H21EOLACvtfcHk0li8kI9ya4DqLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOgsrzO&md5=3a77ab6ea2ee8f54d09e4f509167a67b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2014.08.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2014.08.042%26sid%3Dliteratum%253Aachs%26aulast%3DLieu%26aufirst%3DT.%26aulast%3DJayaweera%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DPoole%26aufirst%3DD.%2BP.%26aulast%3DJensen%26aufirst%3DD.%26aulast%3DGrace%26aufirst%3DM.%26aulast%3DMcIntyre%26aufirst%3DP.%26aulast%3DBron%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DY.%2BM.%26aulast%3DKrappitz%26aufirst%3DM.%26aulast%3DHaerteis%26aufirst%3DS.%26aulast%3DKorbmacher%26aufirst%3DC.%26aulast%3DSteinhoff%26aufirst%3DM.%2BS.%26aulast%3DNassini%26aufirst%3DR.%26aulast%3DMaterazzi%26aufirst%3DS.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DCorvera%26aufirst%3DC.%2BU.%26aulast%3DBunnett%26aufirst%3DN.%2BW.%26atitle%3DThe%2520Bile%2520Acid%2520Receptor%2520TGR5%2520Activates%2520the%2520TRPA1%2520Channel%2520to%2520Induce%2520Itch%2520in%2520Mice%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D147%26spage%3D1417%26epage%3D1428%26doi%3D10.1053%2Fj.gastro.2014.08.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Nevens, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreone, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strasser, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowlus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Invernizzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drenth, J. P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regula, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuers, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trauner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floreani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenester, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luketic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Erpecum, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirschfield, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindor, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marschall, H.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooshmand-Rad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheeron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pencek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacConell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruzanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D.</span><span> </span><span class="NLM_article-title">A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1056/NEJMoa1509840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1056%2FNEJMoa1509840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=27532829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=631-643&author=F.+Nevensauthor=P.+Andreoneauthor=G.+Mazzellaauthor=S.+I.+Strasserauthor=C.+Bowlusauthor=P.+Invernizziauthor=J.+P.+H.+Drenthauthor=P.+J.+Pockrosauthor=J.+Regulaauthor=U.+Beuersauthor=M.+Traunerauthor=D.+E.+Jonesauthor=A.+Floreaniauthor=S.+Hohenesterauthor=V.+Luketicauthor=M.+Shiffmanauthor=K.+J.+van+Erpecumauthor=V.+Vargasauthor=C.+Vincentauthor=G.+M.+Hirschfieldauthor=H.+Shahauthor=B.+Hansenauthor=K.+D.+Lindorauthor=H.-U.+Marschallauthor=K.+V.+Kowdleyauthor=R.+Hooshmand-Radauthor=T.+Marmonauthor=S.+Sheeronauthor=R.+Pencekauthor=L.+MacConellauthor=M.+Pruzanskiauthor=D.+Shapiro&title=A+Placebo-Controlled+Trial+of+Obeticholic+Acid+in+Primary+Biliary+Cholangitis&doi=10.1056%2FNEJMoa1509840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A placebo-controlled trial of obeticholic acid in primary biliary cholangitis</span></div><div class="casAuthors">Nevens, F.; Andreone, P.; Mazzella, G.; Strasser, S. I.; Bowlus, C.; Invernizzi, P.; Drenth, J. P. H.; Pockros, P. J.; Regula, J.; Beuers, U.; Trauner, M.; Jones, D. E.; Floreani, A.; Hohenester, S.; Luketic, V.; Shiffman, M.; van Erpecum, K. J.; Vargas, V.; Vincent, C.; Hirschfield, G. M.; Shah, H.; Hansen, B.; Lindor, K. D.; Marschall, H.-U.; Kowdley, K. V.; Hooshmand-Rad, R.; Marmon, T.; Sheeron, S.; Pencek, R.; MacConell, L.; Pruzanski, M.; Shapiro, D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-643</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy.  Alk. phosphatase and bilirubin levels correlate with the risk of liver transplantation or death.  Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients with this disease.  METHODS: In this 12-mo, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a dose of 10 mg (the 10-mg group), obeticholic acid at a dose of 5 mg with adjustment to 10 mg if applicable (the 5-10-mg group), or placebo.  The primary end point was an alk. phosphatase level of less than 1.67 times the upper limit of the normal range, with a redn. of at least 15% from baseline, and a normal total bilirubin level.  RESULTS: Of 216 patients who underwent randomization and received at least one dose of obeticholic acid or placebo, 93% received ursodiol as background therapy.  The primary end point occurred in more patients in the 5-10-mg group (46%) and the 10-mg group (47%) than in the placebo group (10%; P<0.001 for both comparisons).  Patients in the 5-10-mg group and those in the 10-mg group had greater decreases than those in the placebo group in the alk. phosphatase level (least-squares mean, -113 and -130 U per L, resp., vs. -14 U per L; P<0.001 for both comparisons) and total bilirubin level (-0.02 and -0.05 mg per dL [-0.3 and -0.9 μmol per L], resp., vs. 0.12 mg per dL [2.0 μmol per L]; P<0.001 for both comparisons).  Changes in noninvasive measures of liver fibrosis did not differ significantly between either treatment group and the placebo group at 12 mo.  Pruritus was more common with obeticholic acid than with placebo (56% of patients in the 5-10-mg group and 68% of those in the 10-mg group vs. 38% in the placebo group).  The rate of serious adverse events was 16% in the 5-10-mg group, 11% in the 10-mg group, and 4% in the placebo group.  CONCLUSIONS: Obeticholic acid administered with ursodiol or as monotherapy for 12 mo in patients with primary biliary cholangitis resulted in decreases from baseline in alk. phosphatase and total bilirubin levels that differed significantly from the changes obsd. with placebo.  There were more serious adverse events with obeticholic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovAIzzX9egK7Vg90H21EOLACvtfcHk0ljtYdEI8i8-OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7zE&md5=613ba0df3a84969560534d87de20420b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509840%26sid%3Dliteratum%253Aachs%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DAndreone%26aufirst%3DP.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DStrasser%26aufirst%3DS.%2BI.%26aulast%3DBowlus%26aufirst%3DC.%26aulast%3DInvernizzi%26aufirst%3DP.%26aulast%3DDrenth%26aufirst%3DJ.%2BP.%2BH.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DRegula%26aufirst%3DJ.%26aulast%3DBeuers%26aufirst%3DU.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DD.%2BE.%26aulast%3DFloreani%26aufirst%3DA.%26aulast%3DHohenester%26aufirst%3DS.%26aulast%3DLuketic%26aufirst%3DV.%26aulast%3DShiffman%26aufirst%3DM.%26aulast%3Dvan%2BErpecum%26aufirst%3DK.%2BJ.%26aulast%3DVargas%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DC.%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DShah%26aufirst%3DH.%26aulast%3DHansen%26aufirst%3DB.%26aulast%3DLindor%26aufirst%3DK.%2BD.%26aulast%3DMarschall%26aufirst%3DH.-U.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DHooshmand-Rad%26aufirst%3DR.%26aulast%3DMarmon%26aufirst%3DT.%26aulast%3DSheeron%26aufirst%3DS.%26aulast%3DPencek%26aufirst%3DR.%26aulast%3DMacConell%26aufirst%3DL.%26aulast%3DPruzanski%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DD.%26atitle%3DA%2520Placebo-Controlled%2520Trial%2520of%2520Obeticholic%2520Acid%2520in%2520Primary%2520Biliary%2520Cholangitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D631%26epage%3D643%26doi%3D10.1056%2FNEJMoa1509840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span>Ocaliva Full Prescribing Information (US Package Insert for Commercial Use); <span class="NLM_publisher-name">US FDA</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ocaliva+Full+Prescribing+Information+%28US+Package+Insert+for+Commercial+Use%29%3B+US+FDA%3A+Silver+Spring%2C+MD%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dgov%26sid%3Dliteratum%253Aachs%26jtitle%3DOcaliva%2520Full%2520Prescribing%2520Information%2520%2528US%2520Package%2520Insert%2520for%2520Commercial%2520Use%2529%26pub%3DUS%2520FDA%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Badman, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laffitte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decristofaro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klickstein, L.</span><span> </span><span class="NLM_article-title">First-in-Human experience with LJN452, an orally available non-bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects. AASLD Abstracts, The Liver Meeting, Boston, MA. Nov 11–15, 2016</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">32</span><span class="refDoi"> DOI: 10.1002/hep.28796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;key=10.1002%2Fhep.28796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=32&issue=1&author=M.+K.+Badmanauthor=S.+Desaiauthor=B.+Laffitteauthor=M.+Decristofaroauthor=T.+Linauthor=J.+Chenauthor=J.+F.+Reillyauthor=L.+Klickstein&title=First-in-Human+experience+with+LJN452%2C+an+orally+available+non-bile+acid+FXR+agonist%2C+demonstrates+potent+activation+of+FXR+in+healthy+subjects.+AASLD+Abstracts%2C+The+Liver+Meeting%2C+Boston%2C+MA.+Nov+11%E2%80%9315%2C+2016&doi=10.1002%2Fhep.28796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1002%2Fhep.28796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28796%26sid%3Dliteratum%253Aachs%26aulast%3DBadman%26aufirst%3DM.%2BK.%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DDecristofaro%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DKlickstein%26aufirst%3DL.%26atitle%3DFirst-in-Human%2520experience%2520with%2520LJN452%252C%2520an%2520orally%2520available%2520non-bile%2520acid%2520FXR%2520agonist%252C%2520demonstrates%2520potent%2520activation%2520of%2520FXR%2520in%2520healthy%2520subjects.%2520AASLD%2520Abstracts%252C%2520The%2520Liver%2520Meeting%252C%2520Boston%252C%2520MA.%2520Nov%252011%25E2%2580%259315%252C%25202016%26jtitle%3DHepatology%26date%3D2016%26volume%3D64%26issue%3D1%26spage%3D32%26doi%3D10.1002%2Fhep.28796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Laffitte, B.; Hernandez, E. D.; Zheng, L.; Kim, Y.; Liu, B.; Valdez, R. A.; Dietrich, W. F.; Rucker, P.; Chianelli, D.; Schmeits, J.; Bao, D.; Zoll, J.; Chen, L.; Joseph, S. B.; Klickstein, L. B.; Chen, J.; Xu, J.; Tully, D. C.; Molteni, V.; McNamara, P.; Badman, M. K.</span><span> </span><span class="NLM_article-title">Tropifexor (LJN452) Improves Cholestasis, Steatohepatitis and Hepatic Fibrosis in Rodents without Altering Plasma Lipids in Humans</span>. <div class="note"><p class="first last">Submitted for publication</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Laffitte%2C+B.%3B+Hernandez%2C+E.+D.%3B+Zheng%2C+L.%3B+Kim%2C+Y.%3B+Liu%2C+B.%3B+Valdez%2C+R.+A.%3B+Dietrich%2C+W.+F.%3B+Rucker%2C+P.%3B+Chianelli%2C+D.%3B+Schmeits%2C+J.%3B+Bao%2C+D.%3B+Zoll%2C+J.%3B+Chen%2C+L.%3B+Joseph%2C+S.+B.%3B+Klickstein%2C+L.+B.%3B+Chen%2C+J.%3B+Xu%2C+J.%3B+Tully%2C+D.+C.%3B+Molteni%2C+V.%3B+McNamara%2C+P.%3B+Badman%2C+M.+K.+Tropifexor+%28LJN452%29+Improves+Cholestasis%2C+Steatohepatitis+and+Hepatic+Fibrosis+in+Rodents+without+Altering+Plasma+Lipids+in+Humans.+Submitted+for+publication."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLaffitte%26aufirst%3DB.%26atitle%3DTropifexor%2520%2528LJN452%2529%2520Improves%2520Cholestasis%252C%2520Steatohepatitis%2520and%2520Hepatic%2520Fibrosis%2520in%2520Rodents%2520without%2520Altering%2520Plasma%2520Lipids%2520in%2520Humans" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DCT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DCT','PDB','3DCT'); return false;">PDB: 3DCT</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i23"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00907">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_14060"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00907">10.1021/acs.jmedchem.7b00907</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures and analytical data for the synthesis of all compounds, FXR-HTRF coactivator interaction biochemical assay, FXR BSEP-luc reporter gene cellular assay, rat in vitro hepatocyte gene expression assay, PK protocols, in vivo rat PD study protocols (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_001.pdf">jm7b00907_si_001.pdf (307.55 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00907/suppl_file/jm7b00907_si_002.csv">jm7b00907_si_002.csv (1.49 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00907&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00907%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00907" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994542cdd23db2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
